日本臨牀　別冊　血液症候群(第2版)II

出版社： 日本臨牀社
発行日： 2013-03-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 血液症候群（第2版）II―その他の血液疾患を含めて―
電子書籍版： 2013-03-20 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

17,160 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

17,160 円(税込)

購入する

目次

  • 日本臨牀　別冊　血液症候群（第2版）II

    ―目次―

    特集　血液症候群（第2版）II―その他の血液疾患を含めて―

    III． 白血球(顆粒球)の異常(悪性腫瘍を除く) 　 　
    　1 類白血病反応 　 　
    　2 好中球の異常 　 　
    　3 好酸球の異常 　 　
    　4 好塩基球の異常 　 　
    　5 単球の異常 　 　
    　6 肥満細胞の異常 　 　

    IV． リンパ球の異常 　 　
    　1 リンパ球増加症 　 　
    　2 リンパ球減少症 　 　
    　3 伝染性単核症 　 　
    　4 リンパ球機能異常と類縁疾患 　 　

    V． 血小板の異常 　 　
    　1 血小板増加症 　 　
    　2 血小板減少症 　 　
    　3 血小板機能異常症 　 　

    VI． 血管障害による出血傾向 　 　
    　1 先天性血管性紫斑病 　 　
    　2 後天性血管性紫斑病 　 　
    　3 単純性紫斑病　
    　4 老人性紫斑病　

    VII． 凝固・線溶異常による出血傾向 　 　
    　1 先天性凝固線溶異常症 　 　
    　2 後天性凝固線溶異常症 　 　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.10 掲載の参考文献
1) Cortes J, et al : Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 29 : 524-531, 2011.
PubMed
2) 宮地勇人 : 遺伝子関連検査のガイドライン. 日内会誌 100 : 3182-3192, 2011.
 
3) Swerdlow SH, et al (ed) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008.
 
4) Ganz T : Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 : 783-788, 2003.
 
5) Tefferi A : JAK inhibitors for myeloproliferative neoplasms : clarifying facts from myths. Blood 119 : 2721-2730, 2012.
PubMed
6) Hillmen P, et al : The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355 : 1233-1243, 2006.
PubMed
7) Yang LP, et al : Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs 67 : 2211-2230, 2007.
PubMed
8) Bussel JB, et al : Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura : a randomised, double-blind, placebo-controlled trial. Lancet 373 : 641-648, 2009.
PubMed
9) Levy GG, et al : ADAMTS13 turns 3. Blood 106 : 11-17, 2005.
PubMed
10) Saito H, et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 : 31-41, 2007.
PubMed
11) Pfreundschuh M, et al ; MabThera International Trial (MInT) Group : CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma : 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12 : 1013-1022, 2011.
 
12) Cavo M, et al ; GIMEMA Italian Myeloma Network : Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma : a randomised phase 3 study. Lancet 376 : 2075-2085, 2010.
PubMed

III 白血球 ( 顆粒球 ) の異常 ( 悪性腫瘍を除く )

P.17 掲載の参考文献
1) Hill JM, Duncan CN : Leukemoid Reactions. Am J Med Sci 201 : 847-857, 1941.
 
2) 中尾喜久, 三好和夫 : 類白血病性反応に就て-臨牀方面-. 日血会誌 14 (補冊) : 290-309, 1951.
 
3) Halkes CJ, et al : Extreme leucocytosis : not always leukaemia. Neth J Med 65 : 248-251, 2007.
 
4) 林泰秀 : 小児の治療指針類白血病反応. 小児科診療 58 : 374-377, 1995.
 
5) Nimieri HS, et al : Leukemoid reaction response to chemotherapy and radiotherapy in a patient with cervical carcinoma. Ann Hematol 82 : 316-317, 2003.
 
6) Noda I, et al : Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer 80 : 78-84, 1999.
PubMed
7) Ninck S, et al : Expression profiles of angiogenic growth factors in squamous cell carcinomas of thehead and neck. Int J Cancer 106 : 34-44, 2003.
 
8) Gabrilovich DI, et al : The terminology issue for myeloid -derived suppressor cells. Cancer Res 67 : 425 ; author reply 426, 2007.
PubMed
9) Gabrilovich DI, Nagaraj S : Myeloid-derived suppressor cells as regulator s of the immune system. Nat Rev Immunol 9 : 162-174, 2009.
 
10) Gotlib J, Cools J : Five years since the discovery of FIP1L1-PDGFRA : what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22 : 1999-2010, 2008.
PubMed
11) Marinella MA, et al : Leukemoid reactions complicating colitis due to Clostridium difficile. South Med J 97 : 959-963, 2004.
PubMed
12) Azim T, et al : Lipopolysaccharide-specific antibodies in plasma and stools of children with Shigella-associated leukemoid reaction and hemolytic-uremic syndrome. Clin Diagn Lab Immunol 3 : 701-705, 1996.
PubMed
13) McKee LC, Jr : Excess leukocytosis (leukemoid reactions) associated with malignant diseases. South Med J 78 : 1475-1482, 1985.
PubMed
14) Mandrekar SJ, et al : A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer 107 : 781-792, 2006.
PubMed
15) Granger JM, Kontoyiannis DP : Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients : a retrospective, single-institution study. Cancer 115 : 3919-3923, 2009.
PubMed
P.21 掲載の参考文献
1) Lange B : The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 110 : 512-524, 2000.
PubMed
2) Swerdlow S, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008.
 
3) Sandoval C, et al : Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant : case report and review of the literature. Pediatr Blood Cancer 44 : 85-91, 2005.
 
4) Wechsler J, et al : Acquired mutations in CATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32 : 148-152, 2002.
 
5) Shimada A, et al : Fetal origin of the CATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood 103 : 366, 2004.
 
6) Massey GV, et al : A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS) : Children's Oncology Group (COG) study POG-9481. Blood 107 : 4606-4613, 2006.
 
7) Klusmann JH, et al : Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 111 : 2991-2998, 2008.
PubMed
8) Muramatsu H, et al : Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br J Haematol 142 : 610-615, 2008.
PubMed
9) Gamis AS, et al : Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates : a report from the Children's Oncology Group Study A2971. Blood 118 : 6752-6759 ; quiz6996, 2011.
 
10) Hattori H, et al : High expression of platelet-derived growth factor and transforming growth factor-beta 1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis. Br J Haematol 115 : 472-475, 2001.
PubMed
11) Zipursky A : Transient leukaemia-a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 120 : 930-938, 2003.
PubMed
12) Shiozawa Y, et al : A fetal case of transient abnormal myelopoiesis with severe liver failure in Down syndrome : prognostic value of serum markers. Pediatr Hematol Oncol 21 : 273-278, 2004.
PubMed
13) Muramatsu H, et al : Low-dose cytosine arabinoside therapy for neonates with Down syndrome (DS) and transient leukemia (TL). ASH Annual Meeting Abstracts 116 : 1074, 2010.
 
14) 村松秀城, 菊地陽 : 一過性骨髄異常増殖症 (TAM) の治療戦略. 日小児血液会誌 25 : 179-184, 2011.
Medical*Online
P.23 掲載の参考文献
1) Herring WB, et al : Hereditary neutrophilia. Am J Med 56 : 729-734, 1974.
PubMed
2) Ward HN, Reinhard EH : Chronic idiopathic leukocytosis. Ann Intern Med 75 : 193-198, 1971.
PubMed
3) Hasegawa T, et al : Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils : up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 101 : 1164-1171, 2003.
PubMed
P.25 掲載の参考文献
1) Ward HN, Reinhard EH : Chronic idiopathic leukocytosis. Ann Intern Med 75 : 193-198, 1971.
PubMed
2) Hasegawa T, et al : Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils : up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 101 : 1164-1171, 2003.
PubMed
P.27 掲載の参考文献
1) 北川誠一 : 白血球. 標準生理学 (小澤瀞司ほか編), 第7版, p519-527, 医学書院, 2009.
 
2) Athens JW, et al : Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest 40 : 989-995, 1961.
PubMed
3) Boxer LA, et al : Diminished polymorphonuclear leukocyte adherence. Function dependent on release of cyclic AMP by endothelial cells after stimulation of beta-receptors by epinephrine. J Clin Invest 66 : 268-274, 1980.
PubMed
4) Dale DC : Neutropenia and neurophilia. In : Williams Hematology (ed by Lichtman MA, et al), 7th ed, p907-919, Mc Graw-Hill Medical Publishing Division, New York, 2006.
 
5) Patel KJ, et al : Pseudoleucocytosis and pseudothrombocytosis due to cryoglobulinaemia. J Clin Pathol 40 : 120-121, 1987.
PubMed
6) Lombarts AJPF, de Kieviet W : Recognition and prevention of pseudothrombocytopenia and concomitant pseudoleukocytosis. Am J Clin Pathol 89 : 634-639, 1988.
PubMed
P.29 掲載の参考文献
1) Dale DC, et al : Alternate-day prednisolone leukocyte kinetics and susceptibility to infections. N Engl J Med 291 : 1154-1158, 1974.
 
2) Fauci AS, et al : Glucocorticosteroid therapy : mechanism of action and clinical considerations. Ann Intern Med 84 : 304-315, 1976.
PubMed
3) MacGregor RR, et al : Inhibition of granulocyte adherence by ethanol, prednisone and aspirin measured in an assay system. N Engl J Med 291 : 642-646, 1974.
 
4) Shezen E, et al : Opposing effects of dexamethasone on the clonal growth of granulocyte and macrophage progenitor cells and on the phagocytic capability of mononuclear phagocytes at different stages of differentiation. J Cell Physiol 124 : 545-548, 1985.
PubMed
5) Cox G : Glucocorticoid treatment inhibits apoptosis in human neutrophils : separation of survival and activation outcomes. J Immunol 154 : 4719-4725, 1995.
PubMed
6) Haddy TB, Rana SR : Leukocyte response to administration of corticosteroid in healthy black children with neutropenia. J Pediatr 124 : 739-741, 1994.
PubMed
P.31 掲載の参考文献
1) Motoyoshi K : Biological activities and clinical application of M-CSF. Int J Hematol 67 : 109-122, 1998.
PubMed
2) Bailie KEM, et al : Granulocyte and granulocyte-macrophage colony-stimulating factors in cord and maternal serum at delivery. Pediatr Res 35 : 164-168, 1994.
 
3) Cincotta R, et al : Physiological neutrophilia of pregnancy is not associated with a rise in plasma granulocyte colony-stimulating factor (G-CSF). Am J Hematol 48 : 288, 1995.
PubMed
4) Uzumaki H, et al : Identification and characterization of receptors for G-CSF on human placenta and trophoblastic cells. Proc Natl Acad Sci USA 86 : 9323-9326, 1989
 
P.34 掲載の参考文献
1) Suzuki A, et al : Liver damage in patients with colony-stimulating factor-producing tumors. Am J Med 94 : 125-132, 1993.
PubMed
2) 佐藤勉ほか : Granulocyte colony stimulating factor (G-CSF) 産生腎癌. 臨床血液 38 : 1189-1192, 1997.
 
3) Sato K, et al : Granulocyte colony-stimulating factor produced by bladder carcinoma of a patient with leukemoid reaction did not affect proliferation of the tumor cells. J Urol 151 : 1687-1690, 1994.
PubMed
4) 畦西恭彦ほか : 好中球と好酸球の著しい増多を認めた結腸低分化腺癌の一例. 臨床血液 38 : 980, 1997.
 
5) Sawyers CL, et al : Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia. Cancer 69 : 1342-1346, 1992.
PubMed
6) Ohsaka A, et al : Alterations of effector cell molecule expression on neutrophils in granulocyte colony-stimulating factor producing tumour. Br J Haematol 91 : 571-574, 1995.
PubMed
7) Yuo A, et al : Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes : potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood 74 : 2144-2149, 1989.
PubMed
8) Kawakami M, et al : Levels of serum G-CSF in patients with infections. Blood 76 : 1962-1964, 1990.
PubMed
P.37 掲載の参考文献
1) 谷憲三朗 : 好中球減少症. 三輪血液病学, 第3版 (浅野茂隆ほか編), p1293-1298, 文光堂, 2006.
 
2) 厚生労働省 : 重篤副作用疾患別対応マニュアル 無顆粒球症, p9-14, 2007.
 
3) Watanebe N, et al : Antithyroid drug-induced hematopoietic damage : a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab 97 : E49-E53, 2012.
 
4) 田尻淳一ほか : 抗甲状腺剤による無顆粒球症 : 特に "Normal white blood cell count agranulocytosis" について. 日内分泌会誌 69 : 1013-1016, 1993.
 
5) Anderson F, et al : Systematic review : agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146 : 657-665, 2007.
 
P.40 掲載の参考文献
1) Papadaki HA, et al : Prevalence of chronic idiopathic neutropenia of adults among an apparently healthy population living on the island of Crete. Ann Hematol 78 : 293-297, 1999.
PubMed
2) Papadaki HA, et al : Non-immune chronic idiopathic neutropenia of adult : an overview. Eur J Haematol 67 : 35-44, 2001.
PubMed
3) Hirayama Y, et al : Cytokine mRNA expression of bone marrow stromal cells from patients with aplastic anemia and myelodysplastic syndrome. Br J Haematol 85 : 676-683, 1993.
PubMed
4) Kohgo Y, et al : Chronic idiopathic neutropenia associated with abnormal expression of granulocyte colony-stimulating factor mRNA of bone marrow stromal cells. Int J Hematol 59 : 177-180, 1994.
PubMed
5) Hirayama Y, et al : Recovery of neutrophil count by ganciclovir in patients with chronic idiopathic neutropenia associated with cytomegalovirus infection in bone marrow stromal cells. Int J Hematol 79 : 337-339, 2004.
PubMed
6) Hirayama Y, et al : Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 92 : 46-52, 1998.
PubMed
7) Palmblad J, et al : Chronic mild neutropenia in adults-relation to IgG3 deficiency and infection susceptibility. Blood 96 : 31b, 2000.
 
8) Koene HR, et al : Clinical value of soluble IgG Fc receptor type II in plasma from patients with chronic idiopathic neutropenia. Blood 91 : 3962-3966, 1998.
 
P.45 掲載の参考文献
1) Donadieu J, et al : Congenital neutropenia : diagnosis, molecular bases and patient management. Orphanet J Rare Dis 19 (6) : 26, 2011.
 
2) Parikh S, Bessler M : Recent insights into inherited bone marrow failure syndromes. Curr Opin Pediatr 24 : 23-32, 2012.
PubMed
3) Fioredda F, et al : Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Am J Hematol, 2011 doi : 10.1002/ajh. 22242. [Epub ahead of print]
 
4) Alter BP : Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program, p29-39, 2007.
 
5) Dale DC, et al : Severe chronic neutropenia : Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 72 : 82-93, 2003.
PubMed
6) CEREDIH : The French PID study group : The French national registry of primary immunodeficiency diseases. Clin Immunol 135 (2) : 264-272, 2010.
 
7) Klein C, et al : HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 39 : 86-92, 2007.
PubMed
8) Horwitz MS, et al : Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 109 : 1817-1824, 2007.
PubMed
9) Xia J, et al : Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. Br J Haematol 147 : 535-542, 2009.
PubMed
10) Bellanne-Chantelot C, et al : Mutations in the ELA2 gene correlate with more severe expression of neutropenia : a study of 81 patients from the French Neutropenia Register. Blood 103 (11) : 4119-4125, 2004.
PubMed
11) Boocock GR, et al : Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 33 (1) : 97-101, 2003.
PubMed
12) Rosenberg PS, et al ; Severe Chronic Neutropenia International Registry : The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107 (12) : 4628-4635, 2006.
PubMed
13) Germeshausen M, et al : Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis : Results of a long-term survey. Blood 109 (1) : 93-99, 2007.
PubMed
14) Connelly JA, et al : Hematopoietic stem cell transplantation for severe congenital neutropenia. Curr Opin Hematol 19 (1) : 44-51, 2012.
 
15) Oshima K, et al ; Hematopoietic Stem Cell Transplantation Committee of the Japanese Society of Pediatric Hematology : Hematopoietic stem cell transplantation in patients with severe congenital neutropenia : an analysis of 18 Japanese cases. Pediatr Transplant 14 (5) : 657-663, 2010.
PubMed
P.49 掲載の参考文献
1) Dror Y, et al : Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann N Y Acad Sci 1242 : 40-55, 2011.
PubMed
2) Burroughs L, et al : Shwachman-Diamond syndrome : a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol Oncol Clin North Am 23 (2) : 233-248, 2009.
PubMed
3) Liu JM, et al : Sixth International Congress on Shwachman-Diamond syndrome : from patients to genes and back. Ann N Y Acad Sci 1242 : 26-39, 2011.
PubMed
4) Shwachman H, et al : The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr 65 : 645-663, 1964.
PubMed
5) Boocock GR, et al : Mutationsin SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 33 (1) : 97-101, 2003.
 
6) Goobie S, et al : Shwachman-Diamond syndrome with exocrine pancreatic dysfunction and bone marrow failure maps to the centromeric region of chromosome 7. Am J Hum Genet 68 (4) : 1048-1054, 2001.
 
7) Menne TF, et al : The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet 39 (4) : 486-495, 2007.
PubMed
8) Narla A, Ebert BL : Ribosomopathies : human disorders of ribosome dysfunction. Blood 115 (16) : 3196-3205, 2010.
PubMed
9) Shenoy N, et al : Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol 5 (1) : 32, 2012.
 
10) Donadieu J, et al : Classification and risk factors of hematological complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. Haematologica 97 (9) : 1312-1319, 2012.
 
11) Hashmi SK, et al : Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype-phenotype correlation. Clin Genet 79 (5) : 448-458, 2011.
PubMed
12) Cesaro S, et al ; EBMT Severe Aplastic Anaemia and Paediatric Diseases Working Party : Haematopoietic stem cell transplantation for Shwachman-Diamond disease : a study from the European Group for blood and marrow transplantation. Br J Haematol 131 (2) : 231-236, 2005.
 
13) Donadieu J, et al : Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome : experience of the French neutropenia registry. Bone Marrow Transplant 36 (9) : 787-792, 2005.
PubMed
14) Bhatla D, et al : Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant 42 (3) : 159-165, 2008.
PubMed
15) Kerr EN, et al : The behavioral phenotype of school-age children with shwachman diamond syndrome indicates neurocognitive dysfunction with loss of Shwachman-Bodian-Diamond syndrome gene function. J Pediatr 156 (3) : 433-438, 2010.
PubMed
P.53 掲載の参考文献
1) Bux J : Human neutrophil alloantigens. Vox Sang 94 : 277-285, 2008.
PubMed
2) Maheshwari A, et al : Immune neutropenia in the neonate. Adv Pediatr 49 : 317-339, 2002.
PubMed
3) Han TH, et al : Granulocyte Antibodies in Korean Neonates with Neutropenia. J Korean Med Sci 21 : 627-632, 2006.
PubMed
4) Zupanska B, et al : The risk of antibody formation against HNA1a and HNA1b granulocyte antigens during pregnancy and its relation to neonatal neutropenia. Transfus Med 11 : 377-382, 2001.
PubMed
5) Matsuhashi M, et al : The frequencies of human neutrophil alloantigens among the Japanese population. Tissue Antigens 80 : 336-340, 2012.
PubMed
6) 小林正夫 : 小児好中球減少症. 日児誌 109 : 614-622, 2005.
 
7) 中村和洋ほか : 抗好中球抗体と乳幼児自己免疫性好中球減少症. 日小児血液会誌 18 : 17-22, 2004.
 
8) Tomicic M, et al : Alloimmune neonatal neutropenia due to anti-HNA-2a alloimmunization with severe and prolonged neutropenia but mild clinicalcourse : two case reports. Arch Med Res 38 : 792-796, 2007.
 
9) Fung YL, et al : Alloimmune neonatal neutropenia linked to anti-HNA-4a. Transfus Med 13 : 49-52, 2003.
PubMed
10) Porcelijn L, et al : Neonatal alloimmune neutropenia due to immunoglobulin G antibodies against human neutrophil antigen-5a. Transfusion 51 : 574-577, 2011.
PubMed
11) 中村和洋, 小林正夫 : 新生児の好中球減少症. Jpn J Obstet Gynecol Neonatal Hematol 18 : 149-153, 2009.
 
12) Maheshwari A, et al : Resistance to recombinant human granulocyte colony-stimulating factor in neonatal alloimmune neutropenia associated with anti-human neutrophil antigen-2a (NBI) antibodies. Pediatrics 109 : e64, 2002.
 
13) Desenfants A, et al : Intravenous immunoglobulins for neonatal alloimmune neutropenia refractory to recombinant human granulocyte colony-stimulating factor. Am J Perinatol 28 : 461-466, 2011.
PubMed
P.56 掲載の参考文献
1) Bux J, et al : Human neutrophil alloantigens. Vox Sang 94 : 277-285, 2008.
PubMed
2) Nakamura K, et al : Deficiency of regulatory T cells in children with autoimmune neutropenia. Br J Haematol 145 : 642-647, 2009.
PubMed
3) Kobayashi M, et al : Autoimmune neutropenia in infancy due to anti-NA1 antibody : detection of antibody with immunofluorescence and agglutination test. Pediatr Res 26 : 246-249, 1989.
PubMed
4) Bux J, et al : Diagnosis and clinical course of autoimmune neutropenia in infancy : analysis of 240 cases. Blood 91 : 181-186, 1998.
PubMed
5) 浅井康一ほか : 当科で経験した乳幼児自己免疫性好中球減少症の5例. 小児科臨床 62 : 1667-1672, 2009.
Medical*Online
6) 藤木敦ほか : 抗好中球抗体により診断された8例の乳幼児自己免疫性好中球減少症. 松仁会医学誌 47 : 113-119, 2008.
Medical*Online
7) Kobayashi M, et al : Significance of the detection of antineutrophil antibodies in children with chronic neutropenia. Blood 99 : 3468-3471, 2002.
PubMed
8) Kobayashi M, et al : Efficacy of prophylactic use of trimethoprim-sulfamethoxazole in autoimmune neutropenia in infancy. J Pediatr Hematol Oncol 25 : 553-557, 2003.
PubMed
P.59 掲載の参考文献
1) Dale DC, et al : Cyclic neutropenia. Semin Hematol 39 : 89-94, 2002.
PubMed
2) Horwitz MS, et al : Neutrophil elastase in cyclic and severe congenital neutropenia. Blood 109 : 1817-1824, 2007.
PubMed
3) 溝口洋子, 小林正夫 : 好中球減少症. 小児科 51 : 985-994, 2010.
 
4) Horwitz M, et al : Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet 23 : 433-436, 1999.
PubMed
5) Borregaard N, et al : Regulation of human neutrophil granule protein expression. Curr Opin Hematol 8 : 23-27, 2001.
PubMed
6) Dale DC, et al : Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 96 : 2317-2322, 2000.
PubMed
7) Bellanne-Chantelot C, et al : Mutations in the ELA2 gene correlate with more severe expression of neutropenia : a study of 81 patients from the French Neutropenia Register. Blood 163 : 4119-4125, 2004.
 
8) Aprikyan AA, Dale DC : Mutations in the neutrophil elastase gene in cyclic and congenital neutropenia. Curr Opin Immunol 13 : 535-538, 2001.
PubMed
9) Horwitz M, et al : Hereditary neutropenia : dogs explain human neutrophil elastase mutations. Trends Mol Med 10 : 163-170, 2004.
PubMed
10) Benson KF, et al : Mutations associated with neutropenia in dogs and humans disrupt intracellular transport of neutrophil elastase. Nat Genet 35 : 90-96, 2003.
PubMed
11) Newburger PE, et al : Cyclic neutropenia and severe congenital neutropenia in patients with a shared ELANE mutation and paternal haplotype : evidence for phenotype determination by modifying genes. Pediatr Blood Cancer 55 : 314-317, 2010.
PubMed
12) Dale DC, et al : Severe chronic neutropenia : treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 72 : 82-93, 2003.
PubMed
P.63 掲載の参考文献
1) Shubitz KW : Qualitative disorders of leukocytes. In : Wintrobe's Clinical Hematology, 12th ed (ed by Greer JP, et al), p1548-1549, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
2) Pelger K : Demonstratie van een paar zeldzaam voorkomende typen van bloedlichampjes en bespreking der patienten. Ned Tijdschr Geneesk 72 : 1178, 1928.
 
3) Huet GJ : Familial anomaly of leukocytes. Ned Tijdschr Geneesk 75 : 5956-5959, 1931.
 
4) Colella R, Hollensead SC : Understanding and recognizing the Pelger-Huet anomaly. Am J Clin Pathol 137 : 358-366, 2012.
PubMed
5) Hoffmann K, et al : Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huet anomaly). Nat Genet 31 : 410-414, 2002.
PubMed
6) Speeckaert MM, et al : Pelger-Huet anomaly : a critical review of the literature. Acta Haematol 121 : 202-206, 2009.
PubMed
7) Constantino BT : Pelger-Huet anomaly-morphology, mechanism, and significance in the peripheral blood film. Lab Medicine 36 : 103-107, 2005.
 
8) Djaldetti M : Ultrastructural features of the blood cells in a patient with Pelger-Huet anomaly. Am J Clin Pathol 65 : 942-947, 1976.
 
9) Johnson CA, et al : Functional and metabolic studies of polymorphonuclear leukocytes in the congenital Pelger-Huetanomaly. Blood 55 : 466-469, 1980.
PubMed
10) Park BH, et al : Defective chemotactic migration of polymorphonuclear leukocytes in Pelger-Huetanomaly. Proc Soc Exp Biol Med 155 : 51-54, 1977.
PubMed
11) 栗山一孝 : 好中球の形態異常, 三輪血液病学, 第3版 (三輪史朗ほか編), p1287-1293, 文光堂, 2006.
 
12) Konttinen JM : Recurrent attacks of abdominal pain and fever with familial segmentation arrest of granulocytes. Blood 43 : 871-874, 1974.
 
13) Vaya A, Aznar J : Incidence of infections in patients with Pelger-Huet leukocyte anomaly. Br J Haematol 46 : 621-622, 1980.
PubMed
14) Oosterwijk JC, et al : Congenital abnormalities reported in Pelger-Huet homozygosity as compared to Greenberg/HEM dysplasia : highly variable expression of allelic phenotypes. J Med Genet 40 : 937-941, 2003.
PubMed
15) Teshima T, et al : Effect of G-CSF, GM-CSF, and IL-5 on nuclear segmentation of neutrophils and eosinophils in congenital or acquired Pelger-Huet anomaly. Exp Hematol 19 : 322-325, 1991.
PubMed
P.67 掲載の参考文献
1) Shubitz KW : Qualitative disorders of leukocytes. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), 12th ed, p1548-1550, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
2) May R : Leukozyteneinschlusse. Dtsch Arch Klin Med 96 : 1-6, 1909.
 
3) Hegglin R : Simultaneous constitutional changes in neutrophils and platelets. Helv Med Acta 12 : 439-440, 1945.
PubMed
4) Martignetti JA : The gene for May-Hegglin anomaly localizes to a < 1-Mb region on chromosome 22q12.3-13.1. Am J Hum Genet 66 : 1449-1454, 2000.
PubMed
5) Seri M, et al : Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nat Genet 26 : 103-105, 2000.
PubMed
6) Pecci A, et al : Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum Mol Genet 14 : 3169-3178, 2005.
PubMed
7) Kunishima S, et al : Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanismsin MYH9 disorders. Blood 111 : 3015-3023, 2008.
 
8) Kunishima S, et al : Accumulation MYH9 mRNA atleukocyteinclusionbodiesin MYH9 disorders. Eur J Haematol 81 : 325-326, 2008.
PubMed
9) Mhawech P, Saleem A : Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol 113 : 176-190, 2000.
PubMed
10) Noris P, et al : Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly) : clinical and laboratory findings. Am J Med 104 : 355-360, 1998.
PubMed
11) Wassmuth DR, et al : May-Hegglin anomaly. Hereditary affection of granulocytes and platelets. JAMA 2 : 737-740, 1963.
 
12) Pajor A, et al : May-Hegglin anomaly and pregnancy. Eur J Obstet Gynecol Reprod Biol 85 : 229-231, 1999.
PubMed
13) Greinacher A, et al : Sebastian platelet syndrome : a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 61 : 282-288, 1990.
PubMed
14) Pecci A, et al : Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 116 : 5832-5837, 2010.
PubMed
15) Gropper S, et al : A patient with Fechtner syndrome successfully treated with romiplostim. Thromb Haemost 107 : 590-591, 2012.
 
P.69 掲載の参考文献
1) Alder A : Uber konstitutionell bedingte Granultions-vernderungen der Leukozyten. Dtsch Arch Klin Med 183 : 372-378, 1939.
 
2) Reilly WA : The granules in leukocytes in gargoylism. Am J Dis Child 62 : 489-491, 1941.
 
3) Athens JW : Qualitative disorders of leukocytes. In : Wintrobe's Clinical Hematology, 12th ed (ed by Greer JP, et al), p1548-1549, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
4) 栗山一孝 : 好中球の形態異常. 血液学, 第3版 (三輪史朗ほか編), p1287-1293, 文光堂, 2006.
 
5) Meikle PJ, et al : Prevalence of lysosomal storage disorders. JAMA 281 : 249-254 1999.
PubMed
6) Wilson PJ, et al : Sequence of the human iduronate-2-surfactase (IDS) gene. Genomics 17 : 773-775, 1993.
PubMed
7) Yogalingam G, et al : Molecular genetics of mucopolysaccharidosis type IIIA and IIIB. Diagnostic, clinical, and biological implications. Hum Mutat 18 : 264-281, 2001.
PubMed
8) Tomatsu S, et al : Mucopolysaccharidosis type IVA (Morquio A disease) : clinical review and current treatment. Curr Pharm Biotechnol 12 : 931-945, 2011.
PubMed
9) Giugliani R, et al : Management guidelines for mucopolysaccharidosis VI. Pediatrics 120 : 405-418, 2007.
PubMed
10) Tomatsu S, et al : Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome). Hum Mutat 30 : 511-519, 2009.
PubMed
11) Peterson L, et al : Mucopolysaccharidosistype VII : a morphologic cytochemical, and ultra-structural study of the blood and bone marrow. Am J CIin Pathol 78 : 544-548, 1982.
 
12) Levy LA, et al : Ultra structures of Reilly bodies (metachromatic granules) in the Maroteaux-Lamy syndrome (mucopolysaccharidosis VI) : a histochemical study. Am J Clin Pathol 73 : 416-422, 1980.
 
13) Grgic Z, Kalafatic Z : Three cases of in complete Alder's granulation anomaly. Schweiz Med Wochenschr 88 : 994-995, 1958.
 
14) Pearson HA, Lorincz AE : A characteristic bone marrow finding in the Hurler syndrome. Pediatrics 34 : 280-282, 1964.
PubMed
15) Markesbery WR, et al : Mucopolysaccharidoses : Ultra structure of leukocyte inclusions. Ann Neurol 8 : 332-336, 1980.
 
16) Gitzelmann R, et al : Unusually mild course of β-glucuronidase deficiency in two brothers (mucopolysaccharidosis VII). Helv Paediatr Acta 33 : 413-428, 1978.
 
17) Meikle PJ, et al : Newborn screening for lysosomal storage disorders : clinical evaluation of a two-tier strategy. Pediatrics 114 : 909-916, 2004.
PubMed
18) Meikle PJ, et al : Newborn screening for lysosomal storage disorders. Mol Genet Metab 88 : 307-314, 2006.
PubMed
19) Valayannopoulos V, et al : Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 50 (Suppl 5) : v49-59, 2011.
 
P.73 掲載の参考文献
1) Kaplan J, et al : Chediak-Higashi syndrome. Curr Opin Hematol 15 : 22-29, 2008.
PubMed
2) 東音高 : Chediak-Higashi症候群. 日本臨牀 35 (増刊号 : 症候群 1977) : 928-929, 1977.
 
3) Shubitz K M : Qualitative disorders of leukocytes. In : Wintrobe's Clinical Hematology, 12th ed (ed by Greer JP, et al), p1550-1552, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
4) 安井耕三 : 先天性遺伝性食細胞機能異常症のmolecular basisについての最近の知見 Chediak-Higashi症候群の遺伝子異常を中心として. 日臨免疫会誌 20 : 145-151, 1997.
 
5) Barbosa MDFS, et al : Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 382 : 262-265, 1996.
 
6) Perou CM, et al : Identification of the murine beige gene by YAC complementation and positional cloning. Nat Ganet 13 : 303-308, 1996.
 
7) Nagle DL, et al : Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Ganet 14 : 307-311, 1996.
 
8) 石井榮一ほか : 分泌顆粒の異常と血液疾患. 臨床血液 49 : 225-233, 2008.
 
9) 宇山栄一郎ほか : Chediak-Higashi症候群成人例の神経学的検討 parkinsonismと著明な脳脊髄萎縮に注目して. 臨床神経学 31 : 24-31, 1991.
 
10) Amichai B, et al : Picture of month. Chediak-Higashi syndrome. Arch Pediatr Adolesc Med 151 : 425-426, 1997.
PubMed
11) 湯尾明 : 機能異常 好中球の異常. 三輪血液病学, 第3版, p1305-1308, 文光堂, 2006.
 
12) 鈴木信寛 : 血球貪食症候群. 臨床血液 49 : 159-168, 2008.
 
13) Eapen M, et al : Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplantation 39 : 411-415, 2007.
PubMed
14) Tardieu M, et al : Progressive neurologic dysfunctions 20 years after allogenic bone marrow transplantation for Chediak-Higashi syndrome. Blood 106 : 40-42, 2005.
PubMed
15) Haddad BE, et al : Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation : report of 10 cases. Blood 85 : 3328-3333, 1995.
PubMed
P.77 掲載の参考文献
1) Nauseef WM : Contributions myeloperoxidase to proinflammatory events : more than an antibial system. Int J Hematol 74 : 125-133, 2001.
PubMed
2) Lehrer RI, Cline MJ : Leukocyte myeloperoxidase deficiency and disseminated candidiasis : the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 48 : 1478-1488, 1969.
PubMed
3) Becker R, Pfluger KH : Myeloperoxidase deficiency : an epidemiological study and flow-cytometric detection of other granular enzymes in myeloperoxidase-deficient subjects. Ann Hematol 69 : 199-203, 1994.
PubMed
4) Nunoi H, et al : Prevalence of inherited myeloperoxidase deficiency in Japan. Microbiol Immunol 47 : 527-531, 2003.
PubMed
5) Suzuki K : Anti-neutrophile cytoplasmic antibody MPO-ANCA related with disease activity of vasculitis. Jpn Clin Immunol 29 : 94-101, 2006.
 
6) Skubitz KM : Qualitative disorders of leukocytes. In : Wintrobe's Clinical Hematology, 10th ed, Vol 2 (ed by Lee GR, et al), p1899-1900, Williams & Wilkins, Philadelphia, 1999.
 
7) Klebanoff SJ : Myeloperoxidase. Proc Assoc Am Physicians 111 : 383-389, 1999.
PubMed
8) Tobler A, et al : Regulation of gene expression of myeloperoxidase during myeloid differentiation. J Cell Physiol 136 : 215-225, 1988.
PubMed
9) Morishita K, et al : Chromosomal gene structure of human myeloperoxidase and regulation of its expression by granulocyte colony-stimulating factor. J Biol Chem 262 : 15208-15213, 1987.
PubMed
10) Nauseef WM, et al : Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase. J Biol Chem 271 : 9546-9549, 1996.
PubMed
11) DeLeo FR, et al : A novel form of hereditary myeloperoxidase deficiency linked to endoplasmic reticulum/proteasome degradation. J Clin Invest 101 : 2900-2909, 1998.
PubMed
12) Nauseef WM, et al : Pattern of inheritance in hereditary myeloperoxidase deficiency associated with the R569W missense mutation. J Leukoc Biol 63 : 264-269, 1998.
PubMed
13) Petrides PE : Molecular genetics of peroxidase deficiency. J Mol Med 76 : 688-698, 1998.
PubMed
14) Ishida-Okawara A, et al : Contribution of myeloperoxidase to coronary artery vasculitis associated with MPO-ANCA production. Inflammation 25 : 381-387, 2001.
PubMed
15) Fujii A, et al : Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophile cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol 53 : 242-252, 2000.
PubMed
P.80 掲載の参考文献
1) Fierer J, Finley F : Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver. J Clin Invest 63 : 912-921, 1979.
 
2) Trevisani F, et al : Impaired tuftsin activity in cirrhosis : relationship with splenic function and clinical outcome. Gut 50 : 707-712, 2002.
PubMed
3) Konopinska D, et al : Solid-phase synthesis of L-threonyl-L-glutamyl-L-prolyl-L-arginine, as the mutant analog of tuftsin. Arch Immunol Ther Exp 29 : 851-855, 1981.
PubMed
4) Constantopoulos A, et al : Defective phagocytosis due to tuftsin deficiency in splenectomized subjects. Am J Dis Child 125 : 663-665, 1973.
PubMed
5) Spirer Z, et al : Decreased tuftsin concentrations in patients who have undergone splenectomy. Br Med J 2 : 1574-1576, 1977.
PubMed
P.84 掲載の参考文献
1) Borregaard N, et al : Granules of the human neutrophilic polymorphonuclear leukocytes. Blood 89 : 3503-3521, 1997.
PubMed
2) 小宮山淳 : 好中球特殊顆粒欠損症. 好中球機能低下と機能亢進 (笹田昌孝編), p145-157, 医薬ジャーナル社, 1998.
 
3) Strauss RG, et al : An abnormality of neutrophil morphology with impaired function. N Engl J Med 290 : 478-484, 1974.
 
4) Komiyama A, et al : Abnormal neutrophil maturation in a neutrophil defect with morphologic abnormality and impaired function. J Pediatr 94 : 19-25, 1979.
 
5) Tamura A, et al : A marked decrease in defensin mRNA in the only case of congenital neutrophil specific granule deficiency reported in Japan. Int J Hematol 59 : 137-142, 1994.
PubMed
6) Lekstrom-Himes J, et al : Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein ε. J Exp Med 189 : 1847-1852, 1999.
 
P.87 掲載の参考文献
1) Boxer LA, et al : Neutrophil actin dysfunction and abnormal neutrophil behavior. N Engl J Med 291 : 1093-1099, 1974.
PubMed
2) Nunoi H, et al : A heterozygous mutation of beta-actin associated with neutrophil dysfunction and recurrent infection. Proc Natl Acad Sci USA 96 : 8693-8698, 1999.
PubMed
3) Coates TD, et al : An inherited defect of neutrophil motility and microfilamentous cytoskeleton associated with abnormalities in 47-Kd and 89-Kd proteins. Blood 78 : 1338-1346, 1991.
PubMed
4) Ambruso DR, et al : Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci USA 97 : 4654-4659, 2000.
PubMed
5) Kurkchubasche AG, et al : Clinical features of a human Rac2 mutation : a complex neutrophil dysfunction disease. J Pediatr 139 : 141-147, 2001.
 
6) Roos D, et al : A novel syndrome of severe neutrophil dysfunction : unresponsiveness confined to chemotaxin-induced functions. Blood 81 : 2735-2743, 1993.
PubMed
7) Nunoi H, et al : Neutrophil cytoskeletal disease. Int J Hematol 74 : 119-124, 2001.
PubMed
8) 岡村精一, 仁保喜之 : 好中球アクチン機能異常症. 別冊日本臨牀 血液症候群 (II), p73-75, 日本臨牀社, 1998.
 
9) Nishikimi A, et al : Sequential regulation of DOCK2 dynamics by two phospholipids during neutrophil chemotaxis. Science 324 : 384-387, 2009.
PubMed
10) Southwick FS, et al : Neutrophil actin dysfunction is a genetic disorder associated with partial impairment of neutrophil actin assembly in three family members. J Clin Invest 82 : 1525-1531, 1988.
PubMed
11) Drummond DR, et al : Characterisation of missense mutations in the Act88F gene of Drosophila melanogaster. Mol Gen Genet 226 : 70-80, 1991.
PubMed
12) Howard T, et al : The 47-kD protein in creased in neutrophil actin dysfunction with 47- and 89-kD protein abnormalities is lymphocyte-specific protein. Blood 83 : 231-241, 1994.
 
13) Packman CH, Lichtman MA : Activation of neutrophils : measurement of actin conformational changes by flow cytometry. Blood Cells 16 : 193-207, 1990.
PubMed
14) Vindenes HA, Bjerknes R : Impaired actin polymerization and depolymerization in neutrophils from patients with thermal injury. Burns 23 : 131-136, 1997.
PubMed
15) Carulli G, et al : Actin polymerization in neutrophils from patients affected by myelodysplastic syndromes-a flow cytometric study. Leuk Res 21 : 513-518, 1997.
PubMed
P.92 掲載の参考文献
1) Davis SD, et al : Job's Syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet 1 : 1013-1015, 1966.
PubMed
2) Buckley RH, et al : Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 49 : 59-70, 1972.
PubMed
3) Robinson WS, et al : Case report of a young child with disseminated histoplasmosis and review of hyper immunoglobulin e syndrome (HIES). Clin Mol Allergy 9 : 14, 2011.
 
4) Minegishi Y, Karasuyama H : Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome : lessons from a primary immunodeficiency. Int Immunol 21 : 105-112, 2009.
PubMed
5) Minegishi Y, et al : Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448 : 1058-1062, 2007.
PubMed
6) Holland SM, et al : STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357 : 1608-1619, 2007.
PubMed
7) Minegishi Y, et al : Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 : 745-755, 2006.
PubMed
8) Engelhardt KR, et al : Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 124 : 1289-1302, 2009.
PubMed
9) Milner JD, et al : Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452 : 773-776, 2008.
PubMed
10) Heimall J, et al : Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol 38 : 32-38, 2010.
PubMed
11) Hill HR : The syndrome of hyperimmunoglobulinemia E and recurrent infections. Am J Dis Child 136 : 767-771, 1982.
PubMed
12) Borges WG, et al : Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr 136 : 176-180, 2000.
PubMed
13) Szczawinska-Poplonyk A, et al : The hyperimmunoglobulin E syndrome-clinical manifestation diversity in primary immune deficiency. Orphanet J Rare Dis 6 : 76, 2011.
PubMed
14) Woellner C, et al : Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 125 : 424-432, 2010.
PubMed
15) Goussetis E, et al : Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol 126 : 392-394, 2010.
PubMed
P.94 掲載の参考文献
1) Miller ME, et al : Lazy-leucocyte syndrome. A new disorder of neutrophil function. Lancet 1 (7701) : 665-669, 1971.
PubMed
2) Deubelbeiss KA, et al : Neutropenia in disorders of the neutrophil motility. Schweiz Med Wochenschr 105 (47) : 1591-1592, 1975.
PubMed
3) Constantopoulos A, et al : Lazy-leukocyte syndrome. A case report. J Pediatr 87 (6 Pt 1) : 945-946, 1975.
 
4) Pinkerton PH, et al : Lazy leucocyte syndrome-disorder of the granulocyte membrane? J Clin Pathol 31 (4) : 300-308, 1978.
PubMed
5) Patrone F, et al : Lazy leukocyte syndrome. Blut 39 (4) : 265-269, 1979.
PubMed
6) Yoda S, et al : Transient 'lazy-leukocyte' syndrome during infancy. Am J Dis Child 134 (5) : 467-469, 1980.
PubMed
7) Foroozanfar N, et al : Persistent mandibular infection in three patients with lazy and incompetent phagocyte syndromes. J Maxillofac Surg 11 (3) : 124-127, 1983.
PubMed
8) Yasui K, et al : 3 cases of lazy-leukocyte syndrome. Rinsho Ketsueki 24 (8) : 1086-1091, 1983.
PubMed
9) Goldman JM, et al : Lazy leukocyte syndrome. J R Soc Med 77 (2) : 140-141, 1984.
PubMed
10) Aggarwal J, et al : Lazy leukocyte syndrome in a black infant. J Natl Med Assoc 77 (11) : 928-929, 1985.
 
11) 小池正, 柴田昭 : なまけもの白血球症候群. 別冊日本臨牀 血液症候群 II, p79-80, 日本臨牀社, 1998.
 
12) Boogaerts MA, et al : Invitro modulation of normal and diseased human neutrophil function by pentoxifylline. Blut 61 (2-3) : 60-65, 1990.
 
P.98 掲載の参考文献
1) Ishibashi F, et al : Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox deficiency. Hum Genet 106 : 473-481, 2000.
PubMed
2) Arai T, et al : Copy number variations due to large genomic deletion in X-linked chronic granulomatous disease. PloS One 7 : e27782, 2012.
 
3) Hatanaka E, et al : Hyperresponsiveness of neutrophils from gp 91phox deficient patients to lipopolysaccharide and serum amyloid A. Immunol Lett 94 : 43-46, 2004.
PubMed
4) Lekstrom-Himes JA, et al : Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol 174 : 411-417, 2005.
PubMed
5) Fernandez-Boyanapalli RF, et al : Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood 113 : 2047-2055, 2009.
PubMed
6) van de Veerdonk FL, et al : Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Nat Acad Sci USA 107 : 3030-3033, 2010.
PubMed
7) Meissner F, et al : Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 116 : 1570-1573, 2010.
PubMed
8) Marciano BE, et al : Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 114 : 462-468, 2004.
PubMed
9) Marks DJ, et al : Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol 104 : 117-124, 2009.
PubMed
10) Winkelstein JA, et al : Chronic granulomatous disease. Report on an national registry of 368 patients. Medicine (Baltimore) 79 : 155-169, 2000.
 
11) Gallin JI, et al : Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 348 : 2416-2422, 2003.
PubMed
12) 水上智之 : 慢性肉芽腫症. 臨床検査 53 : 593-597, 2009.
 
13) Ott MG, et al : Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12 : 401-409, 2006.
PubMed
14) Stein S, et al : Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16 : 198-204, 2010.
PubMed
15) Grez M, et al : Gene therapy of chronic granulomatous disease : the engraftment dilemma. Mol Ther 19 : 28-35, 2011
 
P.100 掲載の参考文献
1) Davidson WM, et al : Giant neutrophil leucocytes : An inherited anomaly. Br J Haematol 6 : 339-343, 1960.
 
2) Davidson WM : Inherited variations in leukocytes. Semin Hematol 5 : 255-274, 1968.
PubMed
3) Athens JW : Qualitative disorders of leukocytes. In : Wintrobe's Clinical Hematology, 9th ed (ed by Lee GR, et al), p1618, Lea & Febiger Ltd, Philadelphia, 1993.
 
4) Bessis M : Living blood cells and their ultrastructure. Springer-Verlag, New York, 1973.
 
5) Fujita N, et al : Giant neutrophils derived from tetraploid leukemic clone in an acute myeloblastic leukemia : cytofluorometric study. Acta Haematol 84 : 45-48, 1990.
 
6) Campbell LJ, et al : Marrow proliferation and the appearance of giant neutrophils in response to recombinant human granulocyte colony stimulating factor (rhG-CSF). Br J Haematol 80 : 298-304, 1992.
PubMed
P.103 掲載の参考文献
1) Jordans GH : The familial occurrence of fat-containing vacuoles in the leukocytes diagnosed in two brothers suffering from dystrophia musculorum progressiva (ERB.). Acta Med Scand 145 : 419-423, 1953.
PubMed
2) Lefevre C, et al : Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 69 : 1002-1012, 2001.
PubMed
3) Fischer J, et al : The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 39 : 28-30, 2007.
PubMed
4) Angelini C, et al : Multisystem triglyceride storage disorder with impaired long-chain fatty acid oxidation. Ann Neurol 7 : 5-10, 1980.
PubMed
5) Williams ML, et al : Ichthyosis and neutral lipid storage disease. Am J Med Genet 20 : 711-726, 1985.
PubMed
6) Hasebe M : A case of Jordans' anomaly. Rinsho Ketsueki 24 (5) : 553-558, 1983.
PubMed
7) Nagai H, et al : Specific cardiomyopathy caused by multisystemic lipid storage in Jordans' anomaly. Intern Med 42 (7) : 587-590, 2003.
PubMed
8) Fischer J, et al : Two new loci for autosomal recessive ichthyosis on chromosomes 3p21 and 19p12-q12 and evidence for further genetic heterogeneity. Am J Hum Genet 66 : 904-913, 2000.
PubMed
9) Brasaemle DL : Thematic review series : adipocyte biology. The perilipin family of structural lipid droplet proteins : stabilization of lipid droplets and control of lipolysis. J Lipid Res 48 (12) : 2547-2559, 2007.
PubMed
10) Olsen RKJ, et al : ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130 : 2045-2054, 2007.
 
11) Taroni F, et al : Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci USA 89 : 8429-8433, 1992.
PubMed
12) Cakir M, et al : Liver cirrhosis in an infant with Chanarin-Dorfman syndrome caused by a novel splice-site mutation in ABHD5. Acta Paediatr 99 (10) : 1592-1594, 2010.
 
13) Israeli S, et al : Beneficial effect of acitretin in Chanarin-Dorfman syndrome. Clin Exp Dermatol 37 (1) : 31-33, 2012.
PubMed
P.108 掲載の参考文献
1) 小宮山淳 (編) : 好中球機能異常症. 小児の血液疾患, p86-102, 永井書店, 1994.
 
2) Dale DC, et al : The phagocytes : neutrophils and monocytes. Blood 112 : 935-945, 2008.
PubMed
3) Fletcher J, et al : Acquired abnormalities of polymor phonuclear neutrophil function. Blood Rev 4 : 103-110, 1990.
 
4) Engelich G, et al : Acquired disorders of phagocyte function complicating medical and surgical illness. Clin Infect Dis 33 : 2040-2048, 2001.
PubMed
5) Fiedler K, et al : Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood 117 : 1329-1339, 2011.
 
6) Walr and S, et al : In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions. J Leuk Biol 76 : 1104-1110, 2004.
 
7) Alba-Loureiro TC, et al : Diabetes causes marked changes in function and metabolism of rat neutrophils. J Endocrinol 188 : 295-303, 2006.
PubMed
8) Kato S, et al : Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3 : 1526-1533, 2008.
PubMed
9) Sherry B, et al : Dysregulated chemokine receptor expression and chemokine-mediated cell trafficking in pediatric patients with ESRD. Clin J Am Soc Nephrol 3 : 397-406, 2008.
PubMed
10) Haag-Weber M, Horl WH : Dysfunction of polymorphonuclear leukocytes in uremia. Semin Nephrol 16 : 192-201, 1996.
PubMed
11) Wynn JL, Levy O : Role of innate host defenses in susceptibility to early onset neonatal sepsis. Clin Perinatol 37 : 307-337, 2010.
PubMed
12) Levy O, et al : Impaired innate immunity in the newborn : newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 104 : 1327-1333, 1999.
PubMed
13) McNamee LA, Harmsen AG : Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 74 : 6707-6721, 2006.
PubMed
14) Cooper JAD Jr, et al : Effects of influenza A nucleoprotein on polymorphonuclear neutrophil function. J Infect Dis 173 : 279-284, 1996
 
P.111 掲載の参考文献
1) Craddock PR, et al : Acquired phagocyte dysfunction. A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med 290 : 1403-1407, 1974.
PubMed
2) Kiersztejn M, et al : On the mechanisms of impaired phagocytosis in phosphate depletion. J Am Soc Nephrol 2 : 1484-1489, 1992.
PubMed
3) Kawasaki C, et al : Lidocaine enhances apoptosis and suppresses mitochondrial functions of human neutrophil in vitro. J Trauma 68 (2) : 401-408, 2010.
PubMed
4) Theander S, et al : Granule-specific ATP requirements for Ca2+-induced exocytosis in human neutrophils. Evidence for substantial ATP-independent release. J Cell Sci 115 : 2975-2983, 2002.
PubMed
P.113 掲載の参考文献
1) Cunningham JM, et al : Historical perspective and clinical implication of the Pelger-Huet cell. Am J Hematol 84 : 116-119, 2009.
PubMed
2) 朝長万左男 : 好中球の Pelger-Huet核異常をめぐって. 臨床病理 53 : 54-60, 2005.
Medical*Online
3) Kuriyama K, et al : Diagnostic significance of detecting pseudo-Pelger-Huet anomalies and micromegakaryocytes in myelodysplastic syndrome. Br J Haematol 63 : 665-669, 1986.
PubMed
4) 不応性貧血 (骨髄異形成症候群) の形態学的診断基準作成のためのワーキンググループ. 朝長万左男, 松田晃 (編) : 不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究 (平成19年度) (主任研究者小澤敬也), 2008.
 
5) Wang E, et al : Pseudo-Pelger-Huet anomaly induced by medications. A clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huet anomaly. Am J Clin Pathol 135 : 291-303, 2011.
PubMed
6) Dusse LMS, et al : Acquired Pelger-Huet ; what does it really mean? Clin Chim Acta 411 : 1587-1590, 2010.
PubMed
P.115 掲載の参考文献
1) Itoga T, Laszlo J : Dohle bodies and other granulocytic alterations during chemotherapy with cyclophosphamide. Blood 20 : 668-674, 1962.
PubMed
2) Balduini CL, et al : Recent advances in the understanding and management of MYH-9-related inherited thrombocytopenias. Br J Haematol 154 : 161-174, 2011.
 
3) Cawley JC, Hayhoe FG : The inclusions of the May-Hegglin anomaly and Dohle bodies of infection : an ultrastructural comparison. Br J Haematol 22 : 491-496, 1972.
PubMed
P.118 掲載の参考文献
1) Loffler W : Zur Differential-Diagnose der Lungeninfiltrierungen, II. Uber Fluchtige Succedan-Infiltrate (mit Eosinophilie). Beitr Klin Tuberk 79 : 368-392, 1932.
 
2) Loffler W : Transient lung infiltrations with blood eosinophilia. Int Arch Allergy Appl Immunol 8 : 54-59, 1956.
PubMed
3) 矢野平一, 片山俊夫 : 白血球 (顆粒球) の異常 : PIE症候群 : Loffler症候群. 別冊日本臨牀 血液症候群 (II), p98-100, 日本臨牀社, 1998.
 
4) Reeder WH, Goodrich BE : Pulmonary infiltration with eosinophilia (PIE syndrome). Ann Intern Med 36 : 1217-1240, 1952.
PubMed
5) Crofton JW, et al : Pulmonary eosinophilia. Thorax 7 : 1-35, 1952.
PubMed
6) Liebow AA, Carrington CB : The eosinophilic pneumonias. Medicine 48 : 251-285, 1969.
PubMed
7) Carrington CB, et al : Chronic eosinophilic pneumonia. N Engl J Med 280 : 787-798, 1969.
PubMed
8) Allen JN, et al : Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 321 : 569-574, 1989.
PubMed
9) Fraser RS, et al : Eosinophilic lung disease. In : Synopsis of Diseases of the Chest, 3rd ed, p511-514, Elsevier, New York, 2005.
 
10) Weller PF, Bubley GJ : The idiopathic hypereosinophilic syndrome. Blood 83 : 2759-2779, 1994.
PubMed
11) Tan SK, Liu TT : Cutaneous larva migrans complicated by Loffler syndrome. Arch Dermatol 146 : 210-212, 2010.
PubMed
12) Te Booij M, et al : Loffler syndrome caused by extensive cutaneous larva migrans : a case report and review of the literature. Dermatol Online J 16 (10) : 2, 2010.
PubMed
13) Lee HK, et al : Loffler's syndrome associated with Clonorchis sinensis infestation. Korean J Intern Med 18 : 255-259, 2003.
PubMed
14) Amsterdam JD : Loeffler's syndrome : an uncommon adverse reaction to imipramine. Int Clin Psychopharmacol 1 : 260-262, 1986.
PubMed
15) Lazoglu AH, et al : Phenytoin-related immunodeficiency associated with Loeffler's syndrome. Ann Allergy Asthma Immunol 74 : 479-482, 1995
PubMed
P.122 掲載の参考文献
1) Crofton JW, et al : Pulmonary eosinophilia. Thorax 7 : 1-35, 1952.
PubMed
2) Liebow AA, Carrington CB : The eosinophilic pneumonias. Medicine 48 : 251-285, 1969.
PubMed
3) Carrington CB, et al : Chronic eosinophilic pneumonia. N Engl J Med 280 : 787-798, 1969.
PubMed
4) Naughton M, et al : Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest 103 : 162-165, 1993.
PubMed
5) Alam M, Burki NK : Chronic eosinophilic pneumonia : a review. South Med J 100 : 49-53, 2007.
PubMed
6) Katz U, Shoenfeld Y : Pulmonary eosinophilia. Clin Rev Allergy Immunol 34 : 367-371, 2008.
PubMed
7) Fraser RS, et al : Eosinophilic lung disease. In : Synopsis of Diseases of the Chest, 3rd ed, p511-514, Elsevier. New York, 2005.
 
8) Turner-Warwick M, et al : Cryptogenic pulmonary eosinophilia. Clin Allergy 6 : 135-145, 1976.
PubMed
9) Fox B, Seed WA : Chronic eosinophilic pneumonia. Thorax 35 : 570-580, 1980.
PubMed
10) Walker C, et al : Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 150 : 1038-1048, 1994.
PubMed
11) Bochner BS : Road signs guiding leukocytes along the inflammation superhighway. J Allergy Clin Immunol 106 : 817-828, 2000.
PubMed
12) Maillet I, et al : Allergic lung inflammation is mediated by soluble tumor necrosis factor (TNF) and attenuated by dominant-negative TNF biologics. Am J Respir Cell Mol Biol 45 : 731-739, 2011.
PubMed
13) Matsuse H, et al : Diagnostic problems in chronic eosinophilic pneumonia. J Int Med Res 25 : 196-201, 1997.
PubMed
14) Webb WR, et al : Hypersensitivity pneumonitis and eosinophilic lung diseases. In : High-Resolution of the Lung, 4th ed, p335-355, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
P.125 掲載の参考文献
1) Crofton JW, et al : Pulmonary eosinophilia. Thorax 7 : 1-35, 1952.
PubMed
2) Reeder WH,Goodrich BE : Pulmonary infiltration with eosinophilia (PI E syndrome). Ann Intern Med 36 : 1217-1240, 1952.
 
3) 吉澤靖之ほか : アレルギー性気道・肺疾患. EBM現代内科学 (黒川清ほか編), p352-357, 金芳堂, 1997.
 
4) 近藤有好 : 好酸球性肺炎. 呼吸器疾患 (原沢道美, 北村諭編), p358-362, 医歯薬出版, 1994.
 
5) Stevens DA, et al : Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art : Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37 (Suppl 3) : S225-S264, 2003.
 
6) Webb WR, et al : Airways diseases. In : High-Resolution of the Lung, 4th ed, p492-554, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
7) Shoemark A, et al : Aetiology in adult patients with bronchiectasis. Respir Med 101 : 1163-1170, 2007.
PubMed
8) Gibson PG, et al : Induced spurum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J 21 : 582-588, 2003.
 
9) Walker C, et al : Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 150 : 1038-1048, 1994.
PubMed
10) Greenberger PA : Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110 : 685-692, 2002.
PubMed
11) Reiff DB, et al : CT findings in bronchiectasis : limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 165 : 261-267, 1995.
PubMed
12) Stevens DA, et al : A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 342 : 756-762, 2000.
PubMed
13) Erwin GE, Fitzgerald JE : Case report : allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully treated with voriconazole. J Asthma 44 : 891-895, 2007.
PubMed
14) Laoudi Y, et al : Nebulised corticosteroid and amphotericin B : an alternative treatment for ABPA? Eur Respir J 31 : 908-909, 2008.
PubMed
15) Patterson R, et al : Allergic bronchopulmonary aspergillosis : staging as an aid to management. Ann Intern Med 96 : 286-291, 1982.
PubMed
P.132 掲載の参考文献
1) Churg J, Strauss L : Allergic granulomatosis, allergic angiitis and periarteritis nodosa. Am J Pathol 27 : 277-301, 1951.
PubMed
2) Zuelzer WW, Apt L : Disseminated visceral lesions associated with extreme eosinophilia : pathologic and clinical observations on a syndrome of youmg children. Am J Dis Child 78 : 153-181, 1949.
 
3) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
PubMed
4) Luqmani RA, et al : Nomenclature and classification of vasculitis-update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS). Clin Exp Immunol 164 (Suppl 1) : 11-13, 2011.
 
5) Ramentol-Sintas M, et al : Churg-Strauss Syndrome : An evolving paradigm. Autoimmun Rev, 2012. [Epub ahead of print]
 
6) Watts RA, et al : Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 23 : 3928-3931, 2008.
PubMed
7) Matsumoto Y, et al : Nationwide epidemiological survey of refractory vasculitis (anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis, anti-phospholipid syndrome and temporal arteritis) in Japan. Annual Report of the Research Committee on Intractable Vasculitides, the Ministry of Health and Welfare of Japan [in Japanese], p15-23, 1998.
 
8) Amano K, et al : Studies on allergic granulomatous angiitis (Churg Strauss syndrome) in Japan : nationwide epidemiological survey. Annual Report of the Research Committee on Intractable Vasculitides, the Ministry of Health and Welfareof Japan [in Japanese], p98-99, 2010.
 
9) Mukhopadhyay A, et al : Churg-Strauss syndrome associated with montelukast. Postgrad Med J 77 : 390-391, 2001.
PubMed
10) Jamaleddine G, et al : Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 31 : 218-227, 2002.
PubMed
11) Bibby S, et al : Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome : an analysis of the FDA AERS database. Thorax 65 : 132-138, 2010.
PubMed
12) Kanda T, et al : Churg-Strauss syndrome with severe granulomatous angiitis and crescentic glomerulonephritis, which developed during therapy with a leukotriene receptor antagonist. Clin Exp Nephrol 14 : 602-607, 2010.
PubMed
13) Sinico RA, et al : Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52 : 2926-2935, 2005.
PubMed
14) Sable-Fourtassou R, et al : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143 : 632-638, 2005.
PubMed
15) Churg A : Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 14 : 1284-1293, 2001.
PubMed
16) Khoury P, et al : Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 67 : 1149-1156, 2012.
PubMed
17) Lanham JG, et al : Systemic vasculitis with asthma and eosinophilia : a clinical approach to the Churg-Strauss syndrome. Medicine 63 : 65-81, 1984.
 
18) Masi AT, et al : American College of Rheumatology 1990 criteria for the classification of Churg Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33 : 1094-1100, 1990.
PubMed
19) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
P.138 掲載の参考文献
1) Wegener F : Uber eine einartige rhino-gene Granulomatose mit besonderer Beteligungdes arteriensystems und der Nieren. Beitr Pathol 102 : 36-38, 1939.
 
2) Falk RJ, et al : Granulomatosis with polyangiitis (Wegener's) : an alternative name for Wegener's granulomatosis. Arthritis Rheum 63 : 863-864, 2011.
 
3) van der Woude FJ, et al : Autoantibodies against neutrophils and monocytes : tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet i : 425-429, 1985.
PubMed
4) 吉田雅治, 長澤俊彦 : Wegener肉芽腫症における抗好中球細胞質抗体の意義. 医学のあゆみ 145 : 649-650, 1988.
 
5) Bosch X, et al : Antineutrophil cytoplasmic antibodies. Lancet 368 : 404-418, 2006.
PubMed
6) De Remee RA, et al : Wegener's granulomatosis. Anatomic correlates. A proposal classification. Mayo Clin Proc 51 : 777-781, 1975.
 
7) 吉田雅治 : Wegener肉芽腫症. 腎と透析 68 : 59-66, 2010.
Medical*Online
8) Yoshida M, et al : Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with high affinity and a low affinity in small vessel vasculitis. Clin Exp Rheumatol 27 (Suppl 52) : S28-32, 2009.
 
9) Carrington CB, et al : Limited formas of angiitis and granulomatosis of Wegener's type. Am J Med 41 : 497-527, 1966.
 
10) Leavitt RY, et al : The American College of Rheumatology 1990 Criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33 : 1101-1107, 1990.
PubMed
11) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
12) Langford CA, et al : Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis : extended follow-up and rate of relapse. Am J Med 463 : 114-120, 2003.
PubMed
13) 吉田雅治 : 腎炎, ネフローゼ症候群に対する免疫抑制療法の進歩. 日腎会誌 52 : 1, 2010.
 
14) Stegemen CA, et al : Trimethoprim-sulfamethoxazale (co-trimoxazole) for the prevention of relapse of Wegener's granulomatosis. N Engl J Med 335 : 16-20, 1996.
 
15) Yoshida M, et al : Rapid decrease of anti-β-glucan antibody as an indicator for early diagnosis of carinii pneumonitis and deep mycotic infections following immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Rheumatol 28 : 565-571, 2009.
 
P.143 掲載の参考文献
1) Lightfoot RW Jr, et al : The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33 : 1088-1093, 1990.
PubMed
2) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
PubMed
3) de Menthon M, Mahr A : Treating polyarteritis nodosa : current state of the art. Clin Exp Rheumatol 29 (Suppl 64) : S110-116, 2011.
 
4) 中林公正ほか : 結節性多発動脈炎. 血管炎アトラス (尾崎承一, 吉木敬編), p9-12, 厚生労働省難治性疾患克服研究事業難治性血管炎に対する調査研究班, 2005.
 
5) 難治性血管炎調査研究班 : 結節性動脈周囲炎. 難病の診断と治療指針 1 (難病医学研究財団企画委員会編), p107-115, 六法出版, 1997.
 
6) 吉田雅治ほか : 中・小型血管炎の臨床に関する小委員会報告. 厚生省特定疾患免疫疾患調査研究班, 難治性血管炎分科会, 平成10年度研究報告書, p239-243, 1999.
 
7) Watts R, et al : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66 : 222-227, 2007.
PubMed
P.147 掲載の参考文献
1) Hardy WR, Anderson RE : The hypereosinophilic syndromes. Ann Intern Med 68 : 1220-1229, 1968.
PubMed
2) Chusid MJ, et al : The hypereosinophilic syndrome ; analysis of fourteen cases with review of the literature. Medicine 54 : 1-27, 1975.
PubMed
3) Simon HU, et al : Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 : 1112-1120, 1999.
PubMed
4) Bain BJ, et al : Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, p68-73, IARC Press, Lyon, 2008.
PubMed
5) Gleich GJ, et al : The hypereosinophilic syndromes : current concepts and treatments. Br J Haematol 145 : 271-285, 2009.
PubMed
6) Tefferi A, Vardiman JW : Classification and diagnosis of myeloproliferative neoplasms : the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 : 14-22, 2008.
PubMed
7) 定明子, 松井利充 : 本邦における慢性好酸球性白血病/特発性好酸球増多症候群の臨床像と治療. 臨床血液 51 : 515-525, 2010.
 
8) Bain BJ, et al : Chronic eosinophilic leukaemia, not otherwise specified. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, p51-53, IARC Press, Lyon, 2008.
 
9) Gotlib J : World Health Organization-defined eosinophilic disorders : 2011 update on diagnosis, risk stratification, and management. Am J Hematol 86 : 677-688, 2011.
PubMed
10) 江副幸子 : 好酸球増多症の病因・病態と治療. 別冊日本臨牀 造血器腫瘍学, p330-336, 日本臨牀社, 2012.
 
11) Cools J, et al : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 : 1201-1214, 2003.
PubMed
12) Miyazawa K, et al : Clinical features of hypereosinophilic syndrome : FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid. Int J Hematol 85 : 5-10, 2007.
 
13) 小池道明, 友安茂 : 特発性好酸球増加症候群. 別冊日本臨牀 血液症候群 II, p119-122, 日本臨牀社, 1998.
 
14) Baccarani M, et al : The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR α-positive hypereosinophilic syndrome. Results of amulticenter prospective study. Haematologica 92 : 1173-1179, 2007.
 
P.151 掲載の参考文献
1) Engfeldt B, Zetterstrom R : Disseminated eosinophilic collagen disease ; a clinical and pathological study of a clinical entity related to Loffler's syndromes. Acta Med Scand 153 : 337-353, 1956.
 
2) Bousser J : Eosinophilie et leucemie. Sang 28 : 553-580, 1957.
PubMed
3) Odeberg B : Eosinophilic leukemia and disseminated eosinophilic collagen disease-a disease entity? Acta Med Scand 177 : 129-144, 1965.
PubMed
4) Hardy WR, Anderson RE : The hypereosinophilic syndromes. Ann Intern Med 68 : 1220-1229, 1968.
PubMed
5) Chusid MJ, et al : The hypereosinophilic syndrome ; analysis of fourteen cases with review of the literature. Medicine 54 : 1-20, 1975.
PubMed
6) Brito-Babapulle F : Clonal eosinophilic disorders and the hypereosinophilic syndrome. Blood Rev 11 : 129-145, 1997.
PubMed
7) World Health Organization Classification of Tumours : Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (ed by Jaffe ES, et al), IARC Press, Lyon, 2001.
 
8) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), IARC Press, Lyon, 2008.
 
9) Pierce LE, et al : Disseminated eosinophilic collagen disease. Blood 29 : 540-549, 1967.
PubMed
10) 柴田昭 : 播種性好酸球性膠原病. 診断と治療 2 : 299-305, 1980.
 
11) 南陸彦 : Disseminated Eosinophilic Collagen Disease. 小児科診療 41 : 673-676, 1978.
 
12) 津田俊彦ほか : 播種性好酸性膠原病の1例. 臨血 16 : 1124-1130, 1975.
 
13) 更井哲夫ほか : 播種性好酸性膠原病の1例. 臨血 17 : 1198-1206, 1976.
 
14) 大沢修子, 長沼雄峰 : Disseminated eosinophilic collagen diseaseと思われる1症例. 小児科臨床 36 : 63-68, 1983.
Medical*Online
15) 定明子, 松井利充 : 本邦における慢性好酸球性白血病/特発性好酸球増多症候群の臨床像と治療. 臨血 21 : 515-525, 2010.
 
P.154 掲載の参考文献
1) Gleich GJ, et al : Episodic angioedema associated with eosinophilia. N Engl J Med 310 (25) : 1621-1626, 1984.
PubMed
2) 端本宇志ほか : 無治療で自然経過を観察したnon-episodic angioedema with eosinophilia. 日皮会誌 118 : 925-931, 2008.
 
3) Chikama R, et al : Nonepisodic angioedema associated with eosinophilia : report of 4 cases and review of 33 young female patients reported in Japan. Dermatology 197 (4) : 321-325, 1998.
PubMed
4) Wolf C, et al : Episodic angioedema with eosinophilia. J Am Acad Dermatol 20 (1) : 21-27, 1989.
PubMed
5) Butterfield JH, et al : Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 79 (3) : 688-692, 1992.
PubMed
6) Mizukawa Y, Shinohara T : The cytokine profile in a transient variant of angioedema with eosinophilia. Br J Dermatol 144 (1) : 169-174, 2001.
 
7) Ackerman SJ, Butterfield JH : Eosinophilia, eosinophil-associated diseases, chronic eosinophilic leukemia, and the hypereosinophilic syndrome. In : Hematology : Basic Principles and Practice (ed by Hoffman R, et al), 4th ed, p763-786, Elsevier, Philadelphia, 2005.
 
8) 川口康久ほか : 繰り返した好酸球性血管性浮腫. 臨床血液 44 : 1020-1025, 2003.
 
P.158 掲載の参考文献
1) Masterson JC, et al : Update on clinical and immunological features of eosinophilic gastrointestinal diseases. Curr Opin Gastroenterol 27 (6) : 515-522, 2011.
PubMed
2) Lucendo AJ : Eosinophilic diseases of the gastrointestinal tract. Sc and J Gastroenterol 45 (9) : 1013-1021, 2010.
 
3) Klein NC, et al : Eosinophilic gastroenteritis. Medicine (Baltimore) 49 (4) : 299-319, 1970.
PubMed
4) Talley NJ, et al : Eosinophilic gastroenteritis : a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. Gut 31 (1) : 54-58, 1990.
PubMed
5) 木下芳一ほか : 好酸球性胃腸炎の診断と治療. 日消誌 56 (6) : 1797-1805, 2012.
 
6) Mendez-Sanchez N, et al : Eosinophilic gastroenteritis : a review. Dig Dis Sci 52 (11) : 2904-2911, 2007.
PubMed
7) Kinoshita Y, et al : Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis. J Gastroenterol, 2012. [Epub ahead of print]
 
8) Oh HE, Chetty R : Eosinophilic gastroenteritis : a review. J Gastroenterol 43 (10) : 741-750, 2008.
PubMed
9) Yan BM, Shaffer EA : Primary eosinophilic disorders of the gastrointestinal tract. Gut 58 (5) : 721-732, 2009.
PubMed
10) Khan S, Orenstein SR : Eosinophilic gastroenteritis. Gastroenterol Clin North Am 37 (2) : 333-348, 2008.
PubMed
11) Freeman HJ : Adult eosinophilic gastroenteritis and hypereosinophilic syndromes. World J Gastroenterol 14 (44) : 6771-6773, 2008.
PubMed
12) Foster B, et al : Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders. Clin Mol Allergy 9 (1) : 7, 2011.
 
13) Stone KD, Prussin C : Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases. Clin Exp Allergy 38 (12) : 1858-1865, 2008.
PubMed
14) Justinich C, et al : Elemental diet improves steroid-dependent eosinophilic gastroenteritis and reverses growth failure. J Pediatr Gastroenterol Nutr 23 (1) : 81-85, 1996.
PubMed
15) Pineton de Chambrun G, et al : Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol 9 (11) : 950-956, 2011.
PubMed
P.163 掲載の参考文献
1) 岡村精一 : 好酸球増加のプライマリケア. 治療 84 (2) : 236-239, 2002.
Medical*Online
2) 丸山治彦 : 寄生虫疾患と好酸球・好塩基球. 臨床検査 51 (10) : 1047-1052, 2007.
 
3) 有薗直樹 : 国内の寄生虫症の動向. 治療学 37 (6) : 567-570, 2003.
Medical*Online
4) Nakamura-Uchiyama F, et al : The Current Statusof Parasitic Disease in Japan. Intern Med 42 (3) : 222-236, 2003.
 
5) 有薗直樹 : 日本における蠕虫症と蠕虫研究の近年の動向. Clinical Parasitology 22 (1) : 9-17, 2011.
 
6) Yoshimoto T, et al : Basophils contribute to TH2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 10 (7) : 706-712, 2009.
PubMed
7) Yamaguchi Y, et al : Highly purified murine interleukin 5 (I L-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 167 (5) : 1737-1742, 1988.
 
8) Lopez AF, et al : Murine eosinophil differentiation factor. J Exp Med 163 (5) : 1085-1099, 1986.
PubMed
9) Chihara J, et al : IL-5 and IL-5 receptor expression on human eosinophils in relation to eosinophil activation. Biotechnol Ther 4 (3 & 4) : 271-283, 1993.
 
10) Iwasaki K, Torisu M : Anisakis and eosinophil II. Eosinophilic phlegmon experimentally induced in normal rabbits by parasite-derived eosinophil chemotactic factor (ECF-P). Clin Immunol Immunopathol 23 (3) : 593-605, 1982.
PubMed
11) Torisu M, et al : Eosinophilic granuloma formation in Anisakiasis. Basic mechanisms of granulomatous inflammation : proceedings of the International Symposium on Basic Mechanisms of Granulomatous Inflammation, held in Fukuoka, Japan, 28-29 November 1988. p207-219, Excerpta Medica. Amsterdam, 1989.
 
12) 吉村堅太郎 : 寄生虫症における好酸球の寄生虫殺滅作用の機序. 日本臨牀 51 (3) : 657-663, 1993.
Medical*Online
13) Mahmoud AAF, et al : A role for the eosinophil in acquired resistance to Schistosoma mansoni infection as determined by antieosinophil serum. J Exp Med 142 (4) : 805-813, 1975.
 
14) Grove DI, et al : Eosinophils and resistance to Trichinella spiralis. J Exp Med 145 (3) : 755-759, 1977.
PubMed
15) 佐藤直樹ほか : 多包性肝エキノコックス症に対するbenzimidazole系薬剤の効果. 日消誌 91 (7) : 1197-1204, 1994.
Medical*Online
P.167 掲載の参考文献
1) 金井泉, 金井正光 : 末梢血白血球分類の診断的意義. 臨床検査法提要, 第31版, p306-309, 金原出版, 1998.
 
2) 松村到, 金倉譲 : 好塩基球の増加する疾患, 減少する疾患. 三輪血液病学, 第3版 (浅野茂隆ほか監), p1314-1320, 文光堂, 2006.
 
3) Parker RI, Metcalfe DD : Basophils, mast cells, and systemic mastocytosis. In : Hematology-Basic Principles and Practice- (ed by Hoffman R, et al), p911-925, Elsevier, Philadelphia, 2005.
 
4) Chang KL, Forman SJ : Myeloid disorders. In : Atlas of Clinical Hematology (ed by Armitage JO), p149, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
5) Befus AD, Denbrug JA : Chapter 11, Basophilic lymphocytes : mast cells and basophils. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), p236-248, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
6) Lim HD, et al : Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor : identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 314 : 1310-1321, 2005.
PubMed
7) Mitre E, Nutman TB : Basophils, basophilia and helminth infections. Chem Immunol Allergy 90 : 141-156, 2006.
PubMed
8) Xu Y, et al : Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. Arch Pathol Lab Med 128 : 980-985, 2004.
PubMed
9) Chi Y, et al : Acute myelogenous leukemia with t (6 ; 9) (p23 ; q34) and marrow basophilia : an overview. Arch Pathol Lab Med 2132 : 1835-1857, 2008.
 
10) Staal-Viliare A, et al : A case of de novo acute basophilic leukaemia : diagnostic criteria and review of the literature. Ann Biol Clin (Paris) 64 : 361-365, 2006.
PubMed
11) Gupta R, et al : Acute basophilic leukemia : case report. Am J Hematol 76 : 134-138, 2004.
PubMed
12) Matsushima T, et al : Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 101 : 3386-3390, 2003.
PubMed
13) Tallman MS, et al : Basophilic differentiation in acute promyelocytic leukemia. Leukemia 7 : 521-526, 1993.
PubMed
P.169 掲載の参考文献
1) 金井泉, 金井正光 : 末梢血白血球分類の診断的意義. 臨床検査法提要, 第31版, p306-309, 金原出版, 1998.
 
2) 松村到, 金倉譲 : 好塩基球の増加する疾患, 減少する疾患. 三輪血液病学, p1314-1320, 文光堂, 2006.
 
3) Parker RI, Metcalfe DD : Basophils, mast cells, and systemic mastocytosis. In : Hematology-Basic Principles and Practice- (ed by Hoffman R, et al), p911-925, Elsevier, Philadelphia, 2005.
 
4) Befus AD, Denbrug JA : Chapter 11, Basophilic lymphocytes : mast cells and basophils. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), p236-248, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
5) Grattan CE, et al : Flow cytometric analysis of basophil numbers in chronic urticaria : basopenia is related to serum histamine releasing activity. Clin Exp Allergy 27 : 1417-1424, 1997.
PubMed
6) Grattan CE, et al : Blood basophil numbers in chronic ordinary urticaria and healthy controls : diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 33 : 337-341, 2003.
PubMed
7) Saini SS : Basophil responsiveness in chronic urticaria. Curr Allergy Asthma Rep 9 : 186-190, 2009.
 
8) Magen E, et al : Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc 32 : 460-466, 2011.
PubMed
9) Rajan P, et al : Blood basopenia as an indicator of ovulation. Indian J Physiol Pharmacol 36 : 115-117, 1992.
PubMed
10) Deibener-Kaminsky J, et al : Clinical relevance of leukocyte differential in patients with marked leukocytosis in the emergency room. Rev Med Interne 32 : 406-410, 2011.
PubMed
11) Deibener-Kaminsky J, et al : Leukocyte differential for acute abdominal pain in adults. Lab Hematol 17 : 1-5, 2011.
PubMed
P.172 掲載の参考文献
1) 木村文彦 : M-CSF. サイトカインのすべて. 臨床免疫・アレルギー科 57 (Suppl 21) : 588-593, 2012.
 
2) Lichtman MA : Monocytosis and monocytopenia. In : Williams Hematology (ed by Kaushansky K, et al), 8th ed, p1041-1046, McGraw Hill, New York, 2010.
 
3) Tadmor T, et al : Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol, 2012. [Epub ahead of print]
 
4) Lamprecht B, et al : Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 16 : 571-579, 2010.
PubMed
5) Khan E, et al : Demographic and clinical features of dengue fever in Pakistan from 2003-2007 : a retrospective cross-sectional study. PLoS One 5 : e12505, 2010.
PubMed
6) Ruka W, et al : Alterations of routine blood tests in adult patients with soft tissue sarcomas : relationships to cytokine serum levels and prognostic significance. Ann Oncol 12 : 1423-1432, 2001.
PubMed
7) Chen MH, et al : Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. J Cancer Res Clin Oncol 135 : 1783-1790, 2009.
PubMed
8) Weiner LM, et al : Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon : toxicity, monocytosis, and clinical effects. Cancer Res 54 : 4084-4090, 1994.
PubMed
9) Meisel SR, et al : Peripheral monocytosis following acute myocardial infarction : incidence and its possible role as a bedside marker of the extent of cardiac injury. Cardiology 90 : 52-57, 1998.
PubMed
10) Dutta P, et al : Myocardial infarction accelerates atherosclerosis. Nature 487 : 325-329, 2012.
PubMed
11) Suzuki K, et al : Impact of a competitive marathon race on systemic cytokine and neutrophil responses. Med Sci Sports Exerc 35 : 348-355, 2003.
PubMed
12) Wong KL, et al : The three human monocyte subsets : implications for health and disease. Immunol Res 53 : 41-57, 2012.
PubMed
13) Parikh SA, Tefferi A : Chronic myelomonocytic leukemia : 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87 : 610-619, 2012.
PubMed
14) Xu Y, et al : Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 124 : 799-806, 2005.
PubMed
P.176 掲載の参考文献
1) Hilts SV, Shaw CC : Leukemoid blood reactions. N Engl J Med 249 : 434-438, 1953.
PubMed
2) 元吉和夫 : 単球・マクロファージ. 血液病学 (三輪史朗編), p303-313, 文光堂, 2006.
 
3) 木村文彦 : 造血因子 M-CSF. 臨床免疫・アレルギー内科 57 (Suppl 21) : 588-593, 2012.
 
4) Gibson A : Monocytic leukemoid reaction associated with tuberculosis and a mediastinal teratoma. J Pathol Bacteriol 58 : 469-475, 1946.
 
5) 川越富夫ほか : 末梢血白血球数が12万/μlにまで上昇し, 慢性骨髄単球性白血病が疑われた類白血病反応の1例. 内科 106 : 757-760, 2010.
 
6) 元吉和夫 : 単球, マクロファージの疾患. 血液病学 (三輪史朗編), p1321-1322, 文光堂, 2006.
 
7) Janowska-Wieczorek A, et al : Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. Blood 77 : 1796-1803, 1991.
PubMed
8) 吉田勝彦ほか : 単球増加を認めた形質細胞白血病. 臨床血液 38 : 604-609, 1997.
 
9) 元吉和夫 : 単球性類白血病反応. 別冊日本臨牀 血液症候群 II, p146-148, 日本臨牀社, 1998.
 
10) Karayalcin G, et al : Monocytosis in congenital syphilis. Am J Dis Child 131 : 782-783, 1977.
PubMed
11) 原田浩徳 : MDS分子病態. 臨床血液 52 : 113-122, 2011.
 
12) Parikh SA, Tefferi A : Chronic myelomonocytic leukemia : 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87 : 610-619, 2012.
PubMed
13) Melo JV, et al : P190 BCR-ABL chronic myeloid leukaemia : the missing link with chronic myelomonocytic leukaemia? Leukemia 8 : 208-211, 1994.
PubMed
14) Verma D, et al : Chronic myeloid leukemia (CML) with P190 BCR-ABL : analysis of characteristics, outcomes, and prognostic significance. Blood 114 : 2232-2235, 2009.
PubMed
P.180 掲載の参考文献
1) Warman ML, et al : Nosology and classification of genetic skeletal disorders : 2010 revision. Am J Med Genet A 155A : 943-968, 2011.
PubMed
2) Askmyr MK, et al : Towards a better understanding and new therapeutics of osteopetrosis. Br J Haematol 140 : 597-609, 2008.
PubMed
3) Tolar J, et al : Osteopetrosis. N Engl J Med 351 : 2839-2849, 2004.
PubMed
4) Stark Z, Savarirayan R : Osteopetrosis. Orphanet J Rare Dis 4 : 5, 2009.
PubMed
5) Aker M, et al : An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet 49 : 221-226, 2012.
PubMed
6) Campeau PM, et al : Whole-exome sequencing identifies mutations in the nucleoside transportergene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. Hum Mol Genet 21 : 4904-4909, 2012.
 
P.184 掲載の参考文献
1) Quintas-Cardama A, et al : Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117 (24) : 5439-5449, 2011.
PubMed
2) Okayama Y, Kawakami T : Development, migration, and survival of mast cells. Immunol Res 34 (2) : 97-115, 2006.
PubMed
3) Ustun C, et al : Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 35 (9) : 1143-1152, 2011.
PubMed
4) Nagata H, et al : Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92 (23) : 10560-10564, 1995.
PubMed
5) Tefferi A, et al : Frequent TET2 mutations in systemic mastocytosis : clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23 (5) : 900-904, 2009.
PubMed
6) Wilson TM, et al : Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 96 (3) : 459-463, 2011.
PubMed
7) Stoecker MM, Wang E : Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease : a clinicopathologic review. Arch Pathol Lab Med 136 (7) : 832-838, 2012.
PubMed

IV リンパ球の異常

P.190 掲載の参考文献
1) Penn I, et al : Malignant lymphomas in transplantation patients. Transplant Proc 1 : 106-112, 1969.
 
2) Evens AM, et al : Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease : outcomes and prognostic factors in the modern era. J Clin Oncol 28 : 1038-1046, 2010.
PubMed
3) Loren AW, et al : Post-transplant lymphoproliferative disorder : a review. Bone Marrow Transplant 31 : 145-155, 2003.
PubMed
4) Nourse JP, et al : Epstein-Barr Virus-related post-transplant lymphoproliferative disorders : pathogenetic insights for targeted therapy. Am J Transplant 11 : 888-895, 2011.
PubMed
5) Cockfield SM : Identifying the patient at risk for post-trasplant lymphoproliferative disorders. Transpl Infect Dis 3 : 70-78, 2001.
 
6) Nelson BP, et al : Epstein-Barr virus-negative post-transplant lymphoproliferative disorders : a distinct entity? Am J Surg Pathol 24 : 375-385, 2000.
PubMed
7) Oton AB, et al : Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 49 : 1738-1744, 2008.
PubMed
8) Tsao L, Hsi ED : The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 131 : 1209-1218, 2007.
PubMed
9) Swerdlow SH, et al : Post-transplant lymphoproliferative disorder. In : WHO classification of tumours of haematopoietic and lymphoid tissues, edn4 (ed by Swerdlow SH, et al), p343-349, Internal agency for research on cancer, Lyon, France, 2008.
 
10) Swerdlow SH : T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol 127 : 887-895, 2007.
PubMed
11) Funch DP, et al : Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5 : 2894-2900, 2005.
PubMed
12) Reshef R, et al : Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 11 : 336-347, 2011.
PubMed
13) Benkerrou M, et al : Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder : prognostic factors and long-term outcome. Blood 92 : 3137-3147, 1998.
PubMed
14) Trappe R, et al : Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD) : the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13 : 196-206, 2012.
PubMed
15) Choquet S, et al : CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92 : 273-274, 2007.
PubMed
16) Haque T, et al : Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease : results of a phase 2 multicenter clinical trial. Blood 110 : 1123-1131, 2007.
PubMed
P.195 掲載の参考文献
1) Chan WC, et al : T-cell large granular lymphocytic leukaemia. In : WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed (ed by Swerdlow SH, et al), p272-273, Internal agency for research on cancer, Lyon, France, 2008.
 
2) Loughran TP Jr, et al : Leukemia of large granular lymphocytes : association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia and hemolytic anemia. Ann Intern Med 102 : 169-175, 1985.
PubMed
3) Sokol L, Loughran TP Jr : Large granular lymphocyte leukemia. Oncologist 11 : 263-273, 2006.
PubMed
4) Wlodarski MW, et al : Pathologic clonal cytotoxic T-cell responses : nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood 106 : 2769-2780, 2005.
 
5) Wlodarski MW, et al : Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformationin T-LGL leukemia. J Leukoc Biol 83 : 589-601, 2008.
 
6) Viny AD, et al : MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia. Haematologica 95 : 1713-1721, 2010.
 
7) Kwong YL, et al : T-cell large granular lymphocyte leukemia : an Asian perspective. Ann Hematol 89 : 331-339, 2010.
PubMed
8) Zhang R, et al : The root of many evils : indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol 28 : 105-117, 2010.
PubMed
9) Howard MT, et al : T/NK large granular lymphocyte leukemia and coexisting monoclonal B-cell lymphocytosis-like proliferations. An unrecognized and frequent association. Am J Clin Pathol 133 : 936-941, 2010.
PubMed
10) Bourgault-Rouxel AS, et al : Clinical spectrum of gammadelta+ T cell LGL leukemia : analysis of 20 cases. Leuk Res 32 : 45-48, 2008.
PubMed
11) Osuji N, et al : Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia. Br J Haematol 128 : 645-648, 2005.
 
12) Fortune AF, et al : Large granular lymphocyte leukemia : natural history and response to treatment. Leuk Lymphoma 51 : 839-845, 2010.
PubMed
13) Watters RJ, et al : T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma 52 : 2217-2225, 2011.
PubMed
14) Dearden C : Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol 152 : 273-283, 2011.
PubMed
15) Oshimi K : Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139 : 532-544, 2007.
PubMed
P.199 掲載の参考文献
1) Seemayer TA, et al : X-linked lymphoproliferative disease : twenty-five years after the discovery. Pediatr Res 38 : 471-478, 1995.
PubMed
2) Rigaud S, et al : XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444 : 110-114, 2006.
 
3) Speckmann, et al : Genetic disorders of immune regulation. In : Primary Immunodeficiency Diseases : Definition, Diagnosis and Management (ed by Razaei N, et al), p167-194, Springer-Verlag, Berlin-Hdidelberg, 2008.
 
4) Brandau O, et al : Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 8 : 2407-2413, 1999.
PubMed
5) Sumegi J, et al : Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 96 : 3118-3125, 2000.
 
6) Milone MC, et al : Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105 : 994-996, 2005.
PubMed
7) Coffey A J, et al : Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20 : 129-135, 1998.
 
8) Sayos J, et al : The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395 : 462-469, 1998.
 
9) Ostrakhovitch EA, et al : SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux. Cell Signal 21 : 540-550, 2009.
PubMed
10) Filipovich AH, et al : X-linked lymphoproliferative syndromes : brothers or distant cousins? Blood 116 : 3398-3408, 2010.
 
11) Rezaei N, et al : X-linked lymphoproliferative syndrome : a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 152 : 13-30, 2011.
PubMed
12) Thorley-Lawson DA, Gross A : Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350 : 1328-1337, 2004.
PubMed
13) Diana J, Lehuen A : NKT cells : friend or foe during viral infections? Eur J Immunol 39 : 3283-3291, 2009.
PubMed
14) Nagy N, Klein E : Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and promotes lymphoma development. Immunol Lett 130 : 13-18, 2010.
 
15) Yuling H, et al : EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res 69 : 7935-7944, 2009.
PubMed
16) Ma CS, et al : Selective generation of functional somatically mutated IgM+ CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. J Clin Invest 116 : 322-333, 2006.
PubMed
17) Lankster AC, et al : Allogeneic stem cell transplantation in X-linked lymphoproliferative disease : two cases in one family and review of the literature. Bone Marrow Transplant 36 : 99-105, 2005.
 
P.203 掲載の参考文献
1) 秋山暢 : 白血球増加と類白血病反応. 血液の事典 (平井久丸ほか編), p141-143, 朝倉書店, 2004.
 
2) Carney D : Peripheral blood lymphocytosis-what is the threshold for further investigation? Leuk Lymphoma 49 : 1659-1661, 2008.
PubMed
3) Shanafelt TD, et al : Monoclonal B-cell lymphocytosis (MBL) : biology, natural history and clinical management. Leukemia 24 : 512-520, 2010.
PubMed
4) 青木定夫 : 白血球数の増加. medicina 45 : 2202-2205, 2008.
 
5) Halmos B, et al : Extreme lymphoplasmacytosis and hepatic failure associated with sulfasalazine hypersensitivity reaction and a concurrent EBV infection-case report and review of the literature. Ann Hematol 83 : 242-246, 2004.
 
6) 近藤誠司ほか : 関節リウマチ患者に生じた形質細胞による一過性の類白血病反応. 臨床血液 48 : 632-636, 2007.
 
7) Hutchinson RE, et al : Lymphocytic surface markers in lymphoid leukemoid reaction. Clin Lab Med 8 : 237-245, 1988.
PubMed
8) Rawstron AC, et al : Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359 : 575-583, 2008.
PubMed
9) Fazi C, et al : General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 118 : 6618-6625, 2011.
PubMed
10) Dighiero G, Hamblin TJ : Chronic lymphocytic leukaemia. Lancet 371 : 1017-1029, 2008.
PubMed
11) Marti G, et al : Overview of monoclonal B-cell lymphocytosis. Br J Haematol 139 : 701-708, 2007.
PubMed
12) Ghia P, Caligaris-Cappio F : Monoclonal B-cell lymphocytosis : right track or red herring? Blood 119 : 4358-4362, 2012.
PubMed
13) Luzuriaga K, Sullivan J L : Infectious mononucleosis. N Engl J Med 362 : 1993-2000, 2010.
PubMed
14) Crawford DH, et al : A cohort study among university students : identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 43 : 276-282, 2006.
PubMed
P.207 掲載の参考文献
1) 岩田力 : 原発性免疫不全症の分類と我が国におけるその頻度. 小児科 47 : 3-16, 2006.
 
2) Al-Herz W, et al : Primary immunodeficiency diseases : an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency. Front Immunol 2 : 54, 2011.
PubMed
3) Miale J B : Laboratory Medicine Hematology, 4th ed, p900, C. V. Mosby, 1972.
 
4) 標準血液病学 (池田康夫, 押味和夫編), p285, 医学書院, 2000.
 
P.210 掲載の参考文献
1) Castelino DJ, et al : Lymphocytopenia in a hospital population-what does it signify? Aust N Z J Med 27 : 170-174, 1997.
 
2) Miale JB : Laboratory Medicine Hematology, 4th ed, p900, C. V. Mosby, St. Louis, 1972.
 
3) 標準血液病学 (池田康夫, 押味和夫編), p285, 医学書院, 2000.
 
P.214 掲載の参考文献
1) Luo L, Li T : Idiopathic CD4 lymphocytopenia and opportunistic infection-an update. FEMS Immunol Med Microbiol 54 : 283-289, 2008.
 
2) Centersfor Disease Control (CDC) : Unexplained CD4+ T-lymphocyte depletion in persons without evident HIV infection-United States. MMWR Morb Mortal Wkly Rep 41 : 541-545, 1992.
 
3) De Hovitz JA, et al : Idiopathic CD4+ T-lymphocytopenia. N Engl J Med 329 : 1045-1046, 1993.
PubMed
4) Busch MP, et al : Screening of blood donors for idiopathic CD4+ T-lymphocytopenia. Transfusion 34 : 192-197, 1994.
PubMed
5) Smith DK, et al : Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force. N Engl J Med 328 : 373-379, 1993.
PubMed
6) Ho DD, et al : Idiopathic CD4+ T-lymphocytopenia-immunodeficiency without evidence of HIV infection. N Engl J Med 328 : 380-385, 1993.
PubMed
7) Lee PI, et al : Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia. J Infect Dis 199 : 1664-1670, 2009.
PubMed
8) Scott-Algara D, et al : Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood 115 : 3708-3717, 2010.
PubMed
9) Walker UA, Warnatz K : Idiopathic CD4 lymphocytopenia. Curr Opin Rheumatol 18 : 389-395, 2006.
PubMed
10) Kuijpers TW, et al : Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood 117 : 5892-5896, 2011.
PubMed
11) Gorska MM, Alam R : A mutation in the human Uncoordinated 119 gene impairs TCR signaling and is associated with CD4 lymphopenia. Blood 119 (6) : 1399-1406, 2012.
 
12) Zonios DI, et al : Idiopathic CD4+ lymphocytopenia : natural history and prognostic factors. Blood 112 : 287-294, 2008.
PubMed
13) Eibl MM, et al : Abnormal T-lymphocyte subpopulations in healthy subjects after tetanus booster immunization. N Engl J Med 310 : 198-199, 1984.
PubMed
14) Kony SJ, et al : Tuberculosis-associated severe CD4+ T-lymphocytopeniain HIV-seronegative patients from Dakar. SIDAK Research Group. J Infect 41 : 167-171, 2000.
 
15) Laurence J : T-cell subsets in health, infectious disease, and idiopathic CD4+ T lymphocytopenia. Ann Intern Med 119 : 55-62, 1993.
PubMed
16) Aldrich J, et al : The effect of acute severe illness on CD4+ lymphocyte counts in nonimmunocompromised patients. Arch Intern Med 160 : 715-716, 2000.
PubMed
17) Petersen EJ, et al : Allogeneic bone marrow transplantation can restore CD4+ T-lymphocyte count and immune function in idiopathic CD4+ T-lymphocytopenia. Bone Marrow Transplant 18 : 813-815, 1996.
PubMed
P.218 掲載の参考文献
1) Luzuriaga K, et al : Infectious mononucleosis. N Engl J Med 362 : 1993-2000, 2010.
PubMed
2) Hoagl and RJ : Infectious mononucleosis. Prim Care 2 : 295-307, 1975.
 
3) Rea TD, et al : Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract 14 : 234-242, 2001.
PubMed
4) Peter J, Ray CG : Infectious mononucleosis. Pediatr Rev 19 : 276-279, 1998.
 
5) Macsween KF, et al : Infectious mononucleosis in university students in the United kingdom : evaluation of the clinical features and consequences of the disease. Clin Infect Dis 50 : 699-706, 2010.
PubMed
P.222 掲載の参考文献
1) Cohen JI, Corey GR : Cytomegalovirus infection in the normal host. Medicine (Baltimore) 64 : 100-114, 1985.
PubMed
2) Horwitz CA, et al : Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore) 65 : 124-134, 1986.
PubMed
3) Klemola E, et al : Infectious-mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis 121 : 608-614, 1970.
PubMed
P.226 掲載の参考文献
1) Gitlin D, Janeway CA : Agammablobulinemia, congenital, acquired and transient forms. Prog Hematol 1 : 318-329, 1956.
PubMed
2) Atkinson AR, Roifman CM : Low serum immunoglobulin G2 levels in infancy can be transient. Pediatrics 120 : e543-547.2007.
PubMed
3) Soothill JF : Immunoglobulins in first-degree relatives of patients with hypogammaglobulinaemia. Transient hypogammaglonulinaemia : a possible manifestation of heterozygocity. Lancet 1 : 1001-1003, 1968.
PubMed
4) Fudenberg HH, Fudenberg BR : Antibody to hereditary human gamma-globulin (GM) factor resulting from maternal-fetal incompatibility. Science 145 : 170-171, 1964.
PubMed
5) Siegel RL, et al : Deficiency of T helper cells in transient hypogammaglobulinemia of infancy. N Engl J Med 305 : 1307-1313, 1981.
PubMed
6) Rutkowska M, et al : The number of circulating CD4+ CD25highFox3+T lymphocytes is transiently elevated in the early childhood of transient hypogammablobulinemia of infancy patients. Clin Immunol 140 : 307-310, 2011.
PubMed
7) Dalal I, et al : The outcome of patients with hypogammaglobulinemia in infacy and early childhood. J Pediatr 133 : 144-146, 1998.
 
8) Kanegane H, et al : Clinical and mutation characteristics of X-linked agammaglobulimemia and its carrier identified by flow cytometric assessment combined with genetic analysis. J Allergy Clin Immunol 108 : 1012-1020, 2001.
PubMed
9) Tiller TL Jr, Buckley RH : Transient hypogammaglobulinemia of infancy : review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr 92 : 347-353, 1978.
PubMed
10) Ozen A, et al : Outcome of hypogammaglobulinemia in children : Immunoglobulin levels as predictors. Clin Immunol 137 : 374-383, 2010.
PubMed
11) Cano F, et al : Absent specific viral antibodiesin patients with transient hypogammmaglobulinemia of infancy. J Allergy Clin Immunol 85 : 510-513, 1990.
 
P.230 掲載の参考文献
1) Bruton OC : Agammaglobulinemia. Pediatrics 9 : 722-728, 1952.
PubMed
2) Tsukada S, et al : Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72 : 279-290, 1993.
 
3) Vitrie D, et al : The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature 361 : 226-234, 1993.
 
4) Jouni Valiaho, et al : BTKbase : The mutation database for X-linked agammaglobulinemia. Hum Mutatat 27 : 1209-1217, 2006.
PubMed
5) Mohamed AJ, et al : Bruton's tyrosine kinase (Btk) : function, regulation, and transformation with special emphasis on the PH domain. Immuno Rev 228 : 58-73, 2009.
 
6) Conley ME : Genes required for B cell development. J Clin Invest 112 : 1636-1638, 2003.
PubMed
7) 峯岸克行 : BTK欠損を伴わない無ガンマグロブリン血症. 小児内科 40 (増刊号) : 1271-1274, 2008.
 
8) Winkelstein JA, et al : X-linked agammaglobulinemia : Report on a United States registry of 201 patients. Medicine 85 : 193-2022006.
PubMed
9) Honda F, et al : The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 13 : 369-378, 2012.
PubMed
10) Tai YT, et al : Bruton's tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120 : 1877-1887, 2012.
PubMed
11) Chang BY, et al : The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13 : R115, 2011. [http://arthritis-research.com/content/13/4/R115]
 
12) Takada H, et al : Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused buy extremely skewed X-chromosome inactivation. Blood 103 : 185-187, 2004.
 
13) Futatani T, et al : Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 91 : 595-602, 1998.
PubMed
14) Bayry J, et al : Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 101 : 14210-4215, 2004.
PubMed
P.236 掲載の参考文献
1) 森尾友宏 : 分類不能型免疫不全症. 日本臨牀 70 (11) : 2011-2021, 2012.
Medical*Online
2) 森尾友宏 : 分類不能型免疫不全症 Update. 日臨免疫会誌 35 : 14-22, 2012.
 
3) Yong PFK, et al : "A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol 111 : 47-107, 2011.
 
4) Al-Herz W, et al : Primary immunodeficiency diseases : an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2 : 54, 2011.
PubMed
5) Ombrello MJ, et al : Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 366 : 330-338, 2012.
PubMed
6) Lopez-Herrera G, et al : Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 90 : 986-1001, 2012.
PubMed
7) Salzer U, et al : Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 113 : 1967-1976, 2009.
PubMed
8) Warnatz K, et al : B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci USA 106 : 13945-13950, 2009.
PubMed
9) Takahashi N, et al : Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol 182 : 5515-5527, 2009.
PubMed
10) Borte S, et al : Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. Blood 119 (11) : 2552-2555, 2012.
PubMed
11) Kamae C, et al : Classification of common variable immunodeficiency by quantification of T cell receptor and Ig kappa-deleting recombination circles. J Allerg Clin Immunol. (inpress)
 
12) Kanegane H, et al : Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun 8 : 663-670, 2007.
 
13) Orange JS, et al : Impact of trough IgG on pneumonia incidence in primary immunodeficiency : a meta-analysis of clinical studies. Clin Immunol 137 : 21-30, 2010.
PubMed
14) Chapel H, et al : Common variable immunodeficiency disorders : division into distinct clinical phenotypes. Blood 112 : 277-286, 2008.
PubMed
P.241 掲載の参考文献
1) Kracker S, et al : Immunoglobulin class switch recombination deficiencies. Clin Immunol 135 (2) : 193-203, 2010.
PubMed
2) Hennig C, et al : "A bad wound may heal, but a bad name can kill" -lessons learned from "hyper-IgM syndrome". J Allergy Clin Immunol 128 (6) : 1380-1382, 2011.
 
3) Gathmann B, et al : The European internet-based patient and research database for primary immunodeficiencies : results 2006-2008. Clin Exp Immunol 157 (Suppl 1) : 3-11, 2009.
 
4) CEREDIH TFPSG : The French national registry of primary immunodeficiency diseases. Clin Immunol 135 (2) : 264-272, 2010.
 
5) Winkelstein JA, et al : The X-linked hyper-IgM syndrome : clinical and immunologic features of 79 patients. Medicine (Baltimore) 82 (6) : 373-384, 2003.
PubMed
6) Levy J, et al : Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 131 (1 Pt 1) : 47-54, 1997.
 
7) Ferrari S, et al : Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA 98 (22) : 12614-12619, 2001.
PubMed
8) Revy P, et al : Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102 (5) : 565-575, 2000.
PubMed
9) Imai K, et al : Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 4 (10) : 1023-1028, 2003.
PubMed
10) Gardes P, et al : Human MSH6 deficiency is associated with impaired antibody maturation. J Immunol 188 (4) : 2023-2029, 2012.
PubMed
11) Peron S, et al : Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 205 (11) : 2465-2472, 2008.
PubMed
12) Imai K, et al : Hyper-IgM syndrome type 4 with a B lymphocyte-intrinsic selective deficiency in Ig class-switch recombination. J Clin Invest 112 (1) : 136-142, 2003.
 
13) Buck D, et al : Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 124 (2) : 287-299, 2006.
PubMed
14) Aghamohammadi A, et al : Ataxia-telangiectasia in a patient presenting with hyper-immunoglobulin M syndrome. J Investig Allergol Clin Immunol 20 (5) : 442-445, 2010.
 
15) Quartier P, et al : Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol 110 (1) : 22-29, 2004.
PubMed
16) Gennery AR, et al : Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation : a survey of the European experience, 1993-2002. Blood 103 (3) : 1152-1157, 2004.
PubMed
P.244 掲載の参考文献
1) Conley ME, et al : Diagnostic criteria forprimary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93 : 190-197, 1999.
 
2) Geha RS, et al : Primary immunodeficiency diseases : an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 120 : 776-794, 2007.
 
3) Yel L : Selective IgA deficiency. J Clin Immunol 30 : 10-16, 2010.
PubMed
4) Gathmann B, et al : The European internet-based patient and research database for primary immunodeficiencies : results 2006-2008. Clin Exp Immunol 157 : 3-11, 2009.
PubMed
5) Kerr MA : The structure and function of human IgA. Biochem J 271 : 285-296, 1990.
PubMed
6) Cunningham-Rundles C : Physiology of IgA and IgA deficiency. J Clin Immunol 21 : 303-309, 2001.
PubMed
7) Wang Z, et al : Discordance between IgA switching at the DNA level and IgA expression at the mRNA level in IgA-deficient patients. Clin Immunol 91 : 263-270, 1999.
PubMed
8) Borte S, et al : Interleukin-21 restores immunoglobulin production ex vivo in patients with common variable immunodeficiency and selective IgA deficiency. Blood 114 : 4089-4098, 2009.
PubMed
9) Castigli E, et al : TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37 : 829-834, 2005.
PubMed
10) Jin R, et al : Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency. Int J Mol Med 21 : 233-238, 2008.
PubMed
11) Janzi M, et al : Selective IgA deficiency in early life : association to infections and allergic diseases during childhood. Clin Immunol 133 : 78-85, 2009.
PubMed
12) Aghamohammadi A, et al : IgA deficiency : correlation between clinical and immunological phenotypes. J Clin Immunol 29 : 130-136, 2009.
PubMed
13) Jacob CM, et al : Autoimmunity in IgA deficiency : revisiting the role of IgA as a silent housekeeper. J Clin Immunol 28 : S56-61, 2008.
 
14) Kutukculer N, et al : Increases in serum immunoglobulins to age-relatednormallevels in children with IgA and/or IgG subclass deficiency. Pediatr Allergy Immunol 18 : 167-173, 2007
 
P.248 掲載の参考文献
1) Kouvalainen K, et al : Chronic moniliasis, pyodermia and impaired capacity to form gamma-M antibodies. Ann Paediatr Fenn 12 : 256-262, 1966.
 
2) Schaller J, et al : Hypergammaglobulinaemia, antibody deficiency, autoimmune haemolytic anaemia, and nephritis in an infant with a familial lymphopenic immune defect. Lancet 88 : 825-829, 1966.
 
3) Cassidy T, Nordby GL : Human serum immunogloblin conentrations : prevalence of immunoglobulin deficiencies. J Allergy Clin Immunol 55 : 35-48, 1975.
 
4) Ross IN, Thompson RA : Severe selective IgM deficiency. J Clin Pathol 29 : 773-777, 1976.
PubMed
5) Hobbs JR : Immune imbalance in dysgammaglobulinaemia type IV. Lancet 291 : 110-114, 1968.
 
6) Goldstein MF : Selective IgM immunodeficiency : retrospective analysis of 36 adult patients with review of the literature. Ann Allergy Asthma Immunol 97 : 717-730, 2006.
PubMed
7) Goldstein MF, et al : Pediatric selective IgM immunodeficiency. Clin Dev Immunol 2008 : 624850, 2008.
PubMed
8) Belgemen T, et al : Selective immunoglobulin M deficiency presenting with recurrent impetigo : a case report and review of the literature. Int Arch Allergy Immunol 149 : 283-288, 2009.
PubMed
9) Yel L, et al : Clinical and immunological features in IgM deficiency. Int Arch Allergy Immunol 150 : 291-298, 2009.
PubMed
10) Sugita K, Eguchi M : Chronic idiopathic thrombocytic purpura in a young male patient with isolated IgM deficiency. Int J Hematol 73 : 532-533, 2001.
 
11) Ochs HD : Patients with abnormal IgM levels : assessment, clinical interpretation, and treatment. Ann Allergy Asthma Immunol 100 : 509-511, 2008.
PubMed
12) Kimura S, et al : Selective IgM deficiency in a patient with Hashimoto's disease. Intern Med 32 : 302-307, 1993.
 
13) 鳥羽剛ほか : 健康小児の血清免疫グロブリン (IgG, IgA, IgM) 年齢別正常値および正常範囲に関する一考察. アレルギー 21 : 608-613, 1972.
 
P.252 掲載の参考文献
1) Conley ME, et al : Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93 : 190-197, 1999.
 
2) Gathmann B, et al : The Europeaninternet-based patient and research database for primary immunodeficiencies : results 2006-2008. Clin Exp Immunol 157 : 3-11, 2009.
PubMed
3) Jefferis R, Kumararatne DS : Selective IgG subclass deficiency : quantification and clinical relevance. Clin Exp Immunol 81 : 357-367, 1990.
PubMed
4) Stiehm ER, et al : IgG subclass deficiency. In : Immunological Disorders in Infants & Children (ed by Stiehm ER, et al), p393-398, Elsevier Saunders, Philadelphia, 2004.
 
5) Tashita H, et al : Molecular basis of selective IgG2 deficiency. The mutated membrane-bound form of gamma 2 heavy chain caused complete IGG2 deficiency in two Japanese siblings. J Clin Invest 101 : 677-681, 1998.
 
6) Zhao Y, et al : Selective IgG2 deficiency due to a point mutation causing abnormal splicing of the Cgamma 2 gene. Int Immunol 17 : 95-101, 2005.
 
7) Terada T, et al : Analysis of Ig subclass deficiency : First reported caseof IgG2, IgG4, and IgA deficiency caused by deletion of C alpha 1, psi C gamma, Cgamma 2, Cgamma 4, and C epsilon in a Mongoloid patient. J Allergy Clin Immunol 108 : 602-606, 2001.
 
8) Lacombe C, et al : Selective IgG1 deficiency. Clin Immunol Immunopathol 84 : 194-201, 1997.
PubMed
9) Nahm MH, et al : Immunologic and clinical status of blood donors with subnormal levels of IgG2. J Allergy Clin Immunol 85 : 769-777, 1990.
PubMed
10) Oxelius VA, et al : IgG3 deficiency : common in obstructive lung disease. Hereditary in families with immunodeficiency and autoimmune disease. Monogr Allergy 20 : 106-115, 1986.
PubMed
11) Kim JH, et al : Immunoglobulin G subclass deficiency is the major phenotype of primary immunodeficiency in a Korean adult cohort. J Korean Med Sci 25 : 824-828, 2010.
 
12) Soderstrom T, et al : Immunoglobulin subclasses and prophylactic use of immunoglobulin in immunoglobulin G subclass deficiency. Cancer 68 : 1426-1429, 1991.
PubMed
13) de Moraes Lui C, et al : Immunoglobulin G subclass concentrations and infections in children and adolescents with severe asthma. Pediatr Allergy Immunol 13 : 195-202, 2002.
PubMed
14) Edwards E, et al : IgA deficiency : clinical correlates and responses to pneumococcal vaccine. Clin Immunol 111 : 93-97, 2004.
PubMed
15) Abdou NI, et al : Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults. Int Arch Allergy Immunol 149 : 267-274, 2009.
PubMed
P.256 掲載の参考文献
1) Hakami N, et al : Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med 285 : 1163-1170, 1971.
PubMed
2) 奥田邦雄ほか : トランスコバラミンII欠乏症 血液と脈管シリーズ 4. ビタミン B12-基礎と臨床-, p179-186, 科学評論社, 1978.
 
3) Colob-Otero G, et al : Disorder of cobalamin and folate metabolism. In : Fundamental of Clinical Hematology (ed by Thorup O), p185-211, WB Saunders Company, Philadelphia-London-Toronto-Sydney-Tokyo-Hong Kong, 1987.
 
4) Rogec A, et al : The cloning and characterization of the human transcobalamin II gene. Blood 85 : 2711-2719, 1995.
PubMed
5) Li N, et al : Genomic structure of human transcobalamin II : comparison to human intrinsic factor and transcobalamin I. Biochem Biophys Res Commun 208 : 756-764, 1995.
PubMed
6) Haberle J, et al : TC II deficiency : avoidance of false-negative molecular genetics by RNA-based investigation. J Hum Genet 54 : 331-334, 2009.
PubMed
7) Qian L, et al : Congenital transcobalamin II deficiency due to errors in RNA editing. Blood cells Mol Dis 28 : 134-142, disucussion 143-145, 2002.
 
8) Manuel S, et al : Should transcobalain deficiency be treated aggressively? J Inherit Metab Dis 33 : 223-229, 2010.
 
9) 渡辺文雄ほか : ビタミン B12. 日本臨牀 57 : 2205-2210, 2000.
 
10) Seger R, et al : Granulocyte dysfunction in transcobalamin II deficiency responding to leucovorin or hydroxycobalamin-plasma transfusion. J Inherit Metab Dis 3 : 3-9, 1980.
PubMed
11) Hall CA : The neurologic aspects of transcobalamin II deficiency. Br J Haematol 80 : 117-120, 1992.
PubMed
12) Barshop BA, et al : Transcobalamin II deficiency presenting with methylmalonic aciduria and homocystinuria and abnormal absorption of cobalamin. Am J Med Gene 35 : 222-228, 1990.
 
13) Gottleb C, et al : Rapid charcoal assay for intrinsic factor (IF), gastric juice unsaturated B12 binding capacity. Blood 25 : 875-884, 1965.
 
14) 内山幸信 : トランスコバラミン欠乏症. Jpn J Electroph 38 (6) : 403-410, 1994.
 
15) 内山幸信 : ビタミンの臨床. Modern Physician 27 (9) : 1216-1219, 2007.
 
P.260 掲載の参考文献
1) Di George AM : Discussion on a new concept of the cellular basis of immunity. J Pediatr 67 : 907, 1965 (abstract).
 
2) 岩田力 : 胸腺の発生障害と免疫不全症. 免疫・ Immunology Frontier 11 : 43-45, 2001.
Medical*Online
3) Wilson DI, et al : DiGeorge syndrome : part of CATCH 22. J Med Genet 30 : 852-856, 1993.
PubMed
4) Franke UC, et al : Interstitial deletion of 22q11 in DiGeorge syndrome detected by high resolution and molecular analysis. Clin Genet 46 : 187-192, 1994.
PubMed
5) McDonald-McGinn DM, et al : 22q11.2 Deletion Syndrome. In : Gene Reviews TM (ed by Pagon RA, et al) [internet], University of Washington, Seattle, 1993-.
 
6) Bassett AS, et al : Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 159 : 332-339.e1, 2011.
 
7) Kobrynski LJ, Sullivan KE : Velocardiofacial syndrome, DiGeorge syndrome : the chromosome 22q11.2 deletion syndromes. Lancet 370 : 1443-1452, 2007.
PubMed
8) Bockman DE, Kirby ML : Dependence of thymus development on derivatives of the neural crest. Science 223 : 498-500, 1984.
PubMed
9) Yamagashi H, Srivastava D : Unravelling the genetic and developmental mysteries of 22q11 deletion syndrome. Trends Mol Med 9 : 383-389, 2003.
 
10) Lammer EJ, Opitz JM : The DiGeorge anomaly as a developmental field defect. Am J Med Genet Suppl 2 : 113-127, 1986.
PubMed
11) Gennery AR : Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci 69 : 17-27, 2012.
PubMed
12) Hisato Y, et al : Role of TBX1 in human del22q11.2 syndrome. Lancet 362 : 1366-1373, 2003.
 
13) Markert ML, et al : Review of 54 patients with complete DiGeorge anomaly enrolled in protocol for thymus transplantation : outcome of 44 consecutive transplants. Blood 109 : 4539-4547, 2007.
PubMed
14) Conley ME, et al : The spectrum of the DiGeorge syndrome. J Pediatr 94 : 883-890, 1979.
PubMed
15) Chinn IK, Markert ML : Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly. J Allergy Clin Immunol 127 : 1351-1355, 2011.
PubMed
P.264 掲載の参考文献
1) Giblett ER, et al : Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1 : 1010-1013, 1975.
 
2) Hirshhorn R, Canotti F : Immunodeficiency due to defects of purine metabolism. In : Primary Immunodeficiency Diseases : A Molecular and Genetic Approach, 2nd ed (ed by Ochs HD, et al), p169-196, Oxford University Press, Inc, New York, 2007.
 
3) Hershfield MS, Mitchell BS : Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In : The Metabolic and Molecular Basis of Inherited Disease, 8th ed (ed by Scriver CR, et al), p2585-2625, McGraw-Hill, New York, 2001.
 
4) Knutsen AP : Purine Nucleoside Phosphorylase Deficiency. In : Medscape Reference [Internet] (ed by Jyonouchi H, et al), Updated Aug 29, 2011.
 
5) Markert ML : Purine nucleoside phosphorylase deficiency. Immunodefic Rev 3 : 45-81, 1991.
PubMed
6) 吉田泰祥ほか : Purine nucleoside phosphorylase欠損症の一例. 日児誌 90 : 2497-2502, 1986.
 
7) 崎山武志 : プリンヌクレオシドホスホリラーゼ (PNP). 日本臨牀 54 : 3220-3225, 1996.
Medical*Online
8) Arpaia E, et al : Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 191 : 2197-2208, 2000.
PubMed
9) Williams SR, et al : Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization. Nucleic Acids Res 12 : 5779-5787, 1984.
PubMed
10) Markert ML, et al : Mutations in purine nucleoside phosphorylase deficiency. Hum Mutat 9 : 118-121, 1997.
PubMed
11) Pannicke U, et al : Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patient. Hum Genet 98 : 706-709, 1996.
 
12) Grunebaum E, et al : Novel mutations and hot-spots in patients with purine nucleoside phosphorylase deficiency. Nucleosides Nucleotides Nucleic Acids 23 : 1411-1415, 2004.
PubMed
13) Al-Saud B, et al : A novel mutation in purine nucleoside phosphorylase in a child with normal uric acid levels. Clin Biochem 42 : 1425-1727, 2009.
 
14) Hershfield MS : Enzyme replacement therapy of adenosine deaminase with polyethylene glycol-modified adenosine deaminase (PEG-ADA). Immunodeficiency 4 : 93-97, 1993.
 
15) Toro A, et al : Intracellular delivery of purine nucleoside phosphorylase (PNP) fused to protein transduction domain corrects PNP deficiency in vitro. Cell Immunol 240 : 107-115, 2006.
PubMed
16) Classen CF, et al : Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning. Bone Marrow Transplant 28 : 93-96, 2001.
 
17) Myers LA, et al : Purine nucleoside phosphorylase deficiency (PNP-def) presenting with lymphopenia and developmental delay : successful correction with umbilical cord blood transplantation. J Pediatr 145 : 710-712, 2004.
PubMed
18) Delicou S, et al : Successful HLA-identical hematopoietic stem cell transplantation in a patient with purine nucleoside phosphorylase deficiency. Pediatr Transplant 11 : 799-803, 2007.
 
19) Liao P, et al : Lentivirus gene therapy for purine nucleoside phosphorylase deficiency. J Gene Med 10 : 1282-1293, 2008.
PubMed
P.268 掲載の参考文献
1) Wolf B : Disorders of biotin metabolism. In : The metabolic and molecular bases of inherited disease (ed by Scriver CR, et al), p3151-3177, McGraw-Hill, NY, 1995.
 
2) Cowan MJ, et al : Multiple biotin-dependent carboxylase deficiencies associated with defects in T-cell and B-cell immunity. Lancet 2 : 115-118, 1979.
 
3) Sander JE, et al : Intermittent ataxia and immunodeficiency with multiple carboxylase deficiencies : a biotin responsive disorder. Ann Neurol 8 : 544-547, 1980.
PubMed
4) Munnich A, et al : Biotin-responsive immunoregulatory dysfunction in multiple carboxylase deficiency. J Inher Metab Dis 4 : 113-114, 1981.
 
5) Wolf B, Feldman GL : The biotin-dependent carboxylase deficiencies. Am J Hum Genet 34 : 699-716, 1982.
PubMed
6) Suzuki Y, et al : Mutations in the holocarboxylase synthetase gene HLCS. Hum Mutat 26 : 285-290, 2005.
PubMed
7) Pindolia K, et al : Analysis of mutations causing biotinidase deficiency. Hum Mutat 31 : 983-991, 2010.
PubMed
8) Packman S, et al : The neonatal form of biotin responsive multiple carboxylase deficiency. J Pediatr 99 : 418-420, 1981.
PubMed
9) Hurvitz H, et al : Biotinidase deficiency assosiated with severe combined immunodeficiency. Lancet 2 : 228-229, 1989.
 
10) Mock DM, Dyken ME : Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants. Neurology 49 : 1444-1447, 1997.
PubMed
11) Mayende L, et al : A novel molecular mechanism to explain biotin-unresponsive holocarboxylase synthetase deficiency. J Mol Med 90 : 81-88, 2012.
PubMed
P.276 掲載の参考文献
1) International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies ; Notarangelo LD, et al : Primary immunodeficiencies : 2009 update. J Allergy Clin Immunol 124 : 1161-1178, 2009.
PubMed
2) ESIDホームページ : http://www.esid.org/statistics
 
3) Notarangelo LD : Primary immunodeficiencies. J Allergy Clin Immunol 125 : S182-194, 2010.
PubMed
4) Fischer A : Human primary immunodeficiency diseases. Immunity 27 : 835-845, 2007.
PubMed
5) Swanson PC : The bounty of RAG : recombination signal complexes and reaction outcomes. Immunol Rev 200 : 90-114, 2004.
PubMed
6) Buckley RH : The multiple causes of human SCID. J Clin Invest 114 : 1409-1411, 2004.
PubMed
7) Villa A, et al : Omenn syndrome : Inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol 122 : 1082-1086, 2008.
PubMed
8) Buckley RH : The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol 129 : 597-604, 2012.
 
9) More states screen for severe combined immunodeficiency : screening finds other genetic syndromes marked by immunodeficiency. Am J Med Genet A 158 A (8) : viii-ix, 2012.
 
10) Buckley RH : Transplantation of hematopoietic stem cells in human severe combined immunodeficiency : longterm outcomes. Immunol Res 49 : 25-43, 2011.
PubMed
P.280 掲載の参考文献
1) Hirschhorn R, Candotti F : Immunodeficiency due to defects of purine metabolism. In : Primary Immunodeficiency Diseases (ed by Ochs DH, et al), p169-196, Oxford Universtiy Press, New York, 2007.
 
2) Giblett ER, et al : Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2 : 1067-1069, 1972.
PubMed
3) Sauer AV, Aiuti A : New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr Opin Allergy Clin Immunol 9 : 496-502, 2009.
PubMed
4) Ishimura M, et al : Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol 31 : 968-976, 2011.
PubMed
5) Puck JM : Laboratory technology for population-based screening for severe combined immunodeficiency in neonates : the winner is T-cell receptor excision circles. J Allergy Clin Immunol 129 : 607-616, 2012.
 
6) Gaspar HB, et al : How I treat ADA deficiency. Blood 114 : 3524-3532, 2009.
 
7) Gaspar HB : Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am 30 : 221-236, 2010.
PubMed
8) Blaese RM, et al : T lymphocyte-directed gene therapy for ADA-SCID : initial trial results after 4 years. Science 270 : 475-480, 1995.
PubMed
9) Onodera M, et al : Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91 : 30-36, 1998.
PubMed
P.283 掲載の参考文献
1) de Vaal OM, Seynhaeve V : Reticular dysgenesia. Lancet 2 : 1123-1125, 1959.
 
2) Alonso K, et al : Thymic alymphoplasia and congenital aleukocytosis (reticular dysgenesia). Arch Pathol 94 : 179-183, 1972.
PubMed
3) Ownby DR, et al : Severe combined immunodeficiency with leucopenia (reticular dysgenesis) in siblings : immunologic and histopathologic findings. J Pediatr 89 : 382-387, 1976.
PubMed
4) Small TN, et al : Association of reticular dysgenesis (thymic alymphoplasia and congenital aleukocytosis) with bilateral sensorineural deafness. J Pediatr 135 : 387-389, 1999.
PubMed
5) Reticular dysgenesis : http://www.orpha.net/
 
6) Pannicke U, et al : Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nat Genet 41 : 101-105, 2009.
PubMed
7) Lagresle-Peyrou C, et al : Human adenylate kinase 2 deficiency causes a profound haematopoietic defect associated with sensorineural deafness. Nat Genet 41 : 106-111, 2009.
PubMed
8) Kohler C, et al : Release of adenylate kinase 2 from the mitochondrial intermemberane space during apoptosis. FEBS Lett 447 : 10-12, 1999.
PubMed
9) Lee HJ, et al : AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10. Nat Cell Biol 9 : 1303-1310, 2007.
PubMed
10) Wangemann P : Supporting sensory transduction : cochlear fluid homeostasis and the endocochlear potential. J Physiol 576 : 11-21, 2006.
PubMed
11) Barjaktarevic I, et al : Altered functional balance of Gfi-1 and Gfi-1b as an alternative cause of reticular dysgenesis? Med Hypotheses 74 : 445-448, 2010.
PubMed
12) Bujan W, et al : Effect of recombinant human granulocyte colony-stimulating factor in reticular dysgenesis. Blood 82 : 1684, 1993.
PubMed
13) Cosar H, et al : Reticular dysgenesis in a preterm infant : a case report. Pediatr Hematol Oncol 27 : 646-649, 2010.
 
P.287 掲載の参考文献
1) Grandea AG III, Van Kaer L : Tapasin : an ER chaperone that controls MHC class I assembly with peptide. Trends Immunol 22 : 194-199, 2001.
 
2) Touraine JL, et al : Combined immunodeficiency disease associated with absence of cell-surface HLA-A and -B antigens. J Pediatr 93 : 47-51, 1978.
 
3) Gadola SD, et al : TAP deficiency syndrome. Clin Exp Immunol 121 : 173-178, 2000.
PubMed
4) Yabe T, et al : A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination. Blood 100 : 1496-1498, 2002.
PubMed
5) Nekrep N, et al : When the lymphocyte loses its clothes. Immunity 18 : 453-457, 2003.
PubMed
6) Reith W, Mach B : Bare lymphocyte syndrome and the regulation of MHC expression. Ann Rev Immunol 19 : 331-373, 2001.
 
7) Shrestha D, et al : Bare lymphocyte syndrome : An opportunity to discover our immune system. Immunol Lett 141 : 147-157, 2011.
PubMed
8) Steimle V, et al : Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75 : 135-146, 1993.
 
9) Wiszniewski W, et al : Founder effect for a 26-bp deletion in the RFXANK gene in North Africa major histocompatibility complex class II-deficient patients belonging to complementation group B. Immunogenetics 51 : 261-267, 2000.
 
10) Ouederni M, et al : Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation : a survey of 35 patients. Blood 118 : 5108-5118, 2011.
PubMed
11) Steimle V, et al : A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 9 : 1021-1032, 1995.
PubMed
12) Nekrep N, et al : Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nat Immunol 3 : 1075-1081, 2002.
 
13) Durand B, et al : RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 16 : 1045-1055, 1997.
PubMed
14) Klein C, et al : Major histocompatibility complex class II deficiency : clinical manifestations, immunologic features, and outcome. J Pediatr 123 : 921-928, 1993.
PubMed
15) Picard C, Fischer A : Hematopoietic stem cell transplantation and other management strategies for MHC class II deficiency. Immunol Allergy Clin N Am 30 : 173-178, 2010.
 
P.292 掲載の参考文献
1) Boder E, Sedgwick RP : Ataxia-telangiectasia. (Clinical and immunological aspects). Psychiatr Neurol Med Psychol Beih 13-14 : 8-16, 1970.
 
2) Swift M, et al : The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 39 : 573-583, 1986.
PubMed
3) Chun HH, Gatti RA : Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 3 : 1187-1196, 2004.
PubMed
4) 森尾友宏 : Ataxia telangiectasiaの臨床的特徴-全国調査から明らかになったこと-. 小児科臨床 61 : 1805-1810, 2008.
Medical*Online
5) Morio T, et al : Phenotypic variations between affected siblings with ataxia-telangiectasia : ataxia-telangiectasia in Japan. Int J Hematol 90 : 455-462, 2009.
PubMed
6) Savitsky K, et al : A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268 : 1749-1753, 1995.
PubMed
7) 高木正稔 : DNA損傷応答と血液腫瘍. 臨床血液 51 : 539-545, 2010.
 
8) Gilad S, et al : Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet 5 : 433-439, 1996.
PubMed
9) Chun HH, et al : Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. Mol Genet Metab 80 : 437-443, 2003.
PubMed
10) Honda M, et al : Rapid diagnosis of ataxia-telangiectasia by flow cytometric monitoring of DNA damage-dependent ATM phosphorylation. Leukemia 23 : 409-414, 2009.
PubMed
11) Nowak-Wegrzyn A, et al : Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 144 : 505-511, 2004.
PubMed
12) Carney EF, et al : Classical ataxia telangiectasia patients have a congenitally aged immune system with high expression of CD95. J Immunol 189 : 261-268, 2012.
PubMed
13) Bredemeyer AL, et al : Aberrant V (D) J recombination in ataxia telangiectasia mutated-deficient lymphocytes is dependent on nonhomologous DNA end joining. J Immunol 181 : 2620-2625, 2008.
PubMed
14) Giardino G, et al : Betamethasone therapy in Ataxia Telangiectasia : unraveling the rationale of this serendipitous observation on the basis of the pathogenesis. Eur J Neurol, 2012. [Epub ahead of print]
 
P.296 掲載の参考文献
1) Aldrich RA, et al : Pedigree demonstrating as ex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics 13 : 133-139, 1954.
 
2) Stray-Pedersen A, et al : Primary immunodeficiency diseases in Norway. J Clin Immunol 20 : 477-485, 2000.
PubMed
3) Jin Y, et al : Mutations of the Wiskott-Aldrich Syndrome Protein (WASP) : hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 104 : 4010-4019, 2004.
PubMed
4) Ochs HD, Thrasher AJ : The Wiskott-Aldrich syndrome. J Allergy Clin Immunol 117 : 725-738, 2006.
PubMed
5) Blundell MP, et al : The Wiskott-Aldrich syndrome : The actin cytoskeleton and immune cell function. Dis Markers 29 : 157-175, 2010.
PubMed
6) Meyer-Bahlburg A, et al : Wiskott-Aldrich syndrome protein deficiency in B cells results in impaired peripheral homeostasis. Blood 112 : 4158-4169, 2008.
 
7) Shcherbina A, et al : Pathological events in platelets of Wiskott-Aldrich syndrome patients. Br J Haematol 106 : 875-883, 1999.
PubMed
8) Mehmet D, et al : Eczematous skin lesions in an infant. Am Fam Physician 15 : 191-193, 2009.
 
9) Dupuis-Girod S, et al : Autoimmunity in Wiskott-Aldrich syndrome : risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 111 : 622-627, 2003.
 
10) Ochs HD, et al : The Wiskott-Aldrich syndrome : studies of lymphocytes, granulocytes, and platelets. Blood 55 : 243-252, 1980.
PubMed
11) Orange JS, et al : Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci 99 : 11351-11356, 2002.
PubMed
12) Albert MH, et al : X-linked thrombocytopenia (XLT) due to WAS mutations : clinical characteristics, long-term outcome, and treatment options. Blood 115 : 3231-3238, 2010.
PubMed
13) Ozsahin H, et al : Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome : collaborative study of the European Society for Immunodeficiencies and European Groupfor Blood and Marrow Transplantation. Blood 111 : 439-445, 2008.
 
14) Boztug K, et al : Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363 : 1918-1927, 2010.
PubMed
15) Imai K, et al : Clinical course of patients with WASP gene mutation. Blood 103 : 456-464, 2004.
PubMed
P.299 掲載の参考文献
1) Bloom D : Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs. Am J Dis Child 88 : 754-758, 1954.
 
2) Ellis NA, et al : The Bloom syndrome gene product is homologous to RecQ helicases. Cell 83 : 655-666, 1995.
PubMed
3) German J : Bloom syndrome : a mendelian prototype of somatic mutational disease. Medicine (Baltimore) 72 : 393-406, 1993.
PubMed
4) 金子英雄 (研究代表者) : 遺伝子修復異常症 (Bloom症候群, Rothmund-Thomson症候群, PAPADILINO症候群, Baller-Gerold症候群) の実態調査, 早期診断法の確立に関する研究. 厚生労働省科学研究費補助金難治性疾患克服研究事業. 平成23年度 総括・分担研究報告書.
 
5) German J, et al : Syndrome-causing mutations of the BLM gene in persons in the Bloom's syndrome registry. Hum Mutat 28 : 743-753, 2007.
PubMed
6) Kaneko H, et al : BLM (the causative gene of Bloom syndrome) protein translocation into the nucleus by a nuclear localization signal. Biochem Biophys Res Commun 240 : 348-353, 1997.
PubMed
7) Wang Y, et al : BASC, a super complex of BRACA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14 : 927-939, 2000.
 
8) Kaneko H, Kondo N : Clinical features of Bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn 4 : 393-401, 2004.
PubMed
P.302 掲載の参考文献
1) Good RA : Agammaglobulinemia-a provocative experiments of nature. Bull Univ Minn Hosp 26 : 1-19, 1954.
 
2) Al-Herz W, et al : Primary immunodeficiency diseases : an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2 : 54, 2011.
PubMed
3) 岩田力 : 原発性免疫不全症候群症例登録調査. 厚労省特定疾患血液疾患調査研究班 原発性免疫不全症候群分科会. 平成19年度研究業績報告書, 2007.
 
4) Montella L, et al : B-cell lymphopenia and hypogammaglobulinemia in thymoma patients. Ann Hematol 82 : 343-347, 2003.
 
5) Morgenthaler TI, et al : Thymoma. Mayo Clin Proc 68 : 1110-1123, 1993.
PubMed
6) Masci AM, et al : Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B lymphopenia. Blood 101 : 3106-3108, 2003.
PubMed
7) Shimizu T, et al : [Analysis of T cell subset in a case of Good syndrome]. Nihon Naika Gakkai Zasshi 97 : 3052-3055, 2008.
 
8) Yamazaki K, et al : Good's syndrome with a block in the early stage of B cell differentiation and complicated by Campylobacter fetus sepsis. Intern Med 33 : 496-500, 1994.
 
9) Watta RG, Kelly DR : Fatal varicella infection in a child associated with thymoma and immunodeficiency (Good's syndrome). Med Pediatr Oncol 18 : 246-251, 1990.
 
10) Kitamura A, et al : Durable hypogammaglobulinemia associated with thymoma (Good syndrome). Intern Med 48 : 1749-1752, 2009.
PubMed
P.309 掲載の参考文献
1) Davis SD, Schaller J : Job's syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet 1 : 1013-1015, 1966.
PubMed
2) Buckley RH, et al : Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 49 : 59-70, 1972.
PubMed
3) 高田英俊, 峯岸克行 : 高IgE症候群の最近の話題. 日臨免疫会誌 33 : 15-19, 2010.
 
4) Holland SM, et al : STAT3 Mutations in the Hyper-IgE Syndrome. N Engl J Med 357 : 1608-1619, 2007.
PubMed
5) Blaschitz C, Raffatellu M : Th17 cytokines and the gut mucosal barrier. J Clin Immunol 30 : 196-203, 2010.
 
6) Minegishi Y, et al : Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 : 745-755, 2006.
PubMed
7) Minegishi Y, Takada T : Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome : lessons from a primary immunodeficiency. Int Immunol 22 : 105-112, 2010.
 
8) Zhang Q, et al : Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 361 : 2046-2055, 2009.
PubMed
9) Grimbercher B, et al : Genetic linkage of heper-IgE syndrome to chromosome 4. Am J Hum Genet 65 : 735-744, 1999.
 
10) Szczawindka-Poponyk A, et al : The hyperimmunoglobulin E syndrome-clinical manifestation diversity in primary immune deficiency. Orphanet J Rare Dis 6 : 76-85, 2011.
PubMed
11) Fukunaga Y : Primary immunodeficiency diseases. J Nippon Med Sch 67 : 83-91, 2000.
PubMed
12) Zhang Q, Su HC : Hyperimmunoglobulin E syndrome in pediatrics. Curr Opin Pediatr 23 : 653-658, 2011.
 
P.316 掲載の参考文献
1) Al-Herz W, et al : Primary immunodeficiency diseases : an update on the classification from the International Union of Immunological Societies Expert Committeefor Primary Immunodeficiency. Front Immunol 2 : 54, 2011.
PubMed
2) Mayilyan KR : Complement genetics, deficiencies, and disease associations. Protein Cell 3 (7) : 487-496, 2012.
PubMed
3) Richard BJ Jr : Disorder of the complement System. In : Nelson Textbook of Pediatrics, 19th ed, chapter 128, p753-756, 2011.
 
4) Hayakawa J, et al : An infantile case of early manifestation of SLE-like symptoms in complete C1q deficiency. J Nihon Med Sch 78 : 322-328, 2011.
 
5) Laich A, Sim RB : Cross-talk between the human complement classical and alternative pathways : evidence for a C4bBb 'hybrid' C3 convertase. Mol Immunol 38 : 105, 2011.
 
6) Yang Y, et al : The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 7 : 98-132, 2004.
PubMed
7) Mayilyan KR, et al : Complement C4B protein in schizophrenia. World J Biol Psychiatry 9 (3) : 225-230, 2008.
PubMed
8) Cicardi M, Johnston DT : Hereditary and acquired complement component 1 esterase inhibitor deficiency : a review for the hematol ogist. Acta Haematol 127 (4) : 208-220, 2012.
 
9) Turner MW : The role of mannose-binding lectin in health and disease. Mol Immunol 40 : 423-429, 2003.
PubMed
10) Figueroa JE, Densen P : Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4 : 359-395, 1991.
PubMed
11) Linton S : Animal models of inherited complement deficiency. Mol Biotechnol 18 : 135-148, 2001.
PubMed
12) 原寿郎 : 先天性補体欠損症. 小児内科 40 (増刊号) : 1360-1364, 2008.
 
13) Takeda J, et al : Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 : 703-711, 1993.
PubMed
P.320 掲載の参考文献
1) Barre-Sinoussi F, et al : Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 : 868-871, 1983.
 
2) Dragic T, et al : HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 : 667-673, 1996.
PubMed
3) Gottlieb MS, et al : Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men : evidence of a new acquired cellular immunodeficiency. N Engl J Med 305 : 1425-1431, 1981.
PubMed
4) Takahashi H : Species-specific CD1-restricted innate immunity for the development of HIV vaccine. Vaccine 28 (Suppl 2) : B3-B7, 2010.
 
5) Ho DD, et al : Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 : 123-126, 1995.
PubMed
6) van der Vlist M, et al : Innate signaling in HIV-1 infection of dendritic cells. Curr Opin HIV AIDS 6 : 348-352, 2011.
PubMed
7) Rodriguez B, et al : Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296 : 1498-1506, 2006.
PubMed
P.325 掲載の参考文献
1) Takahashi H : Antigen processing and presentation. Microbiol Immunol 37 : 1-9, 1993.
PubMed
2) Takahashi H : Species-specific CD1-restricted innate immunity for the development of HIV vaccine. Vaccine 28 (Suppl 2) : B3-7, 2010.
 
3) Hammond WPT, et al : Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 320 : 1306-1311, 1989.
 
4) Lipsky PE, et al : Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti- Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 : 1594-1602, 2000.
 
5) Chung SJ, et al : Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36 : 2416-2420, 2009.
PubMed
6) Hughes WT, et al : From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161 : 381-396, 1990.
 

V 血小板の異常

P.332 掲載の参考文献
1) Thiele J, et al : Essential thrombocythaemia. In : WHO classification of tumours of haematopoietic and lymphoid tissues (ed by Swerdlow SH, et al), p48-50, IARC, Lyon, 2008.
 
2) Vainchenker W, et al : New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118 : 1723-1735, 2011.
PubMed
3) Theocharides A, et al : Leukemic blasts in transformed JAK2-V617-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110 : 375-379, 2007.
 
4) Harrison, et al : Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353 : 35-45, 2005.
 
5) Dan K, et al : Clinical features of polycythemia vera and essential thrombocythemia in Japan : Retrospective analysis of a nationwide survey by the Japanese elderly leukemia and lymphoma study group. Int J Hematol 83 : 443-449, 2006.
 
6) Thiele J, et al : Essential thrombocythemia versus early primary myelofibrosis : a multicenter study to validate the WHO classification. Blood 117 : 5710-5718, 2011.
PubMed
7) Beer P, et al : How I treat essential thrombocythemia. Blood 117 : 1472-1482, 2011.
 
8) Barbui T, et al : Philadelphila-negative classical myeloproliferative neoplasms : Critical concepts and management recommendations from European Leukemia Net. J Clin Oncol 29 : 761-770, 2011.
 
9) Lussana F, et al : Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia of idiopathic myelofibrosis : a systematic review. Thromb Res 124 : 409-417, 2009.
PubMed
10) Cortelazzo S, et al : Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332 : 1132-1136, 1995.
 
11) Landolfi R, et al : Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350 : 114-124, 2004.
PubMed
12) Jensen MK, et al : Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 65 : 132-139, 2000.
 
13) Alvarez-Larran A, et al : Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116 : 1205-1210, 2010.
PubMed
14) Verstovsek S, et al : A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366 : 799-807, 2012.
PubMed
P.336 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, WHO, 4th ed, 2008.
 
2) Buss DH, et al : Occurrence, etiology, and clinical significance of extreme thrombocytosis a study of 280 cases. Am J Med 96 (3) : 247-253, 1994.
PubMed
3) Lok S, et al : Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369 (6481) : 565-568, 1994.
PubMed
4) Kaushansky K, et al : Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369 (6481) : 568-571, 1994.
 
5) Ishida Y, et al : Effects of c-mpl ligand on cytoplasmic maturation of murineme gakaryocytes and on platelet production. J Histochem Cytochem 46 (1) : 49-57, 1998.
 
6) Dempfle CE, et al : Increase in platelet count in response to rHuEpo in a patient with thrombocytopenia and absent radii syndrome. Blood 97 (7) : 2189-2190, 2001.
 
7) Ishibashi T, et al : Thrombopoietic effects of interleukin-6 in long-term administration in mice. Exp Hematol 21 (5) : 640-646, 1993.
PubMed
8) Nagata Y, et al : Proplatelet formation of megakaryocytes is triggered by autocrine-synthesized estradiol. Genes Dev 17 (23) : 2864-2869, 2003.
PubMed
9) Ishida Y, et al : Purification of proplatelet formation (PPF) stimulating factor : thrombin/antithrombin III complex stimulates PPF of megakaryocytes in vitro and platelet production in vivo. Thromb Haemost 85 (2) : 349-355, 2001.
PubMed
10) Ishiguro A, et al : Elevation of serum thrombopoietin precedes thrombocytosis in acute infections. Br J Haematol 116 (3) : 612-618, 2002.
PubMed
11) Akan H, et al : Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis. Acta Haematol 103 (3) : 152-156, 2000.
PubMed
12) Bilic E, Bilic E : Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia. J Pediatr Hematol Oncol 25 (8) : 675-676, 2003.
PubMed
13) Broudy VC, et al : Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85 (7) : 1719-1726, 1995.
PubMed
14) Balcik OS, et al : Increased erythropoietin levels in reactive thrombocytosis. Haematologia 32 (1) : 59-65, 2002.
PubMed
15) Tsuji K, et al : Interferon-gamma and human megakaryocytopoiesis. Leuk Lymphoma 31 (1-2) : 107-113, 1998.
 
16) Dan K, et al : Clinical features of polycythemia vera and essential thrombocythemia in Japan : retrospective analysis of a nationwide survey by the Japanese elderly leukemia and lymphoma study group. Int J Hematol 83 : 443-449, 2006.
 
P.340 掲載の参考文献
1) Cines DB, Blanchette VS : Immune thrombocytopenic purpura. N Engl J Med 346 : 995-1008, 2002.
PubMed
2) 冨山佳昭 : 特発性血小板減少性紫斑病. 臨床血液 49 : 1298-1305, 2008.
 
3) Rodeghiero F, et al : St and ardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 113 : 2386-2393, 2009.
 
4) 藤沢康司 : 特発性血小板減少性紫斑病 (小児) 血液疾患診療ハンドブック-診療の手引きと臨床データ集-改訂版 (吉田彌太郎編), p557-571, 医薬ジャーナル社, 2009.
 
5) 白幡聡ほか : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小血会誌 18 : 210-218, 2004.
 
P.344 掲載の参考文献
1) Cuker A, Cines DB : Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010 : 377-384, 2010.
PubMed
2) 冨山佳昭ほか : ITP (特発性血小板減少性紫斑病) 研究報告. 厚生労働科学研究費補助金難治性疾患克服研究事業血液凝固異常症に関する調査研究 (主任研究者村田満). 平成20-22年度総括・分担研究報告書. p15-37, 2011.
 
3) McMillan R, et al : Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood 70 : 1040-1045, 1987.
PubMed
4) Kuwana M, et al : Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura ; role in production of anti-platelet autoantibody. J Clin Invest 102 : 1393-1402, 1998.
PubMed
5) Kuwana M, et al : Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 168 : 3675-3682, 2002.
 
6) Miossec P, et al : Mechanisms of desease : Interleukin-17 and type 17 helper T cells. N Engl J Med 361 : 888-898, 2009.
 
7) Panitsa FP, et al : Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103 : 2645-2647, 2004.
 
8) Wang JD, et al : Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP). Pediatr Blood Cancer 57 : 636-640, 2011.
 
9) Zhang XL, et al : De novo induction of platelet-specific CD4+ CD25+ regulatory T cells from CD4+ CD25- cells in patients with idiopatghic thrombocytopenic purpura. Blood 113 : 2568-2577, 2009.
PubMed
10) Fabis F, et al : Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 103 : 4562-4564, 2004.
 
11) Kuwana M, et al : Detection of circulating B cells secreting platelet-specific autoantibody is a sensitive and specific test for the diagnosis of autoimmune thrombocytopenia. Am J Med 114 : 322-325, 2003.
 
12) Mukai H, et al : Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenic are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 76 : 675-678, 1996.
PubMed
13) Fujimura K, et al : Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? analysis of 207 eradicated chronic ITP casesin Japan. Int J Hematol 81 : 162-168, 2005.
 
14) Stasi R, et al : Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 : 952-957, 2001.
PubMed
15) Nomura S, et al : Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100 : 728-730, 2002.
PubMed
16) Bussel JB, et al : Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 : 2237-2247, 2007.
PubMed
17) Kuter DJ, et al : Efficacy of romiplostim in patients with chronic immune thombocytopenic purpura : a double-blind randomized controlled trial. Lancet 371 : 395-403, 2008.
 
18) 藤村欣吾ほか : 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液 53 : 433-442, 2012.
 
P.350 掲載の参考文献
1) 日本小児血液学会疾患登録委員会 : 平成21年度日本小児血液学会疾患登録集計報告. 日小児血液会誌 24 : 182-189, 2010.
Medical*Online
2) Kurata Y, et al : Epidemiology of primary immune thrombocytopenia in children and adults in Japan : a population-based study and literature review. Int J Hematol 93 : 329-335, 2011.
PubMed
3) Shirahata A, et al : A nationwide survey of newly diagnosed childhood idiopathic thrombocytopenic purpura in Japan. J Pediatr Hematol Oncol 31 : 27-32, 2009.
PubMed
4) Kuwana M, et al : Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 98 : 130-139, 2001.
PubMed
5) Kuwana M, Ikeda Y : The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol 81 : 106-112, 2005.
PubMed
6) 今泉益栄 : 特発性血小板減少性紫斑病, あるいは免疫性血小板減少症 (ITP) を取り巻く最近の動向. 日小児血液会誌 25 : 8-16, 2011.
Medical*Online
7) 白幡聡ほか : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小児血液会誌 18 : 210-218, 2004.
 
8) Rodeghiero F, et al : St and ardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an intrnational working group. Blood 113 : 2386-2393, 2009.
 
9) Kubota M, et al : Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children : a retrospective multi-center study. Int J Hematol 91 : 252-257, 2010.
PubMed
10) Bredlau AL, et al : Management of immune thrombocytopenic purpura in children. Pediatr Drugs 13 : 213-223, 2011.
 
11) 今泉益栄ほか : ITPに関する最近の展開. 日小血・がん会誌 49 : 373-381, 2012.
 
12) Cheng G, et al : Eltrombopag for management of chronic immune thrombocytopenia (RAISE) : a 6-month, randomised, phase 3 study. Lancet 377 (9763) : 393-402, 2011.
 
13) Kuter DJ, et al : Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomised controlled trial. Lancet 371 : 395-403, 2008.
PubMed
14) Provan D, et al : International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115 : 168-186, 2010.
PubMed
P.354 掲載の参考文献
1) 冨山佳昭 : 特発性血小板減少性紫斑病. 臨床血液 49 : 1298-1305, 2008.
 
2) Cines DB, et al : Immune thrombocytopenic purpura. N Engl J Med 346 : 995-1008, 2002.
PubMed
3) Rodeghiero F, et al : Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 113 : 2386-2393, 2009.
 
4) 藤村欣吾ほか : 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液 53 : 433-442, 2012.
 
5) Kurata Y, et al : Epidemiology of primary immune thrombocytopenia in childrenand adults in Japan : a population-based study and literaturereview. Int J Hematol 93 : 329-335, 2011.
 
6) Kurata Y, et al : Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 115 : 656-664, 2001.
PubMed
7) 冨山佳昭 : トロンボポエチン受容体作動薬による難治性ITPの治療. 臨床血液 52 : 627-632, 2011.
 
8) Bussel JB, et al : Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 : 2237-2247, 2007.
PubMed
9) Tomiyama Y, et al : A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 10 : 799-806, 2012.
PubMed
10) Kuter DJ, et al : Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomised controlled trial. Lancet 371 : 395-403, 2008.
PubMed
11) Neunert C, et al : The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117 : 4190-4207, 2011.
PubMed
12) Arnold DM, et al : Systematic review : efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146 : 25-33, 2007.
PubMed
13) Portielje JE, et al : Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97 : 2549-2554, 2001.
PubMed
P.357 掲載の参考文献
1) 川口千晴, 高橋幸博 : 周産期をめぐる血液-胎児・新生児編, 新生児血小板減少症. 周産期医学 33 : 356-360, 2003.
 
2) 白川嘉継, 白幡聡 : 症例から学ぶ自己免疫疾患, 新生児同種免疫性血小板減少症. 小児内科 36 : 1634-1637, 2004.
 
3) Ohto H, et al : The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 14 : 399-408, 2004.
PubMed
4) 大戸斉 : 抗血小板抗体. わかりやすい周産期・新生児の輸血療法 (大戸斉, 大久保光夫編), p143-147, メジカルビュー社, 2009.
 
5) 飯野美穂ほか : 本邦における新生児血小板減少症の集計調査. 日輸血細胞治療会誌 56 : 508-514, 2010.
Medical*Online
6) Spencer JA, Burrows RF : Feto-maternal alloimmune thrombocytopenia : a literature review and statistical analysis. Aust NZJ Obstet Gynaecol 41 : 45-55, 2001.
 
7) Skogen B, et al : Neonatal alloimmune thrombocytopenia is not what it was : a lesson learned from a large prospective screening and intervention program. Scand J Immunol 70 : 531-534, 2009.
 
8) Svejgaard A, et al : Isoimmune neonatal purpura caused by anti-PlGrLy BI. Scand J Haematol 4 : 118, 1967.
 
9) Arnold DM, et al : Diagnosis and management of neonatal alloimmune thrombocytopenia. Transfus Med Rev 22 : 255-267, 2008.
PubMed
10) 野村寿博ほか : HPA-3a抗原不適合による新生児同種免疫性血小板減少症の1例. 日小児会誌 113 : 857-860, 2009.
 
11) Curtis BR : Genotyping for human platelet alloantigen polymorphisms : applications in the diagnosis of alloimmune platelet disorders. Semin Thromb Hemost 34 : 539-548, 2008.
PubMed
12) Holzhauer S, Zieger B : Diagnosis and management of neonatal thrombocytopenia. Semin Fetal Neonatal Med 16 : 305-310, 2011.
PubMed
13) Symington A, Paes B : Fetal and neonatal alloimmune thrombocytopenia : harvesting the evidence to develop a clinical approach to management. Am J Perinatol 28 : 137-144, 2011.
PubMed
14) 橋本誠ほか : 抗HPA-1a抗体による新生児同種免疫性血小板減少症の対応. 日輸血細胞治療会誌 56 : 648-650, 2010.
Medical*Online
15) 松橋美佳 : 輸血に関連した血小板の検査. 検査と技術 38 : 848-851, 2010.
 
P.362 掲載の参考文献
1) Kadidal VV, et al : Heparin-induced thrombocytopenia (HIT) due to heparin flushes : a report of three cases. J Intern Med 246 (3) : 325-329, 1999.
 
2) Warkentin TE, et al : Heparin-induced thrombocytopenia : pathogenesis and management. Br J Haematol 121 : 535-555, 2003.
PubMed
3) Selling S, et al : Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 6 : 428-435, 2008.
 
4) Lubenow N : New developments in diagnosis and treatment of heparin-induced thrombocytopenia. Pathophysiol Haemost Thromb 33 : 407-412, 2003/2004.
 
5) Reilly MP, et al : Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through Fcgammma RIIA. Blood 98 : 2442-2447, 2001.
 
6) Warkentin TE, Kelton JG : Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (17) : 1286-1292, 2001.
PubMed
7) Warkentin TE, Kelton JG : Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 (7) : 502-506, 2001.
PubMed
8) Greinacher A, et al : Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94 : 132-135, 2005.
PubMed
9) Lo GK, et al : Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4 (4) : 759-765, 2006.
PubMed
10) 松尾武文 : ヘパリン起因性血小板減少症-その病態と治療. 臨床血液 43 (6) : 464-467, 2002.
 
11) Regnault V, et al : Platelet activation induced by human antibodies to interleukin-8. Blood 101 (4) : 1419-1421, 2003.
PubMed
12) Takemoto CM, Streiff MB : Heparin-induced thrombocytopenia screening and management in pediatric patients. Hematology Am Soc Hematol Educ Program 2011 : 162-169, 2011.
PubMed
13) Chong BH, et al : The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 69 : 344-350, 1993.
PubMed
14) Warkentin TE : Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 135 : 589-593, 2001.
PubMed
15) Lewis BE, et al : Argatroban anticoagulant the therapy in patients with heparin induced thrombocytopenia. Circulation 103 : 1838-1843, 2001.
PubMed
P.367 掲載の参考文献
1) George JN, et al : Drug-induced thrombocytopenia : a systematic review of published case reports. Ann Int Med 129 : 886-890, 1998.
PubMed
2) George JN, Aster RH : Drug-induced thrombocytopenia : pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program : 153-158, 2009.
PubMed
3) Aster RH, Bougie DW : Drug-induced immune thrombocytopenia. N Engl J Med 357 (6) : 580-587, 2007.
PubMed
4) Garner SF, et al : Glycoprotein V : the predominant target antigen in gold-induced autoimmune thrombocytopenia. Blood 100 (1) : 344-346, 2002.
PubMed
5) Christie DJ, et al : Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 75 (1) : 310-314, 1985.
PubMed
6) Lopez JA, et al : The glycoprotein Ib-IX complex-specific monoclonal antibody SZ1 binds to a conformation-sensitive epitope on glycoprotein IX : implications for the target antigen of quinine/quinidine-dependent autoantibodies. Blood 85 (5) : 1254-1258, 1995.
PubMed
7) Chong BH, et al : Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 77 (10) : 2190-2199, 1991.
PubMed
8) Curtis BR, et al : Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 84 (1) : 176-183, 1994.
PubMed
9) Visentin GP, et al : Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 77 (12) : 2668-2676, 1991.
PubMed
10) Berkowitz SD, et al : Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 95 (4) : 809-813, 1997.
PubMed
11) Fiorin F, et al : IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb. Am J Clin Pathol 110 (2) : 178-183, 1998.
PubMed
12) Cancio LC, Cohen DJ : Heparin-induced thrombocytopenia and thrombosis. J Am Coll Surg 186 (1) : 76-91, 1998.
PubMed
13) Coblyn JS, et al : Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 95 (2) : 178-181, 1981.
PubMed
14) Nieminen U, Kekomaki R : Quinidine-induced thrombocytopenic purpura : clinical presentation in relation to drug-dependent and drug-independent platelet antibodies. Br J Haematol 80 (1) : 77-82, 1992.
PubMed
15) Leach MF, et al : Detection of drug-dependent, platelet-reactive antibodies by solid-phase red cell adherence assays. Br J Haematol 97 (4) : 755-761, 1997.
PubMed
P.371 掲載の参考文献
1) Moschcowitz E : Hyaline thrombosis of the terminal arterioles and capillaries : A hitherto undescribed disease. Pro N Y Pathol Soc 24 : 21-24, 1924.
 
2) Amorosi EL, et al : Thrombotic thrombocytopenic purpura : report of 16 cases and review of the literature. Medicine 45 : 139-160, 1966.
 
3) Moake JL, et al : Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307 : 1432-1435, 1982.
PubMed
4) Furlan M, et al : Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87 : 4223-4234, 1996.
PubMed
5) Tsai HM : Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87 : 4235-4244, 1996.
PubMed
6) Soejima K, et al : A novel human metalloprotease synthesized in the liver and secreted into the blood : possibly, thevon Willebrand factor-cleaving protease? J Biochem 130 : 475-480, 2001.
 
7) Levy GG, et al : Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 : 488-494, 2001.
 
8) Tsai HM, Lian EC : Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 : 1585-1594, 1998.
PubMed
9) Furlan M, et al : von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and thehemolytic-uremic syndrome. N Engl J Med 339 : 1578-1584, 1998.
PubMed
10) Lotta LA, et al : ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 31 : 11-19, 2010.
PubMed
11) Tandon NN, et al : Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 88 : 816-825, 1994.
PubMed
12) Rock GA, et al : Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325 : 393-397, 1991.
PubMed
13) George JN : How I treat patients with thrombotic thrombocytopenic purpura : 2010. Blood 116 : 4060-4069, 2010.
 
14) Scully M, et al : Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158 : 323-335, 2012.
PubMed
15) Scully M, et al : A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118 : 1746-1753, 2011.
 
P.374 掲載の参考文献
1) Epstein CJ, et al : Hereditary macrothrombocytopathia, nephritis and deafness. Am J Med 52 : 299-310, 1972.
PubMed
2) Naito I, et al : Normal distribution of collagen IV in renal basement membranes in Epstein's syndrome. J Clin Pathol 50 : 919-922, 1997.
 
3) Kunishima S, Saito H : Advances in the understanding of MYH9 disorders. Curr Opin Hematol 17 : 405-410, 2010.
PubMed
4) Kunishima S, et al : Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations. Eur J Haematol 78 : 220-226, 2007.
PubMed
5) Pecci A, et al : Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 29 : 409-417, 2008.
PubMed
6) Kunishima S, et al : Accumulation of MYH9 mRNA at leukocyte inclusion bodies in MYH9 disorders. Eur J Haematol 81 : 325-326, 2008.
PubMed
7) Chang Y, et al : Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 109 : 4229-4236, 2007.
PubMed
8) Chen Z, et al : The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 110 : 171-179, 2007.
PubMed
9) Sekine T, et al : Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int 78 : 207-214, 2010.
PubMed
10) Kunishima S, et al : Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders : association of subcellular localization with MYH9 mutations. Lab Invest 83 : 115-122, 2003.
PubMed
11) 國島伸治 : 先天性巨大血小板症の鑑別診断. 血栓止血誌 22 : 100-106, 2011.
 
12) Ogura M, et al : ABO-incompatible renal transplantation in Epstein syndrome. Clin Transplant 24 (Suppl 22) : 31-34, 2010.
 
13) Pecci A, et al : Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrol Dial Transplant 23 : 2690-2692, 2008.
PubMed
P.379 掲載の参考文献
1) Lacombe M, D'angelo G : Etudes sur une thrombopathie familial. Nouv Rev Fr Hematol 3 : 611-614, 1963.
PubMed
2) Milton JG, Frojmovic MM : Shape-changing agents produce abnormally large platelets in a hereditary "giant platelet syndrome (mps)". J Lab Clin Med 93 : 154-161, 1979.
 
3) Milton JG, et al : Spontaneous platelet aggregation in a hereditary giant platelet syndrome (MPS). Am J Pathol 114 : 336-345, 1984.
 
4) Okita JR, et al : Montreal platelet syndrome : A defect in calcium-activated neutral proteinase (calpain). Blood 74 : 715-721, 1989.
PubMed
5) Jackson SC, et al : The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF1316M mutation. Blood 113 : 2248-3351, 2009.
 
6) Nurden A, Nurden P : Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemast 9 : 76-91, 2011.
PubMed
7) 嶋緑倫 : von Willebrand病. 血液専門医テキスト (日本血液学会編集), p391-393, 南江堂, 2011.
 
8) 國嶋伸治 : 先天性巨大血小板症の鑑別診断. 血栓止血誌 22 : 100-106, 2011.
 
9) Federici AB, et al : Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B : a cohort study of 67 patients. Blood 113 : 526-534, 2009.
PubMed
10) Nurden P, et al : Abnormal VWF modifies megakaryocytopoiesis : studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 115 : 2649-2656, 2010.
PubMed
11) Bernard J, Soulier JP : Sur une nouvelle variete dedystrophie thrombocttaire hemorrhagipare congenital. Sem Hop Paris 24 : 3217-3223, 1948.
PubMed
12) Lecher K, et al : May-Hegglinshe Anomalie. Acta Haematol 42 : 303-320, 1969.
 
13) Raccuglia G : Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 51 : 818-828, 1971.
PubMed
14) Miller JL, Castalla A : Platelet-type von Willebrand's disease : Characterization of a new bleeding disorder. Blood 60 : 790-794, 1982.
PubMed
15) Othman M : Platelet-type von Willebrand disease : A rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 37 : 464-469, 2011.
PubMed
P.382 掲載の参考文献
1) Greinacher A, et al : A new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 61 : 282-288, 1990.
PubMed
2) Kunishima S, Saito H : Advances in the understanding of MYH9 disorders. Curr Opin Hematol 17 : 405-410, 2010.
PubMed
3) Pecci A, et al : Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 29 : 409-417, 2008.
PubMed
4) Chang Y, et al : Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 109 : 4229-4236, 2007.
PubMed
5) Chen Z, et al : The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 110 : 171-179, 2007.
PubMed
6) Sekine T, et al : Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int 78 : 207-214, 2010.
PubMed
7) 國島伸治 : 先天性巨大血小板症の鑑別診断. 血栓止血誌 22 : 100-106, 2011.
 
8) Greinacher A, Mueller-Eckhardt C : Hereditary types of thrombocytopenia with giant platelets and inclusion bodies in the leukocytes. Blut 60 : 53-60, 1990.
PubMed
9) Kunishima S, et al : Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders : association of subcellular localization with MYH9 mutations. Lab Invest 83 : 115-122, 2003.
PubMed
10) Pecci A, et al : Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrol Dial Transplant 23 : 2690-2692, 2008.
PubMed
P.385 掲載の参考文献
1) Peterson LC, et al : Fechtner syndrome-a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 65 : 397-406, 1985.
PubMed
2) Kunishima S, Saito H : Advances in the understanding of MYH9 disorders. Curr Opin Hematol 17 : 405-410, 2010.
PubMed
3) Pecci A, et al : Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 29 : 409-417, 2008.
PubMed
4) Miyazaki K, et al : Identification of three in-frame deletion mutations in MYH9 disorders suggesting an important hot spot for small rearrangements in MYH9 exon 24. Eur J Haematol 83 : 230-234, 2009.
PubMed
5) De Rocco D, et al : Identification of the first duplication in MYH9-related disease : a hot spot for unequal crossing-over within exon 24 of the MYH9 gene. Eur J Med Genet 52 : 191-194, 2009.
PubMed
6) Chang Y, et al : Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 109 : 4229-4236, 2007.
PubMed
7) Chen Z, et al : The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 110 : 171-179, 2007.
PubMed
8) Sekine T, et al : Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int 78 : 207-214, 2010.
PubMed
9) 國島伸治 : 先天性巨大血小板症の鑑別診断. 血栓止血誌 22 : 100-106, 2011.
 
10) Kunishima S, et al : Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders : association of subcellular localization with MYH9 mutations. Lab Invest 83 : 115-122, 2003.
PubMed
P.388 掲載の参考文献
1) Firkin BG, et al : Lupoid thrombocytopenia. Aust N Z J Med 17 : 295-300, 1987.
PubMed
2) Tan EM, et al : The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 : 1271-1277, 1982.
PubMed
3) Macchi L, et al : Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome : their relationship with the observed thrombocytopenia. Br J Haematol 98 : 336-341, 1997.
PubMed
4) Lawrence J, et al : The cellular hematology of systemic lupus erythematosus. In : Systemic Lupus Erythematosus (ed by Lahita RG), p771-806, Churchill Livingstone, New York, 1992.
 
5) Perez AD, et al : Idiopathic thrombocytopenic purpura with high-titer, speckled pattern antinuclear antibodies : possible marker for systemic lupus erythematosus. Arthritis Rheum 28 : 596-597, 1985.
 
6) Kurata Y, et al : High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 71 : 184-187, 1994.
PubMed
7) Stasi R, et al : Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98 : 436-442, 1995.
PubMed
8) Mestanza-Peralta M, et al : Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 24 : 867-870, 1997.
PubMed
9) Shimizu K, et al : Familial lupoid thrombocytopenia. Am J Hematol 44 : 9-11, 1993.
PubMed
P.391 掲載の参考文献
1) Sekhon SS, Roy V : Thromobocytopenia in Adults : A practical approach to evaluation and management. South Med J 99 : 491-498, 2006.
 
2) Boxer L, Dale DC : Neutropenia : causes and consequences. Semin Hematol 39 : 75-81, 2002.
PubMed
3) Iwasaki H, Akashi K : Hematopoietic develeopmental pathways : on cellular basis. Oncogene 26 : 6687-6696, 2007.
PubMed
4) Arinobu Y, et al : Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell 1 : 416-427, 2007.
PubMed
5) Daar AS, et al : The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 38 : 287-292, 1984.
 
6) Martino R, et al : Combined autoimmune cytopenias. Haematologica 80 (4) : 305-310, 1995.
PubMed
7) Aref SE, et al : Assessment of neutrophilic apoptosis ex vivo in hepatosplenic patients with neutropenia pre and post splenectomy. Hematology 8 : 265-272, 2003.
PubMed
8) Toprak SK, et al : Mirtazapine-induced thrombocytopenia and neutropenia. Turk J Hematol 29 : 297-298, 2012.
 
9) Dale DC, et al : Severe chronic neutropenia : treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 72 : 82-93, 2003.
PubMed
10) Koconis KG, et al : Partial splenic embolization in the treatment of patients with portal hypertension : a review of the english language literature. J Vasc Inter Radiol 18 : 463-481, 2007.
 
11) Bucaneve G, et al ; Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Infection Program : Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 : 977-987, 2005.
PubMed
P.395 掲載の参考文献
1) Bishop JF, et al : The definition of refractriness of platelet transfusions. Transfus Med 2 : 35-41, 1992.
PubMed
2) Schiffer CA, et al : Platelet transfusion for patients with cancer : clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 19 : 1519-1538, 2001.
 
3) Aster RN, Bougie DW : Drug-induced immune thrombocytopenia. N Engl J Med 357 : 580-587, 2007.
 
4) 榎本隆行ほか : 妊娠による血小板反応性抗体 (HLA抗体とhuman platelet antigens抗体) の産生. 日輸血会誌 46 : 467-473, 2000.
Medical*Online
5) 永尾暢夫 : HLA適合血小板の供給. 日輸血会誌 43 : 30-33, 1997.
Medical*Online
6) Pappalardo P, et al : Platelet transfusion refractoriness associated with HPA-1a (PIA1) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusion. Transfusion 41 : 984-987, 2002.
 
P.402 掲載の参考文献
1) Bernard J, Soulier JP : Sur une nouvelle variete de dystrophie thrombocytaire-hemorragipare congenitale. Sem Hop 24 : 3217-3223, 1948.
 
2) Berndt MC, Andrews RK : Bernard-Soulier syndrome. Haematologica 96 : 355-359, 2011.
PubMed
3) Kunishima S, et al : Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 76 : 319-327, 2002.
PubMed
4) Nurden AT, Caen JP : Specific roles for platelet surface glycoproteins in platelet function. Nature 255 : 720-722, 1975.
PubMed
5) Cunningham JG, et al : The cytoplasmic domain of the α-subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology. J Biol Chem 271 : 11581-11587, 1996.
 
6) Kunishima S, et al : Bernard-Soulier syndrome due to GPIX W127X mutation in Japan is frequently misdiagnosed as idiopathic thrombocytopenic purpura. Int J Hematol 83 : 366-367, 2006.
PubMed
7) Kurokawa Y, et al : A missense mutation (Tyr88 to Cys) in the platelet membrane glycoprotein Ibβ gene affects GPIb/IX complex expression : Bernard-Soulier syndrome in the homozygous form and giant platelets in the heterozygous form. Thromb Haemost 86 : 1249-1256, 2001.
 
8) Andrews RK, et al : Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 35 : 1170-1174, 2003.
PubMed
9) Poujol C, et al : Absence of GPIbαis responsible for aberrant membrane development during megakaryocyte maturation : ultrastructural study using a transgenic model. Exp Hematol 30 : 352-360, 2002.
 
10) Balduini A, et al : Megakaryocytes derived from patients with the classical form of Bernard-Soulier syndrome show no ability to extend proplatelets in vitro. Platelets 22 : 308-311, 2011.
PubMed
11) 國島伸治 : 先天性巨大血小板症の鑑別診断. 血栓止血誌 22 : 100-106, 2011.
 
12) Kunishima S, Saito H : Advances in the understanding of MYH9 disorders. Curr Opin Hematol 17 : 405-410, 2010.
PubMed
13) Tefre KL, et al : Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia 15 : 281-284, 2009.
PubMed
14) Rieger C, et al : Allogeneic stem cell transplantation as a new treatment option for patients with severe Bernard-Soulier Syndrome. Thromb Haemost 95 : 190-191, 2006.
PubMed
P.406 掲載の参考文献
1) Alter BP : Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program 2007 : 29-39, 2007.
PubMed
2) Muraoka K, et al : Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol 96 : 287, 1997.
PubMed
3) Ihara K, et al : Identification of mutations in c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 96 : 3132, 1999.
 
4) Ballmaier M, Germeshansen M : Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol 146 : 3, 2009.
 
5) Ballmaier M, Germeshansen M : Congenital amegakaryocytic thrombocytopenia : clinical presentation, diagnosis, and treatment. Semin Thromb Hemost 37 : 673, 2011.
 
6) Ballmaier M, et al : c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 97 : 139, 2001.
PubMed
7) Klopocki E, et al : Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent dadius syndrome. Am J Hum Genet 80 : 232, 2007.
PubMed
8) Thompson AA, Nguyen LT : Amegakaryocytic thrombocytopenia and radio-ulner synostosis are associated with HOXA11 mutation. Nat Genet 26 : 397, 2000.
PubMed
9) Shiozaki H, et al : Auto antibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 95 : 2187, 2000.
 
10) Roberts I, et al : Thrombocytopenia in the neonate. Blood Rev 22 : 173, 2008.
PubMed
11) Agarwal N, et al : Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol 81 : 132, 2006.
PubMed
12) Guinan EC, et al : Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on tyhrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 81 : 1691, 1993.
PubMed
13) Muraoka K, et al : Successful bone marrow transplantation in a patient with c-mpl mutated congenital amegakaryocytic thrombocytopenia from a carrier donor. Pediatr Transplant 9 : 101, 2005.
 
14) Lannutti BJ, et al : Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood 113 : 1778, 2008.
PubMed
P.411 掲載の参考文献
1) Shreiner DP, Bell WR : Pseudothrombocytopenia : Manifestation of a new type of platelet agglutinin. Blood 42 : 541-549, 1973.
PubMed
2) Ahn HL, et al : EDTA-dependent pseudothrombocytopenia confirmed by supplementation of kanamycin ; a case report. Korean J Intern Med 17 : 65-68, 2002.
PubMed
3) Silvestri F, et al : Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. Vox Sang 68 : 35-39, 1995.
 
4) Bizzaro N : EDTA-dependent pseudothrombocytopenia : A clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 50 : 103-109, 1995.
PubMed
5) Onder O, et al : Pseudothrombocytopenia caused by platelet agglutinins that are reactive in blood anticoagulated with chelating agents. Blood 56 : 177-182, 1980.
PubMed
6) Casonato A, et al : EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. J Clin Pathol 47 : 625-630, 1994.
PubMed
7) Sane DC, et al : Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 36 : 75-83, 2000.
PubMed
8) van Vliet HH, et al : Pseudothrombocytopenia : a cold autoantibody against platelet glycoprotein GP IIb. Br J Haematol 62 : 501-511, 1986.
PubMed
9) 西郷勝康ほか : EDTA依存性偽性血小板減少症の抗血小板抗体の認識する抗原について. 臨床血液 27 : 1305-1309, 1986.
 
P.415 掲載の参考文献
1) Raccuglia G : Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 51 : 818-828, 1971.
PubMed
2) 一色郁子, 池田康夫 : α-Storage pool病 (Gray platelet症候群). 別冊日本臨牀 血液症候群 (II), p350-351, 日本臨牀社, 1998.
 
3) Gunay-Aygun M, et al : Gray platelet syndrome : natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 116 : 4990-5001, 2010.
PubMed
4) Mori K, et al : Electron microscopic and functional studies on platelets in gray platelet syndrome. Tohoku J Exp Med 143 : 261-287 : 1984.
PubMed
5) Nurden AT, Nurden P : The gray platelet syndrome : clinical spectrum of the disease. Blood Rev 21 : 21-36, 2007.
PubMed
6) Tubman VN, et al : X-linked gray platelet syndrome due to a CATA1 Arg216Gln mutation. Blood 109 : 3297-3299, 2007.
 
7) Falik-Zaccai TC, et al : A new genetic isolate of gray platelet syndrome (GPS) : clinical, cellular, and hematologic characteristics. Mol Genet Metab 74 : 303-313, 2001.
PubMed
8) Breton-Gorius J, et al : Defective α-granule production in megakaryocytes from gray platelet syndrome : ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol 102 : 10-19, 1981.
 
9) White JG : Ultrastructural studies of the gray platelet syndrome. Am J Pathol 95 : 445-462, 1979.
PubMed
P.418 掲載の参考文献
1) Weiss HJ, et al : A familial defect in platelet function associated with impaired release of adenosine diphosphate. N Engl J Med 281 : 1264-1270, 1969.
 
2) Holmsen H, Weiss HJ : Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia- "storage pool disease". Blood 39 : 197-209, 1972.
PubMed
3) Nieuwenhuis HK, et al : Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency : studies on one hundred six patients. Blood 70 : 620-623, 1987.
PubMed
4) Weiss HJ, Ames RP : Ultrastructural findings in storage pool disease and aspirin-like defects of platelets. Am J Pathol 71 : 447-466, 1973.
PubMed
5) Sladky JL, et al : The PFA-100 does not predict delta-granule platelet storage pool deficiencies. Haemophilia 18 : 626-629, 2012.
 
6) Wall JE, et al : A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 89 : 380-385, 1995.
PubMed
7) Gordon N, et al : Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 89 : 117-123, 1995.
PubMed
8) Castaman G, Rodeghiero F : Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time. Thromb Res 69 : 407-412, 1993.
PubMed
9) Nieuwenhuis HK, Sixma JJ : 1-Desamino-8-D-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency. Ann Intern Med 108 : 65-67, 1988.
PubMed
P.423 掲載の参考文献
1) Yasunaga K : Congenital platelet function disorders : survey findings and pathophysiology. Nihon Ketsueki Gakkai Zasshi 49 : 1499-1508, 1986.
PubMed
2) Nurden AT, Nurden P : Inherited disorders of platelets : an update. Curr Opin Hematol 13 : 157-162, 2006.
PubMed
3) Wagner CL, et al : Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 88 : 907-914, 1996.
PubMed
4) O'Toole TE, et al : Efficient surface expression of platelet GPIIb-IIIa requires both subunits. Blood 74 : 14-18, 1989.
PubMed
5) Kottke-Marchant K, Corcoran G : The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 126 : 133-146, 2002.
PubMed
6) Tomiyama Y : Glanzmann thrombasthenia : integrin alpha IIb beta 3 deficiency. Int J Hematol 72 : 448-454, 2000.
PubMed
7) George JN, et al : Glanzmann's thrombasthenia : the spectrum of clinical disease. Blood 75 : 1383-1395, 1990.
PubMed
8) Di Minno G, et al : Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3) : proposals for management between evidence and open issues. Thromb Haemostasis 102 : 1157-1164, 2009.
 
9) Kiefel V, et al : [Neonatal isoimmune thrombocytopenia by anti-GPIIb/IIIa]. Beitr Infusionsther 30 : 450-453, 1992.
 
10) Tengborn L, Petruson B : A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 75 : 981-982, 1996.
PubMed
11) Poon MC, et al : Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia : results of an international survey. J Thromb Haemost 2 : 1096-1103, 2004.
PubMed
12) Poon MC, et al : Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 94 : 3951-3953, 1999.
PubMed
13) Franchini M : The use of recombinant activated factor VII in platelet disorders : a critical review of the literature. Blood Transfus 7 : 24-28, 2009.
PubMed
P.427 掲載の参考文献
1) Nurden AT, et al : Glanzmann thrombasthenia : a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 118 : 5996-6005, 2011.
PubMed
2) Plow F, et al : Ligand binding to integrins. J Biol Chem 275 : 21785-21788, 2000.
 
3) van der Flier A, Sonnenberg A : Function and interactions of integrins. Cell Tissue Res 305 : 285-298, 2001.
PubMed
4) Giancotti G, Ruoslahti E : Integrin signaling. Science 285 : 1028-1032, 1999.
 
5) Springer A : Folding of the N-terminal, ligand -binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci USA 94 : 65-72, 1997.
 
6) Xiong JP, et al : Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 294 : 339-345, 2001.
PubMed
7) Kamata T, et al : Plateletintegrin αIIbβ3-ligand interactions : what can we learn from the structure? Int J Hematol 74 : 382-389, 2001.
 
8) Peyruchaud O, et al : R to Q substitution in the GFFKR sequence of the cytoplasmic domain of the integrin alphaIIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood 92 : 4178-4187, 1998.
 
9) Nurden AT, et al : Glanzmann thrombasthenia-like syndromes associated with Macrothrombocytopenias and mutations in the genes encoding the αIIbβ3 integrin. Semin Thromb Hemost 37 : 698-706, 2011.
 
10) Moser M, et al : Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 14 : 325-330, 2008.
PubMed
11) Kuijpers W, et al : LAD-1/variant syndrome is caused by mutations in FERMT3. Blood 113 : 4740-4746, 2009.
 
12) Nurden AT, et al : Are bone defects in rare patients with Glanzmann's thrombasthenia associated with ITGB3 or ITGA2B mutations? Platelets 22 : 547-551, 2011.
 
13) Ishaqi MK, et al : Allogeneic stem cell transplantation for Glanzmann thrombasthenia. Pediatr Blood Cancer 52 : 682-683, 2009.
PubMed
14) Miller W, et al : Sustained engraftment and resolution of bleeding phenotype after unrelated cord blood hematopoietic stem cell transplantation for severe glanzmann thrombasthenia. J Pediatr Hematol Oncol 31 : 437-439, 2009.
PubMed
15) Fang J, et al : Platelet gene therapy improves hemostatic function for integrin αIIbβ3-deficient dogs. Proc Natl Acad Sci USA 108 : 9583-9588, 2011.
 
P.431 掲載の参考文献
1) Hermansky F, Pudlak P : Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow : report of two cases with histochemical studies. Blood 14 : 162-169, 1959.
PubMed
2) Huizing M, et al : Disorders of lysosome-related organelle biogenesis : clinical and molecular genetics. Annu Rev Genomics Hum Genet 9 : 359-386, 2008.
PubMed
3) Davies BH, Tuddenham EGD : Familial pulmonary fibrosis associated with oculocutaneous albinism and platelet function defect. A new syndrome. Q J Med 45 : 219-232, 1976.
 
4) Garay SM, et al : Hermansky-Pudlak syndrome. Pulmonary manifestations of a ceroid storage disorder. Am J Med 66 : 737-747, 1979.
PubMed
5) 木村定勝ほか : Hermansky-Pudlak症候群の1例. 日皮会誌 103 : 805-813, 1993.
 
6) Wei ML : Hermansky-Pudlak syndrome : a disease of protein trafficking and organelle function. Pigment Cell Res 19 : 19-42, 2006.
 
7) Falcon-Perez JM, et al : Distribution and dynamics of Lamp1-containing endocytic organelles in fibroblasts deficient in BLOC-3. J Cell Sci 118 : 5243-5255, 2005.
PubMed
8) Clark RH, et al : Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 4 : 1111-1120, 2003.
 
9) 近藤光子, 角田裕美 : Hermansky-Pudlak症候群. 呼吸器科 5 : 149-154, 2004.
 
10) 鈴木民夫 : Hermansky-Pudlak syndrome. Clinical Dermatology 60 : 23-26, 2006.
 
11) Gahl WA, et al : Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 338 : 1258-1263, 1998.
PubMed
12) Sherman A, et al : Perirectal abscess in the Hermansky-Pudlak syndrome with granulomatous colitis in children. Am J Gastroenterol 84 : 552-556, 1989.
 
13) Avila NA, et al : Hermansky-Pudlak syndrome : radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol 179 : 887-892, 2002.
PubMed
14) Gahl WA, et al : Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 76 : 234-242, 2002.
PubMed
15) Nakatani Y, et al : Interstitial pneumonia in Hermansky-Pudlak syndrome : significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch 437 : 304-313, 2000.
PubMed
P.435 掲載の参考文献
1) Hirata M, et al : Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349 (6310) : 617-620, 1991.
PubMed
2) Nakahata N : Thromboxane A2 : physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 118 (1) : 18-35, 2008.
PubMed
3) Malinin NL, et al : Kindlins in FERM adhesion. Blood 115 (20) : 4011-4017, 2010.
PubMed
4) Klages B, et al : Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 144 (4) : 745-754, 1999.
PubMed
5) Schoenwaelder SM, et al : Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces. J Biol Chem 285 (4) : 2886-2896, 2010.
PubMed
6) Paul BZ, et al : Molecular mechanism of thromboxane A (2) -induced platelet aggregation. Essential role for p2t (ac) and alpha (2a) receptors. J Biol Chem 274 (41) : 29108-29114, 1999.
PubMed
7) Hirata T, et al : Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 94 (4) : 1662-1667, 1994.
 
8) Hirata T, et al : Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 97 (4) : 949-956, 1996.
PubMed
9) Mitsui T, et al : Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder : deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation. Thromb Haemost 77 (5) : 991-995, 1997.
 
10) Mao GF, et al : Lineage-specific defect in gene expression in human platelet phospholipase C-beta2 deficiency. Blood 99 (3) : 905-911, 2002.
PubMed
11) Gabbeta J, et al : Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 94 (16) : 8750-8755, 1997.
 
12) Gabbeta J, et al : Human platelet Galphaq deficiency is associated with decreased Galphaq gene expression in platelets but not neutrophils. Thromb Haemost 87 (1) : 129-133, 2002.
 
13) Patel YM, et al : Evidence for a role for Galphai1 in mediating weak agonist-induced platelet aggregation in human platelets : reduced Galphai1 expression and defective Gi signaling in the platelets of a patient with a chronic bleeding disorder. Blood 101 (12) : 4828-4835, 2003.
PubMed
14) Fuse I, et al : Defective signal transduction induced by thromboxane A2 in a patient with a mild bleeding disorder : impaired phospholipase C activation despite normal phospholipase A2 activation. Blood 81 (4) : 994-1000, 1993.
 
15) Fuse I, et al : DDAVP normalized the bleeding time in patients with congenital platelet TxA2 receptor abnormality. Transfusion 43 (5) : 563-567, 2003.
PubMed
P.438 掲載の参考文献
1) Matijevic-Aleksic N, et al : Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) deficiency. Br J Haematol 92 : 212-217, 1996.
PubMed
2) Ehara H, et al : Enzymological and immunological studies on a clinical case of platelet cyclo-oxygenase abnormality. Biochim Biophys Acta 960 : 35-42, 1988.
PubMed
3) Nakanishi K, et al : Platelet cyclo-oxygenase deficiency in a Japanese. Scand J Haematol 32 : 167-174, 1984.
 
4) Takahashi Y, et al : Immunoaffinity purification and cDNA cloning of human platelet prostaglan din endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun 182 : 433-438, 1992.
 
5) Shimokawa T, et al : Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem 265 : 20073-20076, 1990.
PubMed
6) Nyman E, et al : Inherited defective platelet aggregation with arachidonate as the main expression of a defective metabolism of arachidonic acid. Thromb Res 14 : 739-746, 1979.
 
7) Horellou MH, et al : Familial and constitutional bleeding disorder due to platelet cyclo-oxygenase deficiency. Am J Hematol 14 : 1-9, 1983.
PubMed
8) Dargaud Y, et al : Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency. Thromb Res 116 : 483-489, 2005.
PubMed
P.443 掲載の参考文献
1) Weiss HJ, et al : Isolated deficiency of platelet procoagulant activity. Am J Med 67 : 206-213, 1979.
PubMed
2) Kojima H, et al : Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome. J Clin Invest 94 : 2237-2244, 1994.
PubMed
3) Bolton-Maggs PH, et al : A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 135 : 603-633, 2006.
 
4) Weiss HJ, Lages B : Family studies in Scott syndrome. Blood 90 : 475-476, 1997.
PubMed
5) Toti F, et al : Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 87 : 1409-1415, 1996.
PubMed
6) Suzuki J, et al : Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468 : 834-838, 2010.
PubMed
7) Castoldi E, et al : Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome. Blood 117 : 4399-4400, 2011.
 
8) Rosing J, et al : Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood 65 : 1557-1561, 1985.
PubMed
9) Sims PJ, et al : Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome : an isolated defect in platelet procoagulant activity. J Biol Chem 264 : 17049-17057, 1989.
PubMed
10) Flores-Nascimento MC, et al : Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagul Fibrinolysis 23 : 75-77, 2012.
PubMed
11) Percy CL, et al : Laboratory monitoring of Scott Syndrome. Br J Haematol 149 : 803, 2010.
PubMed
P.445 掲載の参考文献
1) Weiss HJ, Lages BA : Possible congenital defect in platelet thromboxane synthase. Lancet 1 : 760-761, 1977.
 
2) Mestel F, et al : Severe bleeding associated with defective thromboxane synthase. Lancet 1 : 157, 1980.
PubMed
3) Ohashi K, et al : Primary structure of human thromboxane synthase determined from the cDNA sequence. J Biol Chem 267 : 789-793, 1992.
PubMed
4) Chase MB, et al : Mapping of the human thromboxane synthase gene (TBXAS1) to chromosome 7q34-q35 by two-color fluorescence in situ hybridization. Genomics 16 : 771-773, 1993.
PubMed
5) Defreyn G, et al : Familial bleeding tendency with partial platelet thromboxane synthase deficiency : reorientation of cyclic endoperoxide metabolism. Br J Haematol 49 : 29-41, 1981.
PubMed
P.449 掲載の参考文献
1) Tay A, et al : Cytosolic phospholipase A2 gene in human and rat : chromosomal localization and polymorphic markers. Genomics 26 : 138-141, 1995.
PubMed
2) Gronich JH, et al : Identification and characterization of a hormonally regulated form of phospholipase A2 in rat renal mesangial cells. J Biol Chem 263 : 16645-16651, 1988.
PubMed
3) Gijon MA, et al : Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J Cell Biol 145 : 1219-1232, 1999.
PubMed
4) Das S, et al : Mechanism of group IVA cytosolic phospholipase A2 activation by phosphorylation. J Biol Chem 278 : 41431-41442, 2003.
PubMed
5) Leslie CC : Properties and regulation of cytosolic phospholipase A2. J Biol Chem 272 : 16709-16712, 1997.
PubMed
6) Adler DH, et al : Inherited human cPLA2α deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest 118 : 2121-2131, 2008.
 
7) Weiss HJ, et al : Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide : absent in storage pool disease, normal after aspirin ingestion. Br J Haematol 32 : 257-272, 1976.
PubMed
8) Rendu F, et al : Studies on a new variant of the Hermansky-Pudlak syndrome : qualitative, ultrastructural, and functional abnormalities of the platelet-dense bodies associated with a phospholipase A defect. Am J Hematol 4 : 387-399, 1978.
PubMed
9) Okuma M : Platelet function and arachidonate metabolism in patients with chronic myeloproliferative disorders. Acta Haematol Jpn 43 : 1139-1144, 1980.
 
10) Jubelirer SJ, et al : Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia. Blood 56 : 728-731, 1980.
PubMed
11) Rao AK, et al : Platelet secretion defect associated with impaired liberation of arachidonic acid and normal myosin light chain phosphorylation. Blood 64 : 914-921, 1984.
PubMed
P.454 掲載の参考文献
1) Bombardier C, et al : Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (21) : 1520-1528, 2000.
 
2) Mukherjee D, et al : Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (8) : 954-959, 2001.
PubMed
3) Bresalier RS, et al : Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (11) : 1092-1102, 2005.
 
4) Solomon SD, et al : Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (11) : 1071-1080, 2005.
 
5) Nussmeier NA, et al : Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (11) : 1081-1091, 2005.
PubMed
6) Meijer WE, et al : Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 164 : 2367-2370, 2004.
PubMed
7) Shinohara Y, et al ; CSPS 2 Group : Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9 (10) : 959-968, 2010.
PubMed
8) ESPRIT Study Group, Halkes PH, et al : Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT) : randomised controlled trial. Lancet 367 (9523) : 1665, 2006.
 
9) 金子誠, 矢冨裕 : 血小板機能異常症の診断と対応. 日血栓止血会誌 20 (5) : 487-494, 2009.
 
P.457 掲載の参考文献
1) 日本血栓止血学会用語集 (血小板) Glanzmann血小板無力症 [http://www.jsth.org/term/kesshoban.html#04]
 
2) Glanzmann WE : Hereditare hamorrhagische Thrombasthenie. Ein Beitrag zur Pathologie der Blutplattchen. Jahrbuch fur Kinderheilkunde 88 : 1-42, 113-141, 1918.
 
3) 渡辺清明 : 血小板機能異常. 日内会誌 80 : 46-51, 1991.
 
4) 金子誠, 矢冨裕 : 血小板機能異常の診断と対応. 血栓止血誌 20 : 487-494, 2009.
 
5) Tholouli E, et al : Acquired Glanzmann's thrombasthenia without thrombocytopenia : a sever aqcuired autoimmune bleeding disorder. Br J Haematol 127 : 209-213, 2004.
 
6) Levy-Toledano S, et al : Acquired IgG antibody occurring in a thrombasthenic patient : its effect on human platelet function. Blood 51 : 1065-1072, 1978.
 
7) Coller BS, et al : A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 72 : 325-338, 1983.
PubMed
8) Niessner H, et al : Acquired trombasthenia due to GPIIb/IIIa-specific platelet autoantibodies. Blood 68 : 571-576, 1986.
 
9) DiMinno G, et al : A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 77 : 157-164, 1986.
 
10) Fuse I, et al : Overproduction of antiplatelet antibody against glicoprotein IIb after splenectomy in a patient with Evans syndrome resulting in acquired thrombasthenia. Acta Haematol 99 : 83-88, 1998.
 
11) Thomas RV, et al : The successful use of plasma exchange and immunosuppression in the management of acquired Glanzmann's thrombasthenia. Br J Haematol 119 : 878-880, 2002.
PubMed
12) Ito K, et al : Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang 61 : 40-46, 1991.
PubMed
13) Kubota T, et al : Autoantibody against platelet glycoprotein IIb/IIIa in a patient with non-Hodgkin's lymphoma. Thromb Res 53 : 379-386, 1989.
 
14) Malik U, et al : Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma. Cancer 82 : 1764-1768, 1998.
PubMed
15) Patel RK, et al : Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies. Br J Haematol 114 : 245-246, 2001.
 
16) Poon MC : The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 21 : 223-236, 2007.
PubMed
17) Solh M, et al : Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy. Am J Hematol 86 : 715-716, 2011.
PubMed

VI 血管障害による出血傾向

P.464 掲載の参考文献
1) McDonald J, et al : Hereditary hemorrhagic telangiectasia : an overview of diagnosis, management, and pathogenesis. Genet Med 13 (7) : 607-616, 2011.
PubMed
2) Dupuis-Girod S, et al : Hereditary hemorrhagic telangiectasia : from molecular biology to patient care. J Thromb Haemost 8 (7) : 1447-1456, 2010.
PubMed
3) Grand' Maison A : Hereditary hemorrhagic telangiectasia. CMAJ 180 (8) : 833-835, 2009.
PubMed
4) Mc Allister KA, et al : Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8 : 345-351, 1994.
PubMed
5) Johnson DW, et al : Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13 : 189-195, 1996.
PubMed
6) Prigoda NL, et al : Hereditary haemorrhagic telangiectasia : mutation detection, test sensitivity and novel mutations. J Med Genet 43 : 722-728, 2006.
PubMed
7) Irani F, Kasmani R : Hereditary hemorrhagic telangiectasia : fatigue and dyspnea. CMAJ 180 : 839, 2009.
PubMed
8) Easey AJ, et al : Should asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened for cerebral vascular malformations? Data from 22,061 years of HHT patientlife. J Neurol Neurosurg Psychiatry 74 : 743-748, 2003.
 
9) Curie A, et al : Long-term follow-up in 12 children with pulmonary arteriovenous malformations : confirmation of hereditary hemorrhagic telangiectasia in all cases. J Pediatr 151 (3) : 299-306, 2007.
 
10) Shovlin CL, et al : Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91 : 66-67, 2000.
PubMed
P.468 掲載の参考文献
1) Malfait F, et al : Ehlers-Danlos Syndrome, Classic Type. Synonym : Ehlers-Danlos Syndrome, Classical Type. Includes : Ehlers-Danlos Syndrome Type I, Ehlers-Danlos Syndrome Type II. GeneReviews(TM) [Internet]. Seattle (WA) : University of Washington, Seattle ; 1993-. Initial Posting : September 2, 1999 ; Last Update : May 3, 2011.
 
2) Levy HP, et al : Ehlers-Danlos Syndrome, Hypermobility Type Synonyms. Synonym : EDS Hypermobility Type, EDS Type III, Ehlers-Danlos Syndrome Type III. GeneReviews(TM) [Internet]. Seattle (WA) : Universityof Washington, Seattle ; 1993-. Initial Posting : October 22, 2004.
 
3) Pepin MG, Byers PH : Ehlers-Danlos Syndrome Type IV. Synonyms : EDS Type IV ; Ehlers-Danlos Syndrome, Vascular Type. GeneReviews(TM) [Internet]. Seattle (WA) : University of Washington, Seattle ; 1993-. Initial Posting : September2, 1999 ; Last Update : May 3, 2011.
 
4) Malfait F, et al : Clinical and geneticaspectsof Ehlers-Danlossyndrome, classictype. Genet Med 12 (10) : 597-605, 2010.
 
5) Beighton P, et al : Ehlers-Danlossyndromes : revisednosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 7 : 31-37, 1998.
 
6) Leistritz DF, et al : COL3A1 haploinsufficiency results in EDS type IV with delayed onset of complications and longer life span when compared to missense and splice-site mutations. Poster session 1670, Washington, DC : American Societyof Human Genetics 60th Annual Meeting, 2010.
 
7) Schwarze U, et al : Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. Am J Hum Genet 69 : 989-1001, 2001.
 
P.471 掲載の参考文献
1) Levin MB, Pinkus H : Autosensitivity to deoxyribonucleic acid (DNA). Report of a case with inflammatory skin lesions controlled by chloroquine. N Engl J Med 264 : 533-537, 1961.
PubMed
2) 河野照隆 : DNA自己感作性紫斑病. 感染・炎症・免疫 16 : 132-137, 1986.
 
3) Brauner F, et al : Autosensitization to DNA. Acta Derm Venereol 60 : 345-348, 1980.
PubMed
4) Rodriguez Fernandez JM, Linares Ruiz MS : DNA autosensitivity ; report of two cases. Sangre (Barc) 26 : 114-122, 1981.
PubMed
5) Sugai S, et al : A case of DNA autosensitivity. Arerugi 31 : 9-17, 1982.
 
6) Pinnas JL, et al : Autosensitization to DNA : evidence for an immunologic basis. J Invest Dermatol 72 : 157-160, 1979.
PubMed
7) Sugai S, et al : DNA autosensitivity in two Japanese sisters. Artritis Rheum 33 : 287-292, 1990.
 
8) Little AS, Bell HE : Painful subcutaneous hemorrhages of the extremities with unusual reaction to injected deoxyribonucleic acid. Ann Intern Med 60 : 886-891, 1964.
PubMed
9) Gardner FH, Diamond LK : Autoerythrocyte sensitization ; a form of purpura producing painful bruising following autosensitization to red blood cells in certain women. Blood 10 : 675-690, 1955.
PubMed
10) Coppola A, et al : Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37 : 929-945, 2011.
PubMed
11) Anderson PC, McCaffree MK : Pseudo DNA autosensitivity. A fractitial disease. JAMA 196 : 104-105, 1966.
PubMed
12) Parker FS, Irvin JL : The interaction of chloroquine with nucleic acid and nucleoproteins. J Biol Chem 199 : 897-909, 1952.
PubMed
P.473 掲載の参考文献
1) Gardner FH, Diamond LK : Autoerythrocyte sensitization : a form of purpura producting painful brusing following autosensitization to red blood cells in certain women. Blood 10 : 675-690, 1955.
 
2) Ivanov OL, et al : Autoerythrocyte sensitization syndrome (Gardner-Diamond syndrome) : review of the literature. J Eur Acad Dermatol Venereol 23 : 499-504, 2009.
PubMed
3) Ratnoff OD : The psychogenic purpuras : review of autoerythrocyte sensitization, autosensitization to DNA, "hysterial" and factitial bleeding, and the religious stigmata. Semin Hematol 17 : 192-213, 1980.
 
4) Hawsawi KA, Pope E : Pediatric psychocutaneous disorders : a review of primary psychiatric disorders with dermatologic manifestations. Am J Clin Dermatol 12 : 247-257, 2011.
 
5) Kremer WB, et al : Recurrent ecchymoses and cutaneous hyperactivity of hemoglobin : a form of autoerythrocyte sensitization. Blood 30 : 62-73, 1967.
 
6) Sudy E, et al : Autoerythrocyte sensitization syndrome with positive anticardiolipin antibodies. Br J Dermatol 138 : 367-368, 1998.
PubMed
7) Durmazlar SP, et al : Is Gardner-Diamond syndrome associated with hormonal influences along with psychosocial problems? A delayed diagnosis. Eur J Dermatol 19 : 259-260, 2009.
 
8) Uthman IW, et al : Autoerythrocyte sensitization (Gardner-Diamond) syndrome. Eur J Haematol 65 : 144-147, 2000.
PubMed
9) Meeder R, Bannister S : Gardner-Diamond syndrome : difficulties in the management of patients with unexplained medical symptoms. Paediatr Child Health 11 : 416-419, 2006.
PubMed
10) Silney W, et al : Gardner-Diamond syndrome. Int J Dermatol 49 : 1178-1181, 2010.
 
11) Levin MB, Pinkus H : Autosensitivity to deoxyribonucleic acid (DNA). Report of a case with inflammatory skin lesions controlled by chloroquine. N Engl J Med 264 : 533-537, 1961.
PubMed
12) Coppola A, et al : Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37 : 929-945, 2011.
PubMed
13) Anderson PC, McCaffree MK : Pseudo DNA autosensitivity. A factitial disease. JAMA 196 : 104-105, 1966.
PubMed
14) Gomi H, Miura T : Autoerythrocyte sensitization syndrome with thrombocytosis. Dermatology 188 : 160-162, 1994.
PubMed
15) Settle EC : Autoerythrocyte sensitization successfully treated with antidepressants. JAMA 250 : 1749, 1983.
PubMed
P.476 掲載の参考文献
1) Cox NH, Piette WW : Purpura and microvascular occlusion. In : Rook's Textbook of Dermatology (ed by Burns T, et al), 7th ed, Blackwell Science, Massachusetts, 2004.
 
2) 塚本克彦 : 血管性紫斑. 紅斑・滲出性紅斑紫斑脈管系の疾患最新皮膚科学大系 4 (玉置俊彦編), 中山書店, 2003.
 
3) Capewell S, et al : Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 300 (6739) : 1548-1551, 1990.
PubMed
4) Shibli-Rahhal A, et al : Cushing's syndrome. Clin Dermatol 24 (4) : 260-265, 2006.
PubMed
5) Schoepe S, et al : Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 15 (6) : 406-420, 2006.
PubMed
6) Schacke H, et al : Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96 (1) : 23-43, 2002.
PubMed
7) Chen SJ, et al : Interaction of smad3 with a proximal smad-binding element of the human alpha 2 (I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 183 (3) : 381-392, 2000.
 
8) Song CZ, et al : Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad 3. Proc Natl Acad Sci USA 96 (21) : 11776-11781, 1999.
 
9) Oishi Y, et al : Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment : effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 147 (5) : 859-868, 2002.
PubMed
P.479 掲載の参考文献
1) Scurvy and its prevention and control in major emergencies. World Health Organization, United Nations High Commissioner for Refugees, 1999.
 
2) 厚生労働省「日本人の食事摂取基準について」, 第6次改定「日本人の栄養所要量」, 1999.
 
3) Magiorkinis E, et al : Scurvy : past, present and future. Eur J Intern Med 22 (2) : 147-152, 2011.
PubMed
4) Rajakumar K : Infantile scurvy : a historical perspective. Pediatrics 108 (4) : E76, 2001.
PubMed
5) 間瀬勘史 : 壊血病, Moller-Barlow病. 別冊日本臨牀 血液症候群 (II), p405-407, 日本臨牀社, 1998.
 
6) Ghedira Besbes L, et al : Infantile scurvy : two case reports. Int J Pediatr 2010 : 717518, 2010.
PubMed
P.483 掲載の参考文献
1) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
PubMed
2) Gedalia A : Henoch-Schonlein purpura. Curr Rheumatol Rep 6 : 195-202, 2004.
PubMed
3) Gardner-Medwin JM, et al : Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360 : 1197-1202, 2002.
PubMed
4) Saulsbury FT : Clinical update : Henoch-Schonlein purpura. Lancet 369 : 976-978, 2007.
PubMed
5) Lau KK, et al : Pathogenesis of Henoch-Schonlein purpura nephritis. Pediatr Nephrol 25 : 19-26, 2010.
 
6) Fervenza FC : Henoch-Schonlein purpura nephritis. Int J Dermatol 42 : 170-177, 2003.
PubMed
7) Brogan P, et al : Small vessel vasculitis. Pediatr Nephrol 25 : 1025-1035, 2010.
PubMed
8) Narchi H : Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings : a systematic review. Arch Dis Child 90 : 916-920, 2005.
PubMed
9) Kaku Y, et al : Renal involvement in Henoch-Schonlein purpura : a multivariate analysis of prognostic factors. Kidney Int 53 : 1755-1759, 1998.
PubMed
10) Shin JI, et al : Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura. Scand J Rheumatol 35 : 56-60, 2006.
PubMed
11) Ozen S, et al : EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II : Final classification criteria. Ann Rheum Dis 69 : 798-806, 2010.
PubMed
12) Reamy BV, et al : Henoch-Schonlein purpura. Am Fam Physician 80 : 697-704, 2009.
PubMed
13) Ronkainen J, et al : Early prednisone therapy in Henoch-Schonlein purpura : a randomized, double-blind, placebo-controlled trial. J Pediatr 149 : 241-247, 2006.
 
14) McCarthy HJ, Tizard EJ : Clinical practice : Diagnosis and management of Henoch-Schonlein purpura. Eur J Pediatr 169 : 643-650, 2010.
PubMed
15) Saulsbury FT : Henoch-Schonlein purpura. Curr Opin Rheumatol 22 : 598-602, 2010.
PubMed
P.487 掲載の参考文献
1) Sunderkotter C, Sindrilaru A : Clinical classification of vasculitis. Eur J Dermatol 16 : 114-124, 2006.
PubMed
2) Calabrese LH, et al : The American Collegeof Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 33 : 1108-1113, 1990.
 
3) Jennette JC, et al : Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 : 187-192, 1994.
PubMed
4) 永渕裕子, 山田秀裕 : 過敏性血管炎. 日本臨牀 67 (11) : 2148-2151, 2009.
Medical*Online
5) Merkel PA : Drug-induced vasculitis. Rheum Dis Clin North Am 27 : 849, 2001.
PubMed
6) ten Holder SM, et al : Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 36 : 130-147, 2002.
PubMed
7) Stein JC, et al : Necrotizing vasculitis as a complication of propylthiouracil. West J Emerg Med 9 : 212-215, 2008.
PubMed
8) Jennette JC, Falk RJ : Small-vessel vasculitis. N Engl J Med 337 : 1512-1523, 1997.
PubMed
9) Bonaci-Nikolic B, et al : Antineutrophil cytoplasmic antibody (ANCA) -associated autoimmune diseases induced by antithyroid drugs : comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 7 : R1072-1081, 2005.
PubMed
10) Radic M, et al : Drug-induced vasculitis : a clinical and pathological review. Neth J Med 70 : 12-17, 2012.
PubMed
11) Stone J : Immune complex-mediated small vessel vasculitis. In : Kelley's Textbook of Rheumatology 8th ed II (ed by Firestein G, et al), p1465-1473, W. B. Saunders, Philadelphia, 2008.
 
12) Uchimiya H, et al : Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib. J Dermatol 37 : 562-564, 2010.
PubMed
13) Rostoker G : Schonlein-Henoch purpura in children and adults : diagnosis, pathophysiology and management. Bio Drugs 15 : 99-138, 2001.
 
14) Wiik A : Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 7 : 191-192, 2005.
PubMed
15) Boomsma MM, et al : Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels : a prospective study. Arthritis Rheum 43 : 2025-2033, 2000.
 
P.489 掲載の参考文献
1) Davis E : Purpura of the skin. A review of 500 cases. Lancet 2 : 160-161, 1943.
 
2) Davis E : Purpura of the skin. Hereditary familiar purpura simplex review of twenty-seven families. Lancet 1 : 145-146, 1941.
 
P.491 掲載の参考文献
1) Rees MM, Rodgers GM : Bleeding disorders caused by vascular abnormalities. In : Wintrobe's Clinical Hematology, 12th ed (ed by Pine JW Jr), p1335-1351, Lippincott W & W, Philadelphia, 2009.
 
2) Wong HY : Hypothesis : senile purpura is a prognostic feature in elderly patients. Age Ageing 17 : 422-424, 1988.
PubMed
3) Shuster S, Scarborough H : Senile purpura. Q J Med 30 : 33-40, 1961.
 

VII 凝固・線溶異常による出血傾向

P.498 掲載の参考文献
1) Bloom AL (ed) : Introduction. In : The Hemophilia, p1, Churchill Livingstone, Philadelphia, 1982.
 
2) 血液凝固異常症全国調査運営委員会 : 厚生労働省委託事業血液凝固異常症全国調査平成23年度報告書, p3, 公益財団法人エイズ予防財団, 2012.
 
3) Kemball-Cook G, et al : The factor VIII Structure and Mutation Resource Site : HAMSTeRS version 4. Nucleic Acids Res 26 : 216-219, 1998.
PubMed
4) 三間屋純一 : II. 診断 1. 臨床症状. みんなに役立つ血友病の基礎と臨床 (白幡聡編), p106-116, 医薬ジャーナル社, 2009.
 
5) Witmer C, et al : Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 152 : 211-216, 2011.
 
6) 西田恭治 : 2 出血症状に対する治療法 (5) 消化管出血. ヘモフィリア治療の最前線, 血友病の診断と治療 (吉岡章編), p58-63, 医科学出版社, 2002.
 
7) Kasper CK, Lin JC : Prevalence of sporadic and familial haemophilia. Haemophilia 13 : 90-92, 2007.
PubMed
8) Schulman S : Mild Hemophilia, p2, World Federation of Hemophilia, Montreal, 2006.
 
9) Huth-Kuhne A, et al : International recommendation on the diagnosis and treatment of patients with acquired hemophilia A. Haemoatologica 94 : 566-575, 2009.
PubMed
10) 松下正ほか : インヒビターのない血友病患者の急性出血, 処置・手術における凝固因子補充療法のガイドライン. 日血栓止血会誌 19 : 510-519, 2008.
 
11) 田中一郎ほか : インヒビター保有先天性血友病患者に対する止血治療ガイドライン. 日血栓止血会誌 19 : 520-529, 2008.
 
12) Nilsson IM, et al : Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232 : 25-32, 1992.
 
13) Tagliaferri A, et al : Effects of secondary prophylaxis started in adolescent and adult haemopiliacs. Haemophilia 14 : 945-951, 2008.
PubMed
14) Ragni MV : Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A : the Hemophilia Adult Prophylaxis Trial. Expert Rev Hematol 4 : 495-507, 2011.
PubMed
P.503 掲載の参考文献
1) Ponder KP : Merry christmas for patients with hemophilia B. N Engl J Med 365 : 2424-2425, 2011.
PubMed
2) 奥村薫, 小嶋哲人 : 3. 血友病の病態 4) 血友病Bの分子生物学. みんなに役立つ血友病の基礎と臨床 (白幡聡編), p52-59, 医薬ジャーナル社, 2009.
 
3) Bloom AL (ed) : Introduction. In : The Hemophilia, p1, Churchill Livingstone, Philadelphia, 1982.
 
4) 血液凝固異常症全国調査運営委員会 : 厚生労働省委託事業血液凝固異常症全国調査平成23年度報告書, p3-12, 公益財団法人エイズ予防財団, 2012.
 
5) Rogaev EI, et al : Genotype analysis identifies the cause of the 'royal disease'. Science 326 : 817, 2009.
PubMed
6) Klamroth R, et al : Haemophilia A and haemophilia B. Are there relevant clinical differences? Hamostaseologie 30 (Suppl 1) : S26-27, 2010.
 
7) Nagel K, et al : Comparing bleed frequency and factor concentrate use between haemophilia A and Bpatients. Haemophilia 17 : 872-874, 2011.
 
8) Warrier I : Inhibitors in hemophilia B. In : Texbook of Hemophilia (ed by Lee CA, et al), p97-100, Blackwell Publishing, Malden, 2005.
 
9) 松下正ほか : インヒビターのない血友病患者の急性出血, 処置・手術における凝固因子補充療法のガイドライン. 日血栓止血会誌 19 : 510-519, 2008.
 
10) 田中一郎ほか : インヒビター保有先天性血友病患者に対する止血治療ガイドライン. 日血栓止血会誌 19 : 520-529, 2008.
 
11) Brown SA : Treatment of inhibitors in hemophilia B. In : Texbook of Hemophilia (ed by Lee CA, et al), p101-105, Blackwell Publishing, Malden, 2005.
 
12) Shibata M, Shima M : Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia 9 : 269-271, 2003.
PubMed
13) Pipe SW : The hope and reality of long-acting hemophilia products. Am J Hematol 87 (Suppl 1) : S33-39, 2012.
 
14) Ikkala E, et al : Changes in the life expectancy of patients with severe hemophilia A in Finl and in 1930-79. Br J Haematol 52 : 7-12, 1982.
 
15) Franchini M, Mannucci PM : Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 148 : 522-533, 2009.
PubMed
P.506 掲載の参考文献
1) Nishino M, et al : New variant of von Willebrand disease with defective binding to factor VIII. Blood 74 : 1591-1599, 1989.
PubMed
2) Gaucher C, et al : The "Normandy" variant of von Willebrand' sdisease : characterization of a point mutation in the von Willebrand factorgene. Blood 77 : 1937-1941, 1991.
 
3) Tuley EA, et al : Expression of von Willebrand factor "Normandy" : an autosomal mutation that mimicshemophilia A. Proc Natl Acad Sci U S A 88 : 6377-6381, 1991.
PubMed
4) Sadler JE : A revised classification of von Willebrand disease. Thromb Haemost 71 : 520-525, 1994.
PubMed
5) Foster PA, etal : A major factor VIIIb dinding dmain residues inding domainresidues with intheamino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 262 : 8443-8446, 1987.
 
6) Mazurier C, et al : Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2 Nvon Willebrand disease, resultsofaninternationalsurvey. Thromb Haemost 76 : 270-274, 1996.
 
7) 嶋緑倫 : 第VIII因子結合能異常症. 別冊日本臨牀 血液症候群 II, p430-433, 日本臨牀社, 1998.
 
P.508 掲載の参考文献
1) Blat Y, Seiffert D : A renaissance for the contact system in blood coagulation. Thromb Haemost 99 : 457-460, 2008.
 
2) Waldmann R, et al : Fitzgerald factor : a hitherto unrecognised coagulation factor. Lancet 1 : 949-951, 1975.
PubMed
3) Colman RW, et al : Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 56 : 1650-1652, 1975.
PubMed
4) Wuepper KD, et al : Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 56 : 1663-1672, 1975.
PubMed
5) Hayashi H, et al : The first cases of Fitzgerald factor deficiency in the Orient : three cases in one family. Acta Haematol 63 : 107-113, 1980.
PubMed
6) Hayashi H, et al : Molecular genetic survey of five Japanese families with high-molecular weight kininogen deificiency. Blood 75 : 1296-1304, 1990.
 
7) Krijanovski Y, et al : Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient : insights into structural requirements for kininogen expression. Blood 101 : 4430-4436, 2003.
PubMed
8) Shigekiyo T, et al : Isolated high-molecular-weight kininogen deficiency : a novel frameshift mutation in exon 10. Blood 109 : 5062-5063, 2007.
PubMed
9) Cheung PP, et al : Genetic basis of total kininogen deficiency in Williams' trait. J Biol Chem 268 : 23361-23365, 1993.
PubMed
10) Davidoson SJ, et al : High molecular weight kininogen deficiency : a patient who underwent cardiac surgery. Thromb Haemost 85 : 195-197, 2001.
 
P.511 掲載の参考文献
1) Lowenberg EC, et al : Coagualtion factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 8 : 2349-2357, 2010.
 
2) Mann KG, Kalafatis M : Factor V : a combination of Dr Jekyll and Mr Hyde. Blood 101 : 20-30, 2003.
 
3) Oeri J, et al : Congenital factor V deficiency (parahemophilia) with true hemophilia I two brothers. Bibl Paediatr 58 : 575-588, 1954.
PubMed
4) Spreafico M, Peyvandi F : Combined factor V and factor VIII deficiency. Semin Thrombhaemost36 : 390-399, 2009.
PubMed
5) Nichols WC, et al : Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factor V and VIII. Cell 93 : 61-70, 1998.
PubMed
6) Zhang B, et al : Bleeding due to disruption of a cargo-specific ER-to-Golgitransport complex. Nat Genet 34 : 220-225, 2003.
 
7) Zhang B, et al : LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem 280 : 25881-25886, 2005.
 
8) Peyvandi F, et al : Bleeding symptoms in 27 Iranian patients with thecombined deficiency of factor V and factor VIII. Br J Haematol 100 : 773-776, 1998.
 
9) Mansouritorgabeh H, et al : Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran. Haemophilia 10 : 271-275, 2004.
PubMed
10) Zhang B, et al : Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood 111 : 5592-5600, 2008.
PubMed
11) Bolton-Maggs PHB, et al : The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 10 : 593-628, 2004.
PubMed
P.515 掲載の参考文献
1) Mann KG, Kalafatis M : Factor V : a combinationof Dr Jekyll and Mr Hyde. Blood 101 : 20-30, 2003.
 
2) Owren PA : Parahaemophilia ; haemorrhagic diathesis due to absence of a previously unknown clottingfactor. Lancet 1 : 446-448, 1947.
 
3) Lak M, et al : Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 103 : 1067-1069, 1998.
PubMed
4) Asselta R, Peyvabdi F : Factor V deficiency. Semin Thromb Haemost 35 : 382-389, 2009.
 
5) Guasch JF, et al : Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 101 : 32-39, 1998.
PubMed
6) Bafunno V, et al : Coinheritance of three novel FV gene mutations in a patient with a severe FV deficiency. Haemophilia 18 : e34-e59, 2012.
 
7) Castol di E, et al : A missensemutation (Y1702C) inthecoagulationfactor V gene is a frequent cause of factor V deficiency in the Italian population. Haematologica 86 : 629-633, 2001.
 
8) Acharya SS, et al ; North American Rare Bleeding Disorder Study Group : Rare Bleeding Disorder Registry : deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2 : 248-256, 2004.
 
9) Bolton-Maggs PHB, et al : The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 10 : 593-628, 2004.
PubMed
10) Salooja N, et al : Severe factor V deficiency and neonatal intracranial hemorrhage : a case report. Haemophilia 6 : 44-46, 2000.
PubMed
11) Gonzalez-Boullosa R, et al : The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenitalseverefactor V deficiency. Haemophilia 11 : 167-170, 2005.
 
P.520 掲載の参考文献
1) Telfer TP, et al : A new coagulation defect. Br J Haematol 2 : 308-316, 1956.
PubMed
2) Hougie C, et al : Stuart clotting defect 1. Segregation of a hereditary hemorrhagic state from a heterogeneous group herefore called stable factors (SPCA, provertin, factor VII) deficiency. J Clin Invest 36 : 485-496, 1957.
 
3) Denson KWE, et al : The factor-X defect : recognition of abnormal forms of factor X. Br J Haematol 18 : 317-327, 1970.
 
4) Zama T, et al : A family with hereditary factor X deficiency with a point mutation Gla32 to Gln in the Gla domain (factor X Tokyo). Br J Haematol 106 : 809-811, 1999.
PubMed
5) Leytus SP, et al : Gene for human factor X : a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 25 : 5098-5102, 1986.
PubMed
6) Royle NJ, et al : The gene for clotting factor 10 is mapped to 13q32-qter. Cytogenet Cell Genet 41 : 185-188, 1986.
PubMed
7) Henkens CM, et al : Plasma levels of protein S, protein C, and factor X : effects of sex, hormonal state and age. Thromb Haemost 74 : 1271-1275, 1995.
PubMed
8) Girolami A, et al : A "new" congenital hemorrhagic condition due to the presence of an abnormal factor X (factor XFriuli) : study of a large kindred. Br J Haematol 19 : 179-192, 1970.
 
9) Watzke HH, et al : Factor XSanto Domino. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 88 : 1685-1689, 1991.
 
10) Reddy SV, et al : Molecular characterization of human Factor XSan Antonio. Blood 74 : 1486-1490, 1989.
PubMed
11) Menegatti M, Pewandi F, et al : Factor X deficiency. Semin Thromb Hemost 35 : 407-415, 2009.
 
12) Greip PR, et al : Factor X deficiency in amyloidosis : a critical review. Am J Hematol 11 : 443-450, 1981.
 
P.523 掲載の参考文献
1) Fujikawa K, et al : Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 25 : 2417-2424, 1986.
PubMed
2) Asakai R, et al : Organization of the gene for human factor XI. Biochemistry 26 : 7221-7228, 1987.
PubMed
3) Mc Mullen BA, et al : Location of the disulfide bonds in human coagulation factor XI : the presence of tandem apple domains. Biochemistry 30 : 2056-2060, 1991.
PubMed
4) He R, et al : Factor XI : Hemostasis, thrombosis, and antithrombosis. Thromb Res 129 : 541-550, 2012.
PubMed
5) Kato A, et al : Factor XI gene (F11) is located on the distal end of the long arm of human chromosome 4. Cytogenet Cell Genet 52 : 77-78, 1989.
 
6) Naito K, et al : Activation of human blood coagulation factor XI independent of factor XII. J Biol Chem 266 : 7353-7358, 1991.
PubMed
7) Kravtsov DV, et al : Factor XI contributes to thrombin generation in the absence of factor XII. Blood 114 : 452-458, 2009.
PubMed
8) vondem Borne P, et al : Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86 : 3035-3042, 1995.
 
9) von dem Borne P, et al : Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 99 : 2323-2327, 1997.
 
10) Tucker E, et al : Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood 119 : 4762-4768, 2012.
PubMed
11) Asakai R, et al : Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 325 : 153-158, 1991.
 
12) Kravtsov DV, et al : A classification system for cross-reactive material-negative factor XI deficiency. Blood 105 : 4671-4673, 2005.
PubMed
13) Salomon O, et al : Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 12 : 490-493, 2006.
PubMed
14) Seligsohn U, Modan M : Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection. Isr J Med Sci 17 : 413-415, 1981.
PubMed
15) Duga S, Salomon O : Factor XI deficiency. Semin Thromb Hemost 35 : 416-425, 2009.
PubMed
P.529 掲載の参考文献
1) Hantgan RR, et al : Fibrinogen structure and physiology. In : Hemostasis and Thrombosis, 4th ed (ed by Colman RW, et al), p203-232, Lippincott Williams & Wilkins, Philadelphia, 2001.
 
2) 諏合輝子 : フィブリノゲンの基礎と臨床. 図説 血栓・止血・血管学 (一瀬白帝編), p280-285. 中外医学社, 2005.
 
3) Tuddenham ED, Cooper DN : Fibrinogen. In : The Molecular Genetics of Haemostasis and Its Inherited Disorders, p248-270, Oxford Medical Publications, NY, 1994.
 
4) 小林隆夫ほか : 先天性無フィブリノゲン血症-妊娠・分娩管理を中心に-. 日血栓止血会誌 12 : 57-65, 2001.
 
5) Asselta R, et al : The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 4 : 2115-2129, 2006.
PubMed
6) Laffan M : Fibrinogen. In : Textbook of Hemophilia, 2nd ed (ed by Lee CA, et al), p369-368, Blackwell Publishing, West Sussex, 2010.
 
7) Soria A, et al : Fibrinogen Troyes-Fibrinogen Metz. Two new cases of congenital dysfibrinogenemia. Thromb Diath Haemorrh 27 : 619-633, 1972.
 
8) Wada Y, et al : A new type of congenital dysfibrinogen, fibrinogen Bremen, with an A alpha Gly-17 to Val substitution associated with hemorrhagic diathesis and delayed wound healing. Thromb Haemost 70 : 397-403, 1993.
 
9) 松田道生ほか : 遺伝性異常フィブリノゲン血症. 日血栓止血会誌 12 : 47-56, 2001.
 
10) Kobayashi T, et al : Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 109 : 364-366, 2000
PubMed
P.532 掲載の参考文献
1) Quick AJ : Congenital hypoprothrombinemia and pseudo-hypoprothrombinemia. Lancet 2 : 379, 1947.
PubMed
2) Shapiro SS, et al : Congenital dysprothrombinemia : an inherited structural disorder of human prothrombin. J Clin Invest 48 : 2251-2259, 1969.
PubMed
3) Fujimura Y, et al : Congenital hypoprothrombinemia : The first reported case in Japan. Acta Paediatr Jpn 1984 : 554-560, 1984.
 
4) Inomoto T, et al : Prothrombin Tokushima : characterization of dysfunctional thrombin derived a variant of human prothrombin. Blood 69 : 565-569, 1987.
PubMed
5) Lancellotti S, De Cristofaro R : Congenital prothrombin deficiency. Semin Thromb Hemost 35 : 367-381, 2009.
PubMed
6) http://www.isth.org/default/index.cfm/publications/registries-databases/mutations-rare-bleeding-disorders/ (2012年9月1日にアクセス).
 
7) Miyata T, et al : A point mutation (Arg271→Cys) of a homozygote for dysfunctional prothrombin, prothrombin Obihiro, which has a region of high sequence variability. Br J Haematol 90 : 688-692, 1995.
 
8) Morishita E, et al : Prothrombin Himi : a compound heterozygote for two dysfunctional prothrombin molecules (Met-337→Thr and Arg-388→His). Blood 80 : 2275-2280, 1992.
 
9) 森下英里子ほか : 先天性複合へテロ接合体プロトロンビン欠乏症の一例. 臨床血液 48 : 848, 1992.
 
10) 瀧正志 : 血液凝固異常症全国調査平成23年度報告書, p9, 公益財団法人エイズ予防財団, 2011.
 
11) Rabiet MJ, et al : Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273. J Biol Chem 261 : 15045-15048, 1986.
PubMed
12) Henriksen RA, Mann KG : Identification of the primary structural defect in the dysthrombin thrombin Quick I : substitution of cysteine for arginine-382. Biochemistry 27 : 9160-9165, 1988.
PubMed
13) Henriksen RA, Mann KG : Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. Biochemistry 28 : 2078-2082, 1989.
PubMed
P.537 掲載の参考文献
1) 一瀬白帝 : 血液凝固と凝固制御機構. 臨床検査 55 : 328-339, 2011.
 
2) Vadivel K, Bajaj SP : Structural biology of factor VIIa/tissue factor initiated coagulation. Front Biosci 17 : 2476-2494, 2012.
PubMed
3) Mariani G, et al : International Factor VII Deficiency Study Group : Thrombosis in inherited factor VII deficiency. J Thromb Haemost 1 : 2153-2158, 2003.
 
4) Mariani G, et al : International Factor VII Deficiency Study Group : Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 93 : 481-487, 2005.
 
5) Hoffman M, Dargaud Y : Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 10 : 1478-1485, 2012.
PubMed
6) 一瀬白帝 : 表紙の図. 図説・分子病態学 第4版 (一瀬白帝・鈴木宏治 (編) ), 中外医学社, 2008.
 
7) Norledge BV, et al : The tissue factor/factor VIIa/factor Xa complex : a model built by docking and site-directed mutagenesis. Proteins 53 : 640-648, 2003.
 
8) Venkateswarlu D, et al : An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VIIa-Xa) : a protein-protein docking and molecular dynamics refinement study. J Thromb Haemost 1 : 2577-2588, 2003.
PubMed
9) Lee CJ, et al : Molecular dynamic simulations of the binary complex of human tissue factor (TF1-242) and factor VIIa (TF1-242/FVIIa) on a 4 : 1 POPC/POPS lipid bilayer. J Thromb Haemost 10 : 2402-2405, 2012.
 
10) Girolami A, et al : Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J Thromb Thrombolysis 30 : 172-178, 2010.
PubMed
11) Girolami A, et al : Congenital FVII Deficiency and Pulmonary Embolism : A Critical Appraisal of All Reported Cases. Clin Appl Thromb Hemost 19 : 55-59, 2013.
 
12) Mariani G, et al : STER and the International Factor VII Deficiency Study Groups : Recombinant, activated factor VII for surgery in factor VII deficiency : a prospective evaluation-the surgical STER. Br J Haematol 152 : 340-346, 2011.
PubMed
13) Benlakhal F, et al : French Study Group of Factor VII Deficiency : A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost 9 : 1149-1156, 2011.
 
14) Shibeko AM, et al : Unifying the mechanism of recombinant FVIIa action : dose dependence is regulated differently by tissue factor and phospholipids. Blood 120 : 891-899, 2012.
PubMed
15) Hoffman M : Hemostatic properties of the FVIIa analog NN1731. Thromb Res 129 (Suppl 2) : S49-50, 2012.
 
16) Mahlangu JN, et al : Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost 10 : 773-780, 2012.
PubMed
P.543 掲載の参考文献
1) Ichinose A : Extracellular transglutaminase : factor XIII. In : Prog Exp Tum Res ; Transglutaminases (ed by Mehta K, Eckert R), p192-208, Karger, Basel, 2005.
 
2) Ichinose A, Davie EW : Characterization of the gene for the A subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci USA 85 : 5829-5833, 1988.
PubMed
3) Bottenus RE, et al : Nucleotide sequence of the gene for the B subunit of human factor XIII. Biochemistry 29 : 11195-11209, 1990.
 
4) Ichinose A : Physiology and regulation of factor XIII. Thromb Haemost 86 : 57-65, 2001.
PubMed
5) Ichinose A : Factor XIII is a key molecule at the interaction of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 95 : 362-370, 2012.
 
6) Biswas A, et al : An update of the mutation profile of factor 13 A and B genes. Blood Rev 25 : 193-204, 2011.
 
7) Ichinose A : Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 37 : 382-388, 2011.
PubMed
8) Hashiguchi T, et al : Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII. Blood 82 : 145-150, 1993.
 
9) Izumi T, et al : Type I factor XIII deficiency is caused by a genetic defect of its b subunit : insertion of triplet AAC inexon III leads to premature termination in the second Sushi domain. Blood 87 : 2769-2774, 1996.
 
10) Koseki S, et al : Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood 97 : 2667-2672, 2001.
PubMed
11) Ivaskevicius V, et al : Mutations affecting disulfide bonds contribute to a fairly common prevalence of F13B gene defects : results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 16 : 675-682, 2010.
PubMed
12) Hashiguchi T, Ichinose A : Molecular and cellular basis of deficiency of the b subunit for factor XIII secondary to a Cys430-Phe mutation in the seventh Sushi domain. J Clin Invest 95 : 1002-1008, 1995.
 
13) Souri M, et al : A founder effect is proposed for factor XIII B subunit deficiency caused by the insertion of triplet AAC in exon III encoding the second Sushi domain. Thromb Haemost 80 : 211-213, 1998.
PubMed
14) Kohler HP, et al ; Factor XIII And Fibrinogen SSC Subcommittee Of the ISTH : Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 9 : 1404-1406, 2011.
 
15) Ichinose A : As many as 12 cases with hemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 105 : 925-927, 2011.
 
P.548 掲載の参考文献
1) Colman RW, Schmaier AH : Contact system : a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90 : 3819-3843, 1997.
PubMed
2) Hathaway WE, et al : Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency. Am J Med 60 : 654-664, 1976.
PubMed
3) Renne T, et al : Mapping of discontinuous h-kininogen binding site of plasma prekallikrein. J Biol Chem 274 : 25777-25784, 1999.
PubMed
4) Katsuda I, et al : A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region. Eur J Haematol 79 : 59-68, 2007.
PubMed
5) Ichinose A, et al : The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261 : 3486-3489, 1986.
PubMed
6) Saito H, et al : Heterogeneity of human prekallikrein deficiency (Fletcher trait) : evidence that five of 18 cases are positive for cross-reacting material. N Engl J Med 305 : 910-914, 1981.
PubMed
7) Shigekiyo T, et al : Prekallikrein (PK) Tokushima : PK deficiency caused by a Gly401→Glu mutation. J Thromb Haemost 1 : 1314-1316, 2003.
 
8) 長屋聡美ほか : 高齢になってから診断された先天性プレカリクレイン欠乏症の1症例. 日老医誌 46 : 348-351, 2009.
 
9) Nakao T, et al : Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation. Blood Coagul Fibrinolysis 22 : 337-339, 2011.
PubMed
10) Francois D, et al : Severe prekallikrein deficiency due to homozygous C529Y mutations. Blood Coagul Fibrinolysis 8 : 283-286, 2007.
 
11) Dasanu CA, Alexandrescu DT : A case of prekallikrein deficiency resulting in severe recurrent mucosal hemorrhage. Am J Med Sci 338 : 429-430, 2009.
PubMed
12) Corno AR, et al : Automated APTT cycle for the rapid identification of plasma prekallikrein deficiency. Thromb Res 126 : e152-e153, 2010.
PubMed
13) Eeckhoudt SL, et al : Management of prekallikrein deficiency during cardiac surgery. Thromb Heamost 103 : 866-867, 2010.
PubMed
14) van Veen JJ, et al : Contact factor deficiencies and cardiopulmonary bypass surgery : detection of the defect and monitoring of heparin. Eur J Haematol 82 : 208-212, 2009.
PubMed
15) Sugi T, Makino T : Autoantibodies to contact proteins in patients with recurrent pregnancy loss. J Reprod Immunol 53 : 269-277, 2002.
 
P.554 掲載の参考文献
1) 瀧正志 : 血液凝固異常症全国調査平成23年度報告書, p3, 公益財団法人エイズ予防財団, 2012.
 
2) Schwaab R, et al : Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 109 : 523-528, 2000.
 
3) Pavlova A, et al : Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 7 : 976-982, 2009.
PubMed
4) Hagiwara T, et al : Female hemophilia B with homozygous missense mutation p.Ala337Val in the factor IX gene. 臨床血液 (abstract) 52 : 1180, 2011.
 
5) Vencesla A, et al : Severe haemophilia A in a female resulting from an inherited gross deletion and a de novo codon deletion in the F8gene. Haemophilia 14 : 1094-1098, 2008.
 
6) Cai XH, et al : Female hemophilia A heterozygous for a de novo frameshift and a novel missense mutation of factor VIII. J Thromb Haemost 4 : 1969-1974, 2006.
 
7) Chuansumrit A, et al : Inversion of intron 22 of the factor VIII gene in a girl with severe hemophilia A and Turner's syndrome. Thromb Haemost 82 : 1379, 1999.
 
8) Schroder W, et al : A de novo translocation 46, X,t (X ; 15) causing haemophilia B in a girl : a case report. Br J Haematol 100 : 750-757, 1998.
 
9) Loreth RM, et al : Haemophilia A in a female caused by coincidence of a Swyer syndrome and a missense mutation in factor VIII gene. Thromb Haemost 95 : 747-748, 2006.
 
10) Favier R, et al : Unbalanced X-chromosome inactivation with a novel FVIII gene mutation resulting in severe hemophilia A in a female. Blood 96 : 4373-4375, 2000.
 
11) Okumura K, et al : Skewed X chromosome inactivation in fraternal female twins results in moderately severe and mild haemophilia B. Haemophilia 14 : 1088-1093, 2008.
PubMed
12) Miyawaki Y, et al : Severe hemophilia A in a Japanese female caused by an F8-intron 22 inversion associated with skewed X chromosome inactivation. Int J Hematol 92 : 405-408, 2010.
 
13) Mazurier C, et al : Factor VIII deficiency not induced by FVIII gene mutation in a female first cousin of two brothers with haemophilia A. Br J Haematol 119 : 390-392, 2002.
 
14) Nishino M, et al : New variant of von Willebrand disease with defective binding to factor VIII. Blood 74 : 1591-1599, 1989.
PubMed
15) Allen RC, et al : Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 51 : 1229-1239, 1992.
PubMed
P.556 掲載の参考文献
1) Rodriguez-Merchan EC : Musculoskeletal complications of hemophilia. HSS J 6 : 37-42, 2010.
PubMed
2) Baudo F, et al ; EACH2 registry contributors : Management of bleeding in acquired hemophilia A : results from the European Acquired Haemophilia (EACH2) Registry. Blood 120 : 39-46, 2012.
 
3) Magallon M, et al : Hemophilic pseudotumor : multicenter experience over 25-year period. Am J Hematol 45 : 103-108, 1994.
PubMed
4) 川中正雄ほか : 幼児に生じた下顎骨血友病性偽腫瘍の1例. 日口腔科会誌 46 : 414-418, 1997.
Medical*Online
5) Rodriguez-Merchan EC : The haemophilic pseudotumour. Haemophilia 8 : 12-18, 2002.
PubMed
6) Rodriguez-Merchan EC : Haemophilic cysts (pseudotumours). Haemophilia 8 : 393-401, 2002.
PubMed
7) Allen DJ, et al : Primary malignancies mistaken for pseudotumours in haemophilic patients. Haemophilia 13 : 383-386, 2007.
PubMed
8) 竹谷英之 : 血友病性関節症と血友病性偽腫瘍. 整形・災害外科 48 : 1247-1254, 2005.
 
9) 竹谷英之ほか : 血友病性偽腫瘍の手術治療. 関節外科 21 : 603-606, 2002.
 
10) 松下正ほか : インヒビターのない血友病患者の急性出血, 処置・手術における凝固因子補充療法のガイドライン. 日血栓止血会誌 19 : 510-519, 2008.
 
11) 田中一郎ほか : インヒビター保有先天性血友病患者に対する止血治療ガイドライン. 日血栓止血会誌 19 : 520-539, 2008.
 
12) Keller A, et al : Pelvic haemophilic pseudotumour : management of a patient with high level of inhibitors. Skelet al Radiol 31 : 550-553, 2002.
 
P.562 掲載の参考文献
1) von Willebrand E : Hereditar pseudohemophili. Fin Laekaresaellsk Hand 68 : 87-112, 1926.
 
2) Nilsson IM, et al : On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Sc and 159 : 35-57, 1957.
 
3) Nilsson IM, et al : Von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Sc and 159 : 179-188, 1957.
 
4) Holmberg L, et al : von Willebrand's disease. Eur J Haematol 48 : 127-141, 1992.
PubMed
5) Rodeghiero F, et al : Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69 : 454-459, 1987.
 
6) Sadler JE : A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 71 : 520-525, 1994.
PubMed
7) Jaffe EA, et al : Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 71 : 1906-1909, 1974.
PubMed
8) Nachman R, et al : Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest 60 : 914-921, 1977.
PubMed
9) Marti T, et al : Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 26 : 8099-8109, 1987.
PubMed
10) Voorberg J, et al : Assembly and routing of von Willebrand factor variants : the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol 113 : 195-205, 1991.
PubMed
11) Katsumi A, et al : Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor. J Biol Chem 275 : 25585-25594, 2000.
PubMed
12) Rehemtulla A, Kaufman RJ : Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes. Blood 79 : 2349-2355, 1992.
PubMed
13) Wagner DD, et al : Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 95 : 355-360, 1982.
PubMed
14) Sporn LA, et al : Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 46 : 185-190, 1986.
PubMed
15) Cramer EM, et al : Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 66 : 710-713, 1985.
 
16) Wagner DD : Cell biology of von Willebrand factor. Annu Rev Cell Biol 6 : 217-246, 1990.
PubMed
17) Mannucci PM, et al : 1-Deamino-8-d-arginine vasopressin : a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1 : 869-872, 1977.
 
18) Ginsburg D, et al : Human von Willebrand factor (vWF) : isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 228 : 1401-1406, 1985.
PubMed
19) Kuwano A, et al : Precise chromosomal locations of the genes for dentatorubral-pallidoluysian atrophy (DRPLA), von Willebrand factor (F8vWF) and parathyroid hormone-like hormone (PTHLH) in human chromosome 12p by deletion mapping. Hum Genet 97 : 95-98, 1996.
PubMed
20) Mancuso DJ, et al : Structure of the gene for human von Willebrand factor. J Biol Chem 264 : 19514-19527, 1989.
PubMed
21) Patracchini P, et al : Sublocalization of von Willebrand factor pseudogene to 22q11.22-q11.23 by in situ hybridization in a 46, X, t (X ; 22) (pter ; q11.21) translocation. Hum Genet 83 : 264-266, 1989.
 
22) Mancuso DJ, et al : Human von Willebrand factor gene and pseudogene : structural analysis and differentiation by polymerase chain reaction. Biochemistry 30 : 253-269, 1991.
PubMed
23) Sadler JE : Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67 : 395-424, 1998.
PubMed
24) Gill JC, et al : The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69 : 1691-1695, 1987.
PubMed
25) Eikenboom JC, et al : Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 88 : 2433-2441, 1996
PubMed
26) Gadisseur A, et al : Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol 121 : 71-84, 2009.
PubMed
27) The Diagnosis, Evaluation, and Management of von Willebrand disease. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, 2007.
 
28) Zhang ZP, et al : Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands. Proc Natl Acad Sci USA 90 : 7937-7940, 1993.
PubMed
29) Zhang ZP, et al : Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 51 : 850-858, 1992.
PubMed
30) Zhang ZP, et al : Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics 21 : 188-193, 1994.
PubMed
31) Schneppenheim R, et al : Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 94 : 640-652, 1994.
PubMed
32) Mannucci PM, et al : Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 39 : 467-470, 1987.
 
P.567 掲載の参考文献
1) Lyons SE, et al : Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 267 : 4424-4430, 1992.
PubMed
2) Sugiura I, et al : Three distinct candidate point mutations of the von Willebrand factor gene in four patients with type IIA von Willebrand disease. Thromb Haemost 67 : 612-617, 1992.
PubMed
3) O'Brien LA, et al : Theoretical structural explanation for Group I and Group II, type2A von Willebrand disease mutations. J Thromb Haemost 3 : 796-797, 2005.
 
4) Kashiwagi T, et al : L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers : an analysis of two patients with type 2A von Willebrand disease. Haemophilia 14 : 556-563, 2008.
 
5) Gaucher C, et al : Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 84 : 1024-1030, 1994.
PubMed
6) Schneppenheim R, et al : Defective dimerization of von Willebrand factor subunits due to a Cys→Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 93 : 3581-3586, 1996.
 
7) Ruggeri ZM, et al : Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 302 : 1047-1051, 1980.
 
8) Sadler JE : Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67 : 395-424, 1998.
PubMed
9) Ozeki M, et al : A family having type 2B von Willebrand disease with an R1306W mutation : Severe thrombocytopenia leads to the normalization of high molecular weight multimers. Thromb Res 125 : e17-e22, 2010.
 
10) Jackson SC, et al : The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 113 : 3348-3351, 2009.
PubMed
11) Fujimura Y, et al : von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 261 : 381-385, 1986.
 
12) Matsushita T, Sadler JE : Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 270 : 13406-13414, 1995.
PubMed
13) Kroner PA, Frey AB : Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemistry 35 : 13460-13468, 1996.
PubMed
14) Matsushita T, et al : Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem 275 : 11044-11049, 2000.
PubMed
15) Rabinowitz I, et al : Type IIB mutation His-505→Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 268 : 20497-20501, 1993.
 
16) Vlot AJ, et al : The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 85 : 3150-3157, 1995.
PubMed
17) Vlot AJ, et al : Kinetics of factor VIII-von Willebrand factor association. Blood 87 : 1809-1816, 1996.
PubMed
18) Lollar P, et al : Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263 : 10451-10455, 1988.
PubMed
19) Leyte A, et al : Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 266 : 740-746, 1991.
PubMed
20) Nishino M, et al : New variant of von Willebrand disease with defective binding to factor VIII. Blood 74 : 1591-1599, 1989.
PubMed
21) Mazurier C, et al : A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 75 : 20-26, 1990.
 
22) Mazurier C, Meyer D : Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 76 : 270-274, 1996.
 
23) Marchese P, et al : Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alpha-thrombin binding. J Biol Chem 270 : 9571-9578, 1995.
 
24) Takahashi H, et al : Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood 85 : 727-733, 1995.
PubMed
25) Huizinga EG, et al : Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 297 : 1176-1179, 2002.
PubMed
P.571 掲載の参考文献
1) Bangert K, et al : Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 291 (Pt 2) : 623-625, 1993.
 
2) Sumi Y, et al : Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem 106 : 703-707, 1989.
PubMed
3) Miura O, et al : Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. J Clin Invest 83 : 1598-1604, 1989.
PubMed
4) Miura O, et al : Hereditary alpha 2-plasmin inhibitor deficiency caused by a transport-deficient mutation (alpha 2-PI-Okinawa). Deletion of Glu137 by a trinucleotide deletion blocks intracellular transport. J Biol Chem 264 : 18213-18219, 1989.
PubMed
5) Holmes WE, et al : Alpha 2-antiplasmin Enschede : alanine insertion and abolition of plasmin inhibitory activity. Science 238 : 209-211, 1987.
PubMed
6) Lijnen HR, et al : Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 93 : 2274-2281, 1999.
PubMed
7) Okada K, et al : The regulation of liver regeneration by the plasmin/alpha 2-antiplasmin system. J Hepatol 40 : 110-116, 2004.
PubMed
8) Kanno Y, et al : alpha2-antiplasmin is associated with the progression of fibrosis. Am J Pathol 176 : 238-245, 2010.
PubMed
9) Aoki N, Harpel PC : Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 10 : 24-41, 1984.
PubMed
P.573 掲載の参考文献
1) Koide T, et al : Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 25 : 2220-2225, 1986.
PubMed
2) Wakabayashi S, Koide T : Histidine-rich glycoprotein : a possible modulator of coagulation and fibrinolysis. Semin Thromb Hemost 37 : 389-394, 2011.
PubMed
3) Poon IKH, et al : Histidine-rich glycoprotein : the Swiss Army knife of mammalian plasma. Blood 117 : 2093-2101, 2011.
PubMed
4) Shigekiyo T, et al : Congenital histidine-rich glycoprotein deficiency. Thromb Haemostas 70 : 263-265, 1993.
 
5) Souto JC, et al : A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia. Thromb Haemostas 75 : 374-375, 1996.
 
6) Shigekiyo T, et al : Histidine-rich glycoprotein (HRG) Tokushima 2 : novel HRG deficiency, molecular and cellular characterization. Thromb Haemostas 84 : 675-679, 2000.
 
7) Shigekiyo T, et al : HRG Tokushima : molecular and cellular characterization of histidine-rich glycoprotein (HRG) deficiency. Blood 91 : 128-133, 1998.
PubMed
8) Lewis AI, et al : Carotid-cavernous fistulas and intracavernous aneurysms. In : Neurosurgery, Vol. II (ed by Wilkins RH, Rengachary SS), p2529-2539, McGraw-Hill, New York, 1996.
 
9) Silverstein RL, et al : Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem 260 : 10346-10352, 1985.
PubMed
10) Vestergaard AB, et al : Histidine-rich glycoprotein inhibits contact activation of blood coagulation. Thromb Res 60 : 385-396, 1990.
PubMed
11) Kazama Y, Koide T : Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4 : role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein. Thromb Haemostas 67 : 50-55, 1992.
 
12) Girolami A, et al : The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors : a study of six patients. Blood Coagul Fibrinolysis 2 : 673-678, 1991.
PubMed
13) Thaler E, Lechner K : Antithrombin III deficiency and thromboembolism. Clin Hematol 10 : 369-390, 1981.
 
14) Shigekiyo T, et al : Congenital deficiency of histidine-rich glycoprotein : Failure to identify abnormalities in routine laboratory assays of hemostatic function, immunologic function, and traceelements. J Lab Clin Med 125 : 719-723, 1995.
 
15) Tsuchida-Straeten N, et al : Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemostas 3 : 865-872, 2004.
 
P.578 掲載の参考文献
1) Schleef RR, et al : Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 83 : 1747-1752, 1989.
PubMed
2) Dieval J, et al : A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 77 : 528-532, 1991.
PubMed
3) Fay WP, et al : Brief report : complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327 : 1729-1733, 1992.
PubMed
4) Iwaki T, et al : Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 9 : 1200-1206, 2011.
PubMed
5) Madoiwa S, et al : Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood 94 : 475-482, 1999.
PubMed
6) Eriksson P, et al : Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92 : 1851-1855, 1995.
PubMed
7) Rijken DC, et al : Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 10 : 2116-2122, 2012.
PubMed
P.582 掲載の参考文献
1) 田中一郎ほか : 日本血栓止血学会後天性血友病 A診療ガイドライン. 血栓止血会誌 22 : 295-322, 2011.
 
2) Collins PW, et al ; UK Haemophilia Centre Doctors' Organization : Acquired hemophilia Ain the United Kingdom : a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organization. Blood 109 : 1870-1877, 2007.
 
3) 田中一郎ほか : わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査-予後因子に関する検討-. 血栓止血会誌 19 : 140-153, 2008.
 
4) 嶋緑倫 : 後天性凝固異常症の病態と治療 : 後天性血友病を中心に. 臨床血液 51 : 211-218, 2010.
 
5) Hay CR, et al : The diagnosis and treatment of factor VIII and IX inhibitors : a guideline from the United Kingdom Haemophilia Centre Doctors' Organization. Br J Haematol 133 : 591-605, 2006.
PubMed
6) Kazmi MA, et al : Acquired haemophilia A : errors in the diagnosis. Blood Coagul Fibrinolysis 9 : 623-628, 1998.
PubMed
7) Hay CR, et al : The treatment of bleeding in acquired haemophilia with recombinant factor VIIa : a multicentre study. Thromb Haemost 78 : 1463-1467, 1997.
PubMed
8) Sallah S : Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 10 : 169-173, 2004.
PubMed
9) Summner MJ, et al : Treatment of acquired haemophilia with recombinant activated FVII : a critical appraisal. Haemophilia 13 : 451-461, 2007.
 
10) Ehrlich HJ, et al : Safety of factor VIII inhibitor bypass activity (FEIBA) : 10-year complication of thrombotic adverse events. Haemophilia 8 : 83-90, 2002.
 
11) Wiestner A, et al : Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100 : 3426-3428, 2002.
PubMed
12) Collins P, et al : Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 3 : 161-168, 2010.
PubMed
P.586 掲載の参考文献
1) Knoble P, Lechner K : Acquired factor Vinhibitors. Baillieres Clin Haematol 11 : 305-318, 1998.
 
2) Streiff MB, Ness PM : Acquired factor V inhibitors : a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42 : 18-26, 2002.
PubMed
3) Franchini M, Lippi G : Acquired factor V inhibitors : a systematic review. J Thromb Thrombolysis 314 : 449-457, 2011.
 
4) Ang AL, et al : Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101 : 852-859, 2009.
PubMed
5) 田中一郎ほか : わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査-予後因子に関する検討-. 血栓止血会誌 19 : 140-153, 2008.
 
6) Ajzner E, et al : Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost 1 : 943-949, 2003.
PubMed
7) Kalafatis M, et al : Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood 99 : 3985-3992, 2002.
PubMed
8) Nesheim ME, et al : Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 77 : 405-415, 1986.
PubMed
P.590 掲載の参考文献
1) Tiede A, et al : How I treat the acquired von Willebrand syndrome. Blood 117 : 6777-6785, 2011.
 
2) Federici AB, et al : Acquired von Willebrand syndrome : data from an international registry. Thromb Haemost 84 : 345-349, 2000.
 
3) Shetty S, et al : Pathophysiology of acquired von Willebrand disease : a concise review. Eur J Haematol 87 : 99-106, 2011.
PubMed
4) 嶋緑倫 : 後天性凝固異常症の病態と治療 : 後天性血友病を中心に. 臨床血液 51 : 211-218, 2010.
 
5) Luo YY, Zhang GS : Acquired factor XIII inhibitor : clinical features, treatment, fibrin structure and epitope determination. Haemophilia 17 : 393-398, 2011.
PubMed
6) Ichinose A, Souri M ; Japanese collaborative research group on "Acquired haemorrha-philia due to factor XIII deficiency" : As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 105 : 925-927, 2011.
 
7) Ichinose A : Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 37 : 382-388, 2011.
PubMed
8) Ajzner E, et al : Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII : a novel form of acquired factor XIII deficiency. Blood 113 : 723-725, 2009.
 
9) Hayashi T, et al : A case of acquired FXIII deficiency with severe bleeding symptoms. Haemophilia 18 : 618-620, 2012.
PubMed
10) Ichinose A, Souri M : Reduced difference of α2-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies. Int J Hematol 95 : 47-50, 2012.
 
11) Miesbach W, et al : Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 93 : 1001-1003, 2005.
PubMed
P.598 掲載の参考文献
1) Levi M, et al : Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145 (1) : 24-33, 2009.
PubMed
2) Taylor FB Jr, et al ; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 (5) : 1327-1330, 2001.
 
3) Kaneko T, Wada H : Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop 51 (2) : 67-76, 2011.
PubMed
4) Colman RW, et al : Disseminated intravascular coagulation (DIC) : an approach. Am J Med 52 (5) : 679-689, 1972.
PubMed
5) Chaput C, Zychlinsky A : Sepsis : the dark side of histones. Nat Med 15 (11) : 1245-1246, 2009.
PubMed
6) Semeraro N, et al : Sepsis, thrombosis and organ dysfunction. Thromb Res 129 (3) : 290-295, 2012.
PubMed
7) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 (1) : 77-113, 2009.
 
8) Gando S, et al ; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med 34 (3) : 625-631, 2006.
 
9) Takemitsu T, et al : Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 105 (1) : 40-44, 2011.
PubMed
10) Okamoto K, et al ; Japanese Society of Thrombosis Hemostasis/DIC subcommittee : Frequency and hemostatic abnormalities in pre-DIC patients. Thromb Res 126 (1) : 74-78, 2010.
PubMed
11) Hook KM, Abrams CS : The loss of homeostasis in hemostasis : new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients. Clin Transl Sci 5 (1) : 85-92, 2012.
PubMed
12) Kawasugi K, et al ; Japanese Society of Thrombosis Hemostasis/DIC Subcommittee : Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res 128 (2) : 186-190, 2011.
PubMed
13) Saito H, et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 (1) : 31-41, 2007.
PubMed
14) Warren BL, et al ; KyberSept Trial Study Group : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 (15) : 1869-1878, 2001.
 
15) Abraham E, et al ; OPTIMIST Trial Study Group : Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis : a randomized controlled trial. JAMA 290 (2) : 238-247, 2003.
 
16) Bernard GR, et al ; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group : Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (10) : 699-709, 2001.
 
P.604 掲載の参考文献
1) Kasabach HH, Merritt KK : Capillary hemangioma with extensive purpura. Am J Dis Child 59 : 1063-1070, 1940.
 
2) Enjolras O, et al : Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 130 : 631-640, 1997.
 
3) Lane A, Darmstadt GL : Kasabach-Merritt syndrome. In : Nelson Textbook of Pediatrics, 15th ed (ed by Behrman RE, et al), p1839, WB Saunders, Philadelphia, 1996.
 
4) Aslan A, et al : Adult Kasabach-Merritt Syndrome due to Hepatic Giant Hemangioma. Case Rep Gastroenterol 3 : 306-312, 2009.
PubMed
5) Koerper MA, et al : Use of aspirin and dipyridamole in children with platelet trapping syndromes. J Pediatr 201 : 311-314, 1983.
 
6) Brizel HE, Raccuglia G : Giant hemangioma with thrombocytopenia. Radioisotopic demonstration of platelet sequestration. Blood 26 : 751-756, 1965.
PubMed
7) Gilon E, et al : Multiple hemangiomata associated with thrombocytopenia : remarks on the pathogenesis of the thrombocytopenia in this syndrome. Blood 14 : 74-79, 1965.
 
8) Enjolras O, et al : Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 42 : 225-235, 2000.
PubMed
9) Sarkar M, et al : Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendotherioma and not with commoninfantile hemangioma. Plast Reconstr Surg 100 : 1377-1386, 1997.
 
10) Drolet BA, et al : Hemangiomas in children. N Engl J Med 341 : 173-181, 1999.
PubMed
11) Velin P, et al : -Neonatal Kasabach-Merritt syndrome healed by complete surgical excision of the angioma-. Arch Pediatr 5 : 295-297, 1998.
PubMed
12) Miller JG, Orton CI : Long term follow-up of a case of Kasabach-Merritt syndrome successfully treated with radiotherapy and corticosteroids. Br J Plast Surg 45 : 559-561, 1992.
PubMed
13) Perez-Payarods J, et al : Treatment of life-threatening hemangiomas with vincristine. N Engl J Med 333 : 69, 1995.
 
14) Hu B, et al : Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol 20 : 567-569, 1998.
PubMed
15) Hall GW : Kasabach-Merritt syndrome : pathogenesis and management. Br J Haematol 112 : 851-862, 2001.
PubMed
P.607 掲載の参考文献
1) Acute Myeloid Leukemia with reccurent genetic abnormalities. In : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, p112-114, International Agency for Research on Cancer (IARC), Lyon, 2008.
 
2) Menell JS, et al : Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340 : 994-1004, 1999.
PubMed
3) Wang J, et al : Thrombogenic role of cell sundergoing apoptosis. Br J Haematol 115 (2) : 382-391, 2001.
PubMed
4) Kwaan HC, Rego EM : Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 36 (8) : 917-924, 2010.
PubMed
5) Falanga A, et al : Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 92 (1) : 143-151, 1998.
PubMed
6) Kwaan HC, et al : Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 20 (1) : 33-41, 2002.
PubMed
7) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 (1) : 77-113, 2009.
 
8) Tallman MS, et al : All-trans retinoic acid in acute promyelocytic leukemia : long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100 : 4298-4302, 2002.
PubMed
9) Sanz MA, et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European Leukemia Net. Blood 113 : 1875-1891, 2009.
 
10) Saito H, et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 (1) : 31-41, 2007.
PubMed
11) British Committee for Standards in Haematology ; Milligan DW, et al : Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 135 (4) : 450-474, 2006.
PubMed
12) Sanz MA, et al : Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy : a multicenter study by the PETHEMA group. Blood 103 : 1237-1243, 2004.
PubMed
13) Brown JE, et al : All-trans retinoic acid (ATRA) and tranexamic acid : a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol 110 : 1010-1012, 2000.
PubMed
14) Kwaan HC, et al : Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 20 (1) : 33-41, 2002.
PubMed
15) Rickles FR, et al : Bleeding and thrombosis in acute leukemia : what does the future of therapy look like? Thromb Res 120 (Suppl 2) : S99-106, 2007.
 
P.611 掲載の参考文献
1) 白幡聡ほか : 新生児・乳児ビタミンK欠乏性出血症に対するビタミンK製剤投与の改訂ガイドライン (修正版). 日児誌 115 : 705-712, 2011.
 
2) Vanakker OM, et al : Functional polymorphism in gamma-glutamylcarboxylase is a risk factor for severe neonatal hemorrhage. J Pediatr 159 : 347-349, 2011.
PubMed
3) Takahashi D, et al : Vitamin K prophylaxis and late vitamin K deficiency bleeding in infants : fifth nationwide survey in Japan. Pediatr Int 53 : 897-901, 2011.
PubMed
4) 白幡聡ほか : 乳児ビタミンK欠乏性出血症全国調査成績 (1999～2004年). 日産婦新生児血会誌 16 : S55-56, 2006.
 
5) 板橋家頭夫 : ビタミンK欠乏性出血症予防のためのガイドライン. 周産期医学 41 : 1197-1201, 2011.
Medical*Online
6) Pichler E, Pichler L : The neonatal coagulation system and thevitamin K deficiency bleeding-a mini review. Wien Med Wochenschr 158 : 385-395, 2008.
 
7) Loughnan PM, Mc Dougall PN : Epidemiology of late onset haemorrhagic disease : a pooled data analysis. J Paediatr Child Health 29 : 177-181, 1993.
PubMed
8) Williams MD, et al ; Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology : The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol 119 : 295-309, 2002.
PubMed
9) Van Winckel M, et al : Vitamin K, an update for the paediatrician. Eur J Pediatr 168 : 127-134, 2009.
PubMed
10) Chapter 10. Vitamin K. In : Human Vitamin and Mineral Requirements. Report of a joint FAO-WHO expert consultation (ed by Nantel G, Tontisirin K), p113-150, World Health Organization Food and Agriculture Organization of the United Nations, Rome, 2002.
 
11) National Academy of Science, Institute of Medicine, Food and Nutrition Board : Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Chapter 5, p12-196, National Academy Press, Washington, DC, 2001.
 
12) Cornelissen M, et al : Prevention of vitamin K deficiency bleeding : efficacy of different multiple oral dose schedules of vitamin K. Eur J Pediatr 156 : 126-130, 1997.
PubMed
P.616 掲載の参考文献
1) Autret-Leca E, Jonville-Bera A : Vitamin K in neonates. Pediatr Drugs 3 : 1-8, 2001.
 
2) 白幡聡ほか : 新生児・乳児ビタミンK欠乏性出血症に対するビタミンK製剤投与の改訂ガイドライン (修正版). 日児誌 115 : 705-712, 2011.
 
3) Suttie JW : Vitamin K and human nutrition. J Am Diet Assoc 92 : 585-590, 1992.
PubMed
4) Shearer MJ : Vitamin K deficiency bleeding (VKDB) in early infancy. Blood Rev 23 : 49-59, 2009.
PubMed
5) 板橋家頭夫 : ビタミンK欠乏性出血症予防のためのガイドライン. 周産期医学 41 : 1197-1201, 2011.
Medical*Online
6) Pichler E, Pichler L : The neonatal coagulation system and the vitamin K deficiency bleeding-a mini review. Wien Med Wochenschr 158 : 385-395, 2008.
PubMed
7) Van Winckel M, et al : Vitamin K, an update for the paediatrician. Eur J Pediatr 168 : 127-134, 2009.
PubMed
8) 鈴木重統ほか : ジヘパプラスチンテストによる肝の異常と新生児期の肝成熟のスクリーニングに対する一考察. 北海道大学医療技術短期大学部紀要 5 : 1-9, 1992.
 
9) Kojima T, et al : Vitamin K concentrations in the maternal milk of Japanese women. Acta Paediatr 93 : 457-463, 2004.
PubMed
10) Motohata K, et al : Relationship of milk intake and vitamin K supplementation to vitamin K status in newborns. Pediatrics 29 : 649-654, 1989.
 
P.618 掲載の参考文献
1) Cunningham MT, et al : Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 126 (4) : 499-505, 2002.
PubMed
2) Lane DA, et al : Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol 35 (2) : 301-308, 1977.
PubMed
3) Reganon E, et al : Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia. Thromb Res 46 (5) : 705-714, 1987.
PubMed
4) Levy J, et al : Dysfibrinogenemia in obstructive liver disease. J Pediatr Gastroenterol Nutr 6 (6) : 967-970, 1987.
PubMed
5) Francis JL, Armstrong DJ : Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 35 (6) : 667-672, 1982.
PubMed
6) Wilde JT, et al : Acquired dysfibrinogenaemia masquerading as disseminated intravascular coagulation in acute pancreatitis. J Clin Pathol 41 (6) : 615-618, 1988.
PubMed
7) Gralnick HR, et al : Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. N Engl J Med 299 (5) : 221-226, 1978.
PubMed
8) Kotlin R, et al : Acquired dysfibrinogenemia secondary to multiple myeloma. Acta Haematol 120 (2) : 75-81, 2008.
PubMed
9) Ashby MA, Lazarchick J : Acquired dysfibrinogenemia secondary to mithramycin toxicity. Am J Med Sci 292 (1) : 53-55, 1986.
PubMed
10) Mori T, et al : Acquired dysfibrinogenemia following allogeneic bone marrow transplantation. Am J Hematol 56 (4) : 294-295, 1997.
PubMed
11) Martinez J, et al : The role of sialic acid in the dysfibrinogenemi aassociated with liver disease : distribution of sialic acid on the constituent chains. Blood 61 (6) : 1196-1202, 1983.
 
12) Herbert JM, et al : Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats. Blood Coagul Fibrinolysis 10 (5) : 239-244, 1999.
PubMed
P.623 掲載の参考文献
1) 毛利博 : 後天性von Willebrand症候群. 血小板血栓形成の分子機構 (関西血栓フォーラム編), p 106-116, 2002.
 
2) Federici AB, et a ; l Subcommittee on von Willebrand Factor : Acquired von Willebrand syndrome : data from an international registry. Thromb Haemost 84 : 345-349, 2000.
 
3) Tiede A, et al : Diagnostic workup of patients with acquired von Willebrand syndrome : a retrospective single-centre cohort study. J Thromb Haemost 6 : 569-576, 2008.
 
4) Federici AB : Acquired von Willebrand syndrome : Is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost 6 : 569-576, 2008.
 
5) Vincentelli A, et al : Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349 : 343-349, 2003.
 
6) Mohri H, et al : Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 91 : 3623-3629, 1998.
 
7) Federici AB : Acquired von Willebrand syndrome associated with hypothyroidism : a mild bleeding disorder to be further investigated. Semin Thromb Hemost 37 : 35-40, 2011.
 
8) Coppola A, et al : Bleeding and thrombosis in multiple myeloma and realted plasma cell disorders. Semin Thromb Hemost 37 : 929-945, 2011.
 
9) Tefferi A : Polycythemia vera and essential thrombocytemia : 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87 : 285-293, 2012.
PubMed
10) Tiede A, et al : How I treat the acquired von Willebrand syndrome. Blood 117 : 6777-6785, 2011.
 
11) Federici AB, et al : Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance : Comparison of three different therapeutic approaches. Blood 92 : 2707-2711, 1998.
 

書評

最近チェックした商品履歴

Loading...